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ABSTRACT OF THE DISSERTATION
Mass Spectrometry-based Strategies for Protein Characterization: Amyloid Formation, ProteinLigand Interactions and Structures of Membrane Proteins in Live Cells
by
Ke Li
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2018
Professor Michael L. Gross, Chair

Mass spectrometry (MS)-based protein footprinting characterizes protein structure and proteinligand interactions by interrogating protein solvent-accessible surfaces by using chemical
reagents as probes. The method is highly applicable to protein or protein-ligand complexes that
are difficult to study by conventional means such as X-ray crystallography and nuclear magnetic
resonance. In this dissertation, we describe the development and application of MS-based protein
footprinting from three perspectives, including I) protein aggregation and amyloid formation
(Chapter 2-3), II) protein-ligand interactions (Chapter 4-5), and III) in-cellulo structures and
dynamic motion of membrane proteins (Chapter 6). Fast Photochemical Oxidation of Proteins
(FPOP) is the main methodology implemented in the work presented in this dissertation. Chapter
1 provides an overview of FPOP and discusses its fundamentals as well as its important
applications in both academic research and biotechnology drug development.
In Part I, Chapter 2 covers the early method development of FPOP for monitoring amyloid beta
(Aβ) aggregation. In this work, we demonstrated the high sensitivity and spatial resolution of the
xii

method in probing the solvent accessibility of Aβ at global, sub-regional, and some amino-acid
residue levels as a function of its aggregation, and revealed Aβ species at various oligomeric
states identified by their characteristic modification levels. In Chapter 3, we extended the
application of the platform to assess the effect of a putative polyphenol inhibitor on amyloid
formation and to provide insights into the mechanism of action of the inhibitor in remodeling Aβ
aggregation pathways.
In Part II, we evaluated different protein footprinting techniques, including FPOP, hydrogendeuterium exchange (HDX), and carboxyl group footprinting, for probing protein-ligand (drug
candidates) interaction in the context of a therapeutic development. Chapter 4 focused on
protein-protein interaction by investigating the epitope of IL-6 receptor for two adnectins that
have similar apparent biophysical properties. In Chapter 5, we probed the hydrophobic binding
cavity of bromodomain protein for a small molecule inhibitor. This study serves as an example
of interrogating protein-small molecule interactions. The two studies in Part II demonstrate the
unique capabilities and limitations of protein footprinting methods in protein structural
characterization.
In Part III, we pushed the boundary of MS-based protein footprinting by applying the method to
footprint live cells and investigate the dynamic structures/motion of membrane-transport proteins
in their native cellular environment. We employed protein engineering, suspension cell
expression and isotopic-encoded carboxyl group footprinting to identify salt bridges in two
proteins, GLUT1 and GLUT5, that control their alternating access motions for substrate
translocation. With functional analysis and mutagenesis, live-cell footprinting provides new
insights into the transport mechanism of proteins in the major facilitator superfamily.

xiii

The five studies in the dissertation demonstrate the powerful capability of MS-based protein
footprinting in protein structural biology and biophysics research. The method also holds great
potential in studying more complicated biological systems and solving demanding problems
related to protein structure and properties.
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Chapter 1: Introduction of Mass
Spectrometry-Based Fast Photochemical
Oxidation of Proteins (FPOP) for Higher
Order Structure Characterization*

_____________________
* This chapter is based on a recent accepted review: Li, K. S.; Shi, L.; Gross, M. L., Mass
Spectrometry-Based Fast Photochemical Oxidation of Proteins (FPOP) for Higher Order
Structure Characterization. Acc. Chem. Res. DOI: 10.1021/acs.accounts.7b00593
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1.1 Abstract
Assessment of protein structure and interaction is crucial for understanding protein
structure/function relationships. Compared to high-resolution structural tools including X-ray
crystallography, nuclear magnetic resonance (NMR) and cryo-EM, and traditional low-resolution
methods such as circular dichroism, UV-Vis and florescence spectroscopy, mass spectrometry
(MS)-based protein footprinting affords medium-to-high resolution (i.e., regional and residuespecific insights) by taking advantage of proteomics methods focused on the primary structure.
The methodology relies on “painting” the reactive and solvent-exposed amino acid residues with
chemical tags and using the pattern of modifications as footprints from analysis by bottom-up
MS-based proteomics to deduce protein higher order structures. The outcome can refer to
proteins in solution or even in cells and is complementary to those of X-ray crystallography and
NMR. It particularly useful in mapping protein-ligand interfaces and conformational changes
resulted from ligand binding, mutation and aggregation.
Fast photochemical oxidation of proteins (FPOP), in its original conception, is a type of
hydroxyl-radical-based protein footprinting that utilizes a pulsed KrF laser (248 nm) to trigger
hydrolysis of hydrogen peroxide to produce solution hydroxyl radicals, which subsequently
modify the protein in-situ. The platform is expanding to adopt other reactive species including
carbenes. The reactivity of the probe depends on the intrinsic reactivity of the radical with the
residue side chain and the solvent accessibility of the residue as a function of the
tertiary/quaternary structures. By introducing an appropriate scavenger to compete with hydroxyl
radical self-quenching, the lifetime of the primary radicals is remarkably shortened to ~ μs. Thus,
the sampling timescale of FPOP is much faster than hydrogen-deuterium exchange and other
covalent labeling methods relying on non-radical reactions.
2

The short footprinting timescale of FPOP offers two major advantages for protein structure
elucidation: 1) it allows the protein to be interrogated in its native or near-native state with
minimum structural perturbation; 2) it exhibits high sensitivity toward alterations in protein
higher order structures because its sampling time is short with respect to protein conformational
changes and dynamic motion. In addition, the covalent and irreversible oxidation by the
hydroxyl radical provides more flexibility in the downstream proteomics workflow and MS
analysis, permitting high spatial resolution with residue-specific information.
Since its invention in 2005 by Hambly and Gross, FPOP has developed from proof-of-concept to
a valuable biophysical tool for interrogating protein structure. In this account, we summarize the
principles and experimental design of FPOP that enable its fast labeling, and describe the current
and unique capabilities of the technique in protein higher order structure elucidation. Application
examples include characterization of amyloid beta self-assembly, protein-ligand interactions with
a special emphasis on epitope mapping for protein therapeutics (e.g., antibody, Fab and adnectin),
protein folding detailed to residue-specific folding kinetics, and protein flexibility/dynamics.
Additionally, the utility of FPOP-based oxidative footprinting should grow with our continuing
developments of novel reagents (e.g., sulfate radical anion, carbene diradical and trifluoromethyl
radical). These reactive reagents are compatible with the current FPOP platform and offer
different reactivity and selectivity towards various types of amino acid residues, providing
complementary insights into protein higher order structures for soluble proteins and ultimately
for membrane-bound proteins.

3

1.2 Introduction
Mass spectrometry (MS)-based protein footprinting has become a compelling tool for proteins
that are incompatible with or simply too demanding for traditional structural techniques of X-ray
crystallography and NMR or not appropriate for cryo-EM. As a highly practical technique that
can be applied routinely, MS affords regional and residue-specific information in assessing
structure and dynamics of proteins.
For perspective, we can view the commonly applied hydrogen-deuterium exchange (HDX) as a
complementary and powerful means of protein footprinting. HDX interrogates protein higher
order structures based on the stability, H-bonding, and structural protection of the protein
backbone.1 The labile N-D bond after exchange, however, is prone to back exchange when the
protein or its constituent peptides are placed in protic solvents for analysis, limiting the capacity
of HDX in structural proteomics applications that require sophisticated sample handling (e.g.,
purification, proteolysis, buffer exchange) prior to MS analysis.
In contrast, hydroxyl-radical (·OH) footprinting, first introduced by Chance2-3 who used
synchrotron radiation to ionize water and produce ·OH, yields irreversible modifications on the
protein. Its elaboration as Fast Photochemical Oxidation of Proteins (FPOP) gives a method
complementary to HDX. Hydroxyl radicals label the protein irreversibly, allowing application of
rigorous downstream proteomics workflows to report accurately on solvent accessibility of the
protein (Figure 1.1A). It accomplishes the labeling more rapidly and provides residue specificity,
although with lower generality than HDX because labeling by ·OH requires the presence of
reactive side chain(s) in a peptide segment.
FPOP was first developed by Hambly and Gross4 to utilize ·OH generated from photolysis of
hydrogen peroxide (H2O2) to monitor solvent accessibility of the protein side chain. Compared to
4

synchrotron radiolysis of water or use of the Fenton reaction, FPOP permits tuning the timescale
of footprinting by introducing a scavenger to control the lifetime of the radical. This allows
investigation of the protein structure in its native or near-native state without sampling altered
conformations induced by modifications.
A
FPOP
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Figure 1.1. A standard workflow of protein footprinting by FPOP. (A) Two different states,
A and B, of a targeted protein (gray ribbon) are labeled by FPOP. The hydroxyl radical abstracts
a hydrogen from the protein, and a series of follow-up reactions occur subsequently to produce
stable covalent modifications (red dots) on the protein. The peptides produced in digestion are
shown as black lines. Signals of unmodified and modified peptides observed in the HPLC
chromatograms are shown in gray and red, respectively. MS2 is used to identify the modified
residues. The extents of modification are quantified based on the signals of the unmodified and
modified species and compared for proteins in different states. (B) Representative extracted-ion
chromatograms showing the separation of the unmodified (grey) and FPOP-modified (red)
peptides from the tryptic digests of interleukin-6 receptor (adapted with permission from ref. 8.
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Copyright 2017 American Chemical Society.). The peptide sequence and numbering are
indicated above the chromatogram. The modified residues corresponding to each signal peak are
labeled on the chromatogram.

During the past decade, FPOP has been elaborated and applied to protein higher-order-structure
characterization in both academic research and biotechnology development labs. Although most
applications are occurring in biophysics, there is a significant need for new methods to support
the discovery, development and quality control of protein therapeutics. In this review, we discuss
the principles of FPOP and highlight selected applications including characterization of amyloid
formation;5 of protein fast/slow folding;6-7 of protein-ligand interactions (emphasis on epitope
mapping);8-10 and of protein dynamics and the identification of hidden conformations.11-12 These
examples illustrate the power of FPOP to decipher the higher order structures of protein and
protein complexes.

1.3 FPOP Fundamentals
1.3.1 FPOP setup
The FPOP apparatus uses a 248 nm KrF excimer laser to cleave H2O2 at low concentration (15
mM, 0.04%) (Figure 1.2). We chose 248 nm because the absorptions of water and most proteins
are low at this wavelength. The laser beam is focused with convex lenses to give an exposure
window of 2.0-3.0 mm wide on a 150 µM i.d. silica tubing (termed the FPOP capillary). The
laser affords a high and converging flux of photons, maximizing the yield of ·OH in a small plug
of an irradiated solution.

6

FPOP uses a flow system for protein footprinting, in which the capillary is placed perpendicular
to the laser beam (Figure 1.2). Prior to FPOP, the protein is mixed with H2O2 and a radical
scavenger (usually a free amino acid). The solution mixture is then immediately transported
through the FPOP capillary by a syringe pump. When the solution passes the transparent window
on the capillary, laser-triggered photolysis of H2O2 produces ·OH in nanoseconds. The radicals
further undergo Haber-Weiss chain reactions in competition with self-quenching to re-form H2O2
(Scheme 1.1).
The hydroxyl radical induces protein oxidation by abstracting a hydrogen from the protein,
which results in a protein radical that further undergoes a series of subsequent reactions to
generate products with stable oxidation.2 Rate constants for reaction with individual amino acids
range from 107 to 1010 M–1 s–1, serving as approximates of the intrinsic reactivities of protein side
chains.2

7

A
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Figure 1.2. FPOP setup. (A) Schematic of the FPOP platform. The laser beam (violet)
generated from an excimer laser (blue square) is focused through an iris and then by two convex
lenses. The FPOP capillary (blue line) made of silica tubing is connected to a syringe pump. The
transparent window without polyimide coating indicates the location of laser irradiation (a blowup of the transparent window is shown in the dashed box). A tube containing catalase and Met is
placed at the end of the FPOP capillary to collect the FPOP-modified sample. (B) Photo of the
FPOP apparatus. Primary components are labeled, and the violet arrow represents a visual
pathway of the laser beam perpendicular to the FPOP capillary.
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Scheme 1.1. Chain reactions involved in the generation of ·OH by FPOP. The rate constant is
shown below each reaction.13
An external pulse generator is incorporated to control frequency of the laser pulse, which
together with a proper flow rate of the solution minimizes multiple laser irradiation to the same
solution plug. To further avoid “double shooting”, a small volume is intentionally excluded from
laser exposure to create a “barrier” between each exposed plug (termed an “exclusion volume”).
The outlet of the FPOP capillary is placed into a sample-collection tube containing catalase and
free methionine in buffer to remove leftover H2O2 and to prevent post-footprinting oxidation
artifacts from any remaining reactive species. The control sample, used for correcting the
background oxidation (< 5%, mainly on Met) of the protein induced by H2O2 or in post-FPOP
sample handling is prepared the exact same way as the experimental sample, except the laser is
omitted during the FPOP workflow.
If there is a concern that significant oxidation will occur when mixing the protein with H 2O2,
then H2O2 can be supplied prior to laser irradiation by using a T-shaped micromixer. In this setup,
one syringe pump delivers the protein in buffer, and another delivers H2O2 and the scavenger for
T-mixing prior to laser irradiation. This setup improves reproducibility by minimizing the
exposure of the protein to H2O2 and hence any non-FPOP oxidation by the peroxide.14
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1.3.2 Timescale of the FPOP probe
The radical lifetime in FPOP is tuned through varying the type and/or concentration of the
scavenger.4,

15

In the absence of a scavenger, the radical lifetime in FPOP is limited by the

recombination reaction and can extend to approximately 100 µs. Allowing a protein to react for
this time may lead to unfolding, exposing buried residues to solvent exposure. Addition of a
scavenger (e.g., 20 mM Gln) to the protein solution effectively shortens the lifetime of the
primary hydroxyl radical to ~ 1 µs, limiting the modification to reactive and solvent-exposed
residues in the native conformation. Gau et al.16 studied the population distribution of the FPOP
oxidation (0, +16, +32 Da etc.) for three oxidation-sensitive proteins (-lactoglobulin, apo
calmodulin and lysozyme), and proposed that a fit of the distribution to a Poisson signals
conformational homogeneity of the protein during FPOP labeling. That is, protein samples with
FPOP properly conducted by including a radical scavenger and suitable quenching of peroxide
(catalase and Met) undergo footprinting of a single conformational state without perturbing the
native conformation during labeling. These results underscore the indispensable roles of the flow
system, the radical scavenger, and the prompt removal of peroxide in FPOP.
Any radical reaction leads to production of a secondary or higher order radicals, which have
lifetimes in the millisec range.17 If these longer-lived radicals modify the protein, the time of
labeling is longer than ~1 μs that we claimed.4 Unfortunately, there is little direct evidence that
reactions of secondary radicals like ·OOH modify the protein. Some indirect demonstration of
the rapid labeling, however, comes from the application of FPOP in probing protein fast folding
(see “Protein folding” section)7. The clear time-dependence seen in that study suggests that the
radical reactions are not continuing onto the millisecond time range.
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Protein modification depends not only on lifetime but also the number of radicals produced by
the laser. Using d0/d5 Phe as an isotope-encoded dosimeter, for 15 mM H2O2, we found that the
initial concentration of ·OH is 0.95 mM.15 Because the amount of the radical scavenger is in a
large excess with respect to the solvent-exposed, reactive sites in the protein (e.g., 20 mM free
Gln vs. 10 µM protein), the dominating chemistry that controls the lifetime of ·OH in FPOP is
the reaction with the scavenger. Therefore, moderate variations in the protein concentration or
the presence of a ligand will not significantly affect the overall oxidative yield on the protein or
the relative yields on various side chains.18 From our experience, this remains valid for
compounds with a size up to that of an antibody (~ 150 kDa).19 Thus, observed FPOP variations
between the protein in different conformational states (e.g., apo and holo) correlate only with
their different solvent accessibilities.

1.3.3 Post-FPOP proteomics workflow
The FPOP-modified protein is usually analyzed by a bottom-up proteomics strategy to obtain
sub-regional and residue-specific structural information (i.e., the footprint) (Figure 1.1). Owing
to the covalent and irreversible modification by FPOP, many improvements made for analysis
and determination of the primary structure (analytical proteomics) can be applied to facilitate the
FPOP approach for higher order structure characterization. For example, the irreversible
modification (unlike in HDX) offers high flexibility in proteolysis. Digestion with specific (e.g.,
trypsin, Asp-N), semi-specific (e.g., chymotrypsin) and nonspecific (e.g., pepsin) proteases can
be performed in tandem or separately to generate overlapping peptide fragments that give
comprehensive coverage of the protein sequence. Unlike identifying primary structure in
proteomics, footprinting requires high coverage of the protein sequence, but this is manageable
because usually a single, known protein or a simple mixture of proteins is used.
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The resultant peptides are analyzed by liquid chromatography and tandem mass spectrometry
(LC-MS2) to identify the modification sites and to quantify the levels. Oxidation by FPOP makes
the peptide less hydrophobic, permitting separation of the modified peptide from its unmodified
form by reversed-phase LC (see Figure 1.1B for an example). Generally, the modified peptides
elute earlier than the unmodified ones, which allows a clear identification of the modified
peptide on the basis of its accurate mass and product-ion spectrum (MS2). We quantify the
peptide modification level based on the primary modification species (i.e., products of OH
substitution (+15.9949 Da)). To calculate the modification percentage for a specific peptide,
signal intensities of the unmodified peptide (Iu) and its modified species (ΣIox) are taken as peak
areas from extracted ion chromatograms (XICs). The modification fraction for a certain peptide
is calculated from the following equation: Fraction-modified = ΣIox/(Iu + ΣIox). This algorithm is
straightforward and sufficiently sensitive to report the solvent accessibility change.5

1.4 Applications of FPOP
To show that the method is reliable and versatile, we now review four topics that show the utility
of FPOP in biophysics and structural proteomics.

1.4.1 Amyloid protein aggregation
Aggregation of amyloid beta (Aβ) is one of the primary pathogenic events leading to
Alzheimer’s disease. Characterizing the products of Aβ aggregation, however, remains
challenging owing to the vast heterogeneity and transient nature of the intermediate aggregates.
We recently used FPOP to monitor amyloid formation and solvent accessibility of Aβ1-42, the 42amino acid form of Aβ, at global, peptide, and amino-acid levels (Figure 1.3).5 FPOP
footprinting immediately captures the solvent accessibilities of Aβ1-42 intermediates, filling in the
12

gap between solution NMR for the early state oligomers and solids NMR and cryo-EM for the
final fibrils. The readout from FPOP is clear, because the irreversible modification by FPOP
should not be affected by Aβ aggregation and/or conformational change occurring postfootprinting.
We modified Aβ1-42 aggregates in various oligomeric states by FPOP. Occurring are extensive
modifications for Aβ1-42 monomer owing to its intrinsically disordered structure (Figure 1.3A).
As Aβ1-42 assembles and reorganizes into higher order oligomers, the FPOP modification of Aβ142

deceases owing to formation of secondary/tertiary structures (Figure 1.3B and C). At the end

of aggregation, the modification extent decreases to a modest level (Figure 1.3D), indicating the
formation of compact amyloid fibrils with a core structure that resists modification. A fit of a
plot of FPOP modifications as a function of incubation time, adopting the conventional
nucleation-condensation mechanism (Finke-Watzky), affords a sigmoidal curve that shows
sequential formation of the major species of Aβ1-42 during aggregation (Figure 1.3E). We also
characterized the interconversion of those representative Aβ species by simulating their
concentration change as a function of the incubation time (Figure 1.3F).
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Figure 1.3. FPOP and kinetic modeling characterize the time-dependent aggregation of Aβ1-42 at

protein, peptide and amino-acid residue levels. (A-D) Mass spectra showing extents of

FPOP modification for intact Aβ1-42 (5+ charge) as a function of the incubation time. The
determined modification percentage is shown in each panel. (E) Characterization of Aβ1-42
aggregation on the global (full-polypeptide) level by a kinetic simulation. Points represent
experimental data, and the solid curve is a model fit based on two auto-catalytic reactions. (F)
Concentrations (in monomeric equivalents) change of representative Aβ1-42 species (M-monomer,
D-paranuclei, D*-protofibrils and D**-fibrils) from kinetic simulation. (G-H) Aggregation
curves of N-terminal region 1-15 and C-terminal region 28-42. (I-J) Aggregation curves of
representative Aβ1-42 residues H6 and F19/F20. In G-J, the solid and dashed curves are model fits
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independent of or constrained by the global rates, respectively. Adapted with permission from
ref. 5. Copyright 2016 American Chemical Society.

FPOP also provides a high-resolution view of aggregation at regional and amino-acid levels for
some residues. We characterized the modification of three Aβ1-42 sub regions, including the Nterminal peptide 1-15, central domain 16-27, and C-terminal peptide 28-42 from digestion of the
full-length Aβ1-42. FPOP modification for the N-terminal peptide remains high (~ 80%) with little
variation as Aβ1-42 aggregates, indicating that the N-terminus remains structurally flexible and
solvent accessible, with little participation in Aβ1-42 aggregation (Figure 1.3G). This finding is
further supported by NMR results showing that the N-terminus of Aβ1-42 is disordered in a
variety of oligomers and in the mature fibril. By contrast, the critical roles of the central domain
and hydrophobic C-terminus in promoting self-association is highlighted by a dramatic decrease
in FPOP modification from monomers to fibrils (Figure 1.3H). Furthermore, measuring the
modification at the amino-acid level allows characterization of the aggregation tendencies for
Aβ1-42 at a residue level. For example, H6 shows relatively constant FPOP modification, during
aggregation, indicating little change in its solvent-accessibility and conformation (Figure 1.3I).
On the other hand, F19/F20 are residues primarily responsible for the modification change
observed for the central domain (Figure 1.3J), and we propose that interactions of F19/F20
contribute a driving force for Aβ1-42 aggregation by serving as the hydrophobic nucleation
interface.
We envision that this FPOP platform can reveal how interactions of Aβ with other molecules
affect site-specific aggregation.

Application to drug candidates and natural products that

promote/inhibit oligomerization should be particularly fruitful.
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1.4.2 Protein folding
Protein folding and stability is crucial in understanding the biological effects of mutations and
the pathogenesis of diseases associated with aggregation of misfolded proteins. Protein folding is
transient and rapid (usually sub-millisecond), challenging structural characterization of kinetic
intermediates formed during folding. Previously, spectroscopic methods, including fluorescence
emission, circular dichroism, and electron-spin resonance, have provided insights into the
underlying mechanism of protein folding. Approaches having high spatial resolution and
sensitivity, however, are still sparse. Because the labeling speed of FPOP is faster than most
protein folding, it should be effective in probing folding by measuring protein solventaccessibility changes accompanying the conformational change. Meanwhile, the high spatial
resolution of FPOP allows direct assessment of the folding down to amino-acid residues in some
cases.
To explore this opportunity, we designed a two laser-based platform that combines a temperature
jump (one laser) and FPOP (second laser) to study protein fast folding (Figure 1.4A).7 This
platform employed a Raman-shifted Nd:YAG laser (1900 nm) to generate a nanosecond
temperature jump (~ 20 C) in the buffer solution and initiate protein (barstar) refolding,
followed by a folding time-dependent FPOP footprinting triggered by the KrF excimer laser.
Control of the heating and the FPOP laser, and hence the folding times is achieved by two delay
circuits, which are used to adjust the time between firing the two lasers.
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Figure 1.4. Folding of barstar characterized by a T-jump FPOP. (A) Schematic
representation of the two-laser FPOP platform. As in Figure 1.2A, the transparent window is
located where the two laser beams (dash lines) are incorporated. (B) Left: FPOP modification
percentage of two representative residues as a function of the protein (barstar) folding time. Solid
lines in the plots are obtained from kinetic fitting. Right: Five critical residues identified by
FPOP mapped on native barstar structure. Two views are provided to show the side chains of the
amino acid L88 (red), F74 (cyan), I5 (blue), L20 (green), and W53 (purple). Adapted with
permission from ref. 7. Copyright 2012 American Chemical Society.

The test protein, barstar, a small globulin protein with a single domain structure composed of
four -helixes and three -sheets, is a well-characterized model for protein folding. We probed
its folding from a fraction of a ms to 2 ms, a time domain spanning its early folding and found
residues with distinct kinetic features in terms of their solvent accessibility (Figure 1.4B).
Modifications of H17, L20 and L24, all located in helix1, show an exponential decrease in the
first 2 ms of folding (a control is represented by L88 in Figure 1.4B). Their modification at 2 ms
time is attenuated owing to its folding. These residues showing dramatically decreased FPOP
17

modification are consistent with folding via hydrophobic interactions in the first 2 ms. Our
findings agree with the spectroscopic results20 but bring spatial resolution, demonstrating that the
hydrophobic collapse on helix1 is the initial step in barstar folding.
FPOP can also be used to probe protein slow folding. An example is study of the refolding of a
viral fusion protein, parainfluenza virus 5 F (PIV5 F).6 We triggered the irreversible refolding of
PIV5 F by heat, and captured five conformations on the basis of their FPOP footprints: PIV5 F in
the pre-fusion state (before heating), three intermediate states (45, 55, and 65 °C), and the postfusion state. The experiment required the FPOP capillary contiguous to the laser window to be
placed in a heated chamber that maintains the temperature of the protein solution. The
modification of the PIV5 F decreases upon transition from the pre-fusion to the post-fusion state,
indicating that the structure of PIV5 F in the pre-fusion state is more open and solvent-exposed.
The modifications of the PIV5 F peptides afford structural information on regions becoming
solvent-exposed or protected along the refolding pathway. This allows us to propose a model
describing the dynamic refolding of PIV5 F and to compare the differences in FPOP
modification of the pre-fusion and post-fusion PIV5 F with changes in the solvent accessible
surface area (SASA) from X-ray structures. There are greater changes in solvent accessibility for
nine regions, as reported by FPOP but not predicted by SASA. This indicates an underestimation
of the pre-fusion PIV5 F’s SASA calculated from the static crystal structure and points to a
higher structural flexibility in solution. Interestingly, most of those regions contain the epitopes
of PIV5 F for the prefusion-specific neutralizing antibodies, suggesting the importance of those
regions for PIV5 F biological function.
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1.4.3 Epitope mapping
Understanding antibody action relies on identifying the binding sites of the antibody on the target
antigen. Methods for this, called epitope mapping, include X-ray crystallography, NMR, sitedirected mutagenesis, and MS-based approaches. Those techniques offer complementary
information on the epitope and on binding-induced conformational changes. To illustrate the
capability of FPOP for epitope mapping, our lab has collaborated with Bristol-Myers Squibb and
Genentech to characterize epitopes for a number of targets upon binding of protein therapeutics.
Early in the development, we applied FPOP to investigate the epitope of human epidermal
growth factor receptor (EGFR) for adnectin binding at both the peptide and amino-acid residue
levels.10 The FPOP-determined binding interface involves various amino-acid and peptide
regions near the N-terminus of EGFR. Our data correlate well with the previously determined
epitopes from the crystal structure. Additionally, successful characterization of epitopes in
thrombin19 and vascular endothelial growth factor
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serves as other good examples of FPOP’s

ability to identify both the epitope and regions with remote conformational changes.
We later combined HDX-MS, site-directed mutagenesis, and FPOP to study the epitope of
interleukin-23 (IL-23) upon binding of an anti-IL-23 antibody (Figure 1.5).9 Using HDX-MS, we
found five peptide regions on IL-23 showing reduced backbone amide solvent accessibility upon
antibody binding. Five different peptides of IL-23 are identified by FPOP, among which three
regions are identified by HDX as well. Additional FPOP analysis at residue level allows us to
assign potential critical-binding residues.
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Figure 1.5. Epitope regions of IL-23 identified by FPOP, HDX-MS, and alanine shave
mutagenesis. (A) Critical peptides discovered by HDX (top) and FPOP (bottom). These regions
are mapped on the linear sequence of IL-23 (in orange for HDX results and blue for FPOP). (B)
Critical residues identified by FPOP (top) and alanine-shave mutagenesis (bottom) mapped on
the IL-23 crystal structure. Amino acids identified by FPOP are in blue, and by mutagenesis in
green. Gray regions suggest no significant difference in the conformation of IL-23 upon binding
with Fab. Adapted with permission from ref. 9. Copyright 2017 American Chemical Society.
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More recently, we implemented FPOP, HDX, and carboxyl group footprinting to map
interactively the epitope of IL-6 receptor (IL-6R) for two adnectins with distinct affinities (Kd,
Adnectin1 ∼ 6.2 pM vs Kd, Adnectin2 ∼ 46 nM).8 Besides identifying the epitope as a flexible
loop that connects two β-strands in the cytokine-binding domain, our results reveal that two
loops, located beyond the conserved epitope undergo reduced dynamic motion upon adnectin1
binding. Those local effects on the IL-6R structure are attenuated or not observed in the case of
adnectin2 binding. Apparently, binding of adnectin1, the stronger ligand, stabilizes IL-6R by
reducing the flexibility of those dynamic regions.
Outcomes from the above studies highlight the capability of FPOP as a sensitive tool for epitope
mapping, motivating its further applications in protein discovery and development either as a
stand-alone method or in conjunction with orthogonal structural approaches (e.g., X-ray, SAXS,
EM) and other MS-based methods (e.g., HDX-MS, ion mobility). In addition, the combined use
of MS-based methods provides critical information on therapeutic targets in the absence of an Xray structure, has high throughput, and may be a major advance for the discovery and
development of biopharmaceuticals.

1.4.4 Protein dynamics and hidden conformations
FPOP can report variations in protein dynamics and flexibility because its sampling time is
short with respect to local dynamics of the protein. For example, a study of the oligomerization
interface of apolipoprotein E3 (ApoE3) reveals that the C-terminal helix of ApoE3 and an
unstructured hinge region proceeding the helix undergo decreases in solvent accessibilities in the
tetramer compared to a monomeric mutant.12 The C-terminal helix of ApoE3 has long been
hypothesized to be the primary interface for self-association leading to tetramer formation.
Evidence for the change in the mobility of the hinge region associated with oligomerization
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cannot be seen by HDX and carboxyl group footprinting on ApoE3, done subsequently. Thus,
the preceding hinge region is stabilized owing to formation of the oligomerization interface by
the C-terminus of ApoE3. The inability to see this by HDX and carboxyl-group footprinting
stems from their relatively long labeling time compared to that of FPOP.
A
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Ω-Loop

C

Ω-Loop

D
Ω-Loop

238-loop

104

Figure 1.6. Modeling and FPOP reveal restricted motion in the Ω-loop in cefotaximase
variant. A crystal structure of TEM-1 (blue) is overlaid with the two most populated structures
taken from modeling of (A) the non-cefotaximase states (green, favored by wild type) and (B)
cefotaximase states (orange, favored by the E104K/G238S). (C) Large structural rearrangements
in the Ω-loop distinguish low-energy non-cefotaximase states from cefotaximase states. (D)
FPOP data reveal experimentally the restricted motion in cefotaximase variant predicted from
modeling. Hydroxyl labelling of TEM variants are shown as the difference in percent labelled
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between cefotaximase variant and wild type. The Ω-loop (164–179) is shaded grey in the
sequence and pink in the graph. Adapted with permission from ref. 11. Copyright 2016 Nature
Publishing Group.

FPOP also effectively reveals the difference in local dynamics between wildtype (WT) TEM-1
and its cefotaximase variant. TEM β-lactamase is an enzyme responsible for the antibiotic
resistance in pathogenic Gram-negative bacteria. The cefotaximase variant of TEM, favored by a
E104K/G238S mutant, hydrolyzes cefotaxime 1,400-fold more efficiently than does WT TEM1.11 Although the function and specificity of various TEM variants can vary dramatically, no
apparent conformational changes are found for those variants (Figure 1.6A and B). To uncover
the structural difference between the cefotaximase variant and WT TEM-1, our collaborators,
using Markov state models-based simulation, proposed that the decreased flexibility of the Ωloop in the cefotaximase variant is responsible for its high enzymatic efficiency by stabilizing the
binding-competent state (Figure 1.6C). To test, we turned to FPOP and found significantly
decreased FPOP modification on the Ω-loop itself and the region preceding the Ω-loop in the
cefotaximase variant (Figure 1.6D). In addition, the decreased solvent accessibility pertains to
the C-terminus, suggesting that the E104K/G238S substitution not only reduces the flexibility in
the Ω-loop, but that of the C-terminus remotely via long-range interaction. In this case, FPOP
provides a test for the theory from molecular dynamics simulation and demonstrates its
capability in probing protein solution dynamics that are inaccessible by static crystal structures.
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1.5 Conclusions and Outlook
FPOP coupled with MS has emerged as a powerful approach to study protein higher order
structures. The robustness of the platform has been further enhanced by recent advances in
methodology, allowing the approach to provide improved quantitative information and broader
coverage in footprinting for various types of amino acid residue.
One example is incorporation of a reporter peptide into the protein sample to resolve
discrepancies in the radical dosage. In this scheme, the protein and the reporter peptide are
modified by FPOP simultaneously under the same condition. Thus, the modification extent of the
reporter peptide correlates with the radical lifetime in the sample. By varying the scavenger
concentration (i.e., the radical lifetime), the reporter peptide approach permits a normalized,
time-dependent measurement of the modification on the protein.21 In addition, the FPOP
platform has been extended by Jones to footprint live cells,22 allowing investigation of protein
conformation and interactions in the native cellular environment.
The versatility of FPOP to accommodate new reagents in addition to the ·OH is illustrated by the
developments of the sulfate radial anion (SO4-∙)23 and iodine radical (I∙)24 as alternative
footprinting reagents. We also adapted the carbene radical, a laser-based footprinting reagent
developed by Schriemer25 using a Nd-YAG laser at 355 nm, into the FPOP platform to modify
Asp/Glu.26 More recently, Cheng et al. developed trifluoromethyl radical (·CF3) as a novel
reagent that can modify 18 of 20 amino acids residues, including Gly, Ala, Ser, Thr, Asp and Glu,
which have low reactivities with ·OH.27
The ability to accommodate new reagents on the FPOP platform allows construction of a “library”
of reagents that offer different chemical reactivities and specificities to footprint proteins and
distinguish structural changes that occur from apo to holo, bound to unbound, and wild type to
24

mutant. As these improvements grow, FPOP-based oxidative footprinting approaches will play
an increasingly important role by serving as constrains of the macromolecule structure, much
like chemical shifts do in NMR. The ultimate goal is to use chemistry and MS-based proteomics
to determine coarse-grained structure of proteins and their assemblies. This will require high
coverage of the protein residues in footprinting and motivates continued development and
application of FPOP.
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Chapter 2: Conformational-Sensitive Fast
Photochemical Oxidation of Proteins and
Mass Spectrometry Characterize Amyloid
Beta 1-42 Aggregation*

_____________________
* This chapter is based on the following publication: Li, K. S.; Rempel, D. L.; Gross, M. L.,
Conformational-Sensitive Fast Photochemical Oxidation of Proteins and Mass Spectrometry
Characterize Amyloid Beta 1–42 Aggregation. J. Am. Chem. Soc. 2016, 138 (37), 12090-12098.
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2.1 Abstract
Preventing and treating Alzheimer’s disease require understanding the aggregation of amyloid
beta 1-42 (Aβ1-42) to give oligomers, protofibrils, and fibrils. Here we describe the footprinting of
Aβ1-42 by hydroxyl radical-based fast photochemical oxidation of proteins (FPOP) and mass
spectrometry (MS) to monitor time-course Aβ1-42 aggregation. We resolved five distinct stages
characterized by two sigmoidal behaviors, showing the time-dependent transitions of monomers–
paranuclei–protofibrils-fibrillar aggregates. Kinetic modeling allows deciphering of the amounts
and interconversion of the dominant Aβ1-42 species. Moreover, the irreversible footprinting probe
provides insights into the kinetics of oligomerization and subsequent fibrillar growth by allowing
the conformational changes of Aβ1-42 at sub-regional and even amino-acid-residue levels to be
revealed. The middle domain of Aβ1-42 plays a major role in aggregation whereas the N-terminus
retains most of its solvent-accessibility during aggregation, and the hydrophobic C-terminus is
involved to an intermediate extent. This approach affords an in-situ, real-time monitoring of the
solvent accessibility of Aβ1-42 at various stages of oligomerization, and provides new insights on
the site-specific information on Aβ1-42 for a sample state beyond the capabilities of NMR or xray crystallography.

2.2 Introduction
The aggregation of the amyloid beta (Aβ) into oligomers and fibrils is a key process associated
with Alzheimer’s disease (AD) (Figure 2.1). Among Aβ isoforms that present in AD, Aβ1-42 is
generally considered to be the most pathogenic.1 Extensive effort has focused on characterizing
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the conformation, size, and shape of Aβ aggregates (e.g., as dimers, pentamers, dodecamers2-7
and fibrils8-13) (Figure 2.2), and the outcomes show a complex picture of Aβ1-42 aggregation.
Although soluble oligomers are thought to be the most critical players in the pathology of AD,
large aggregates and fibrils may also be toxic.1, 14 Unfortunately, we know little of their rates and
extents of formation.
A

BB

C
Aβ1-40
Aβ1-42

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Figure 2.1. Aβ and AD. (A) Accumulation of Aβ peptide leading to the formation of Aβ plaque.
Two major forms of Aβ peptide, Aβ1-40 and Aβ1-42, are derived from amyloid precursor protein
(APP) by enzymatic cleavage. (B) Aβ peptides are implicated in AD pathogenesis. (C)
Sequences of Aβ1-40 and Aβ1-42. (A) and (B) are adapted from Kung, H. F., ACS Medicinal
Chemistry Letters 2012, 3 (4), 265-267.
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Figure 2.2. Aβ and its aggregates. (A) Aggregation pathway of Aβ1-42 is a complicated
multistep process. (B) Some proposed models of Aβ monomer, dimer, pentamer by solutionphase NMR. (C) Three structures of Aβ1-40 fibrils reported by solid-phase NMR. Adapted from
ref 6.

The most common approach in methodology for characterizing structure is multiphase NMR and
X-ray crystallography, giving an essential, high resolution picture of the final state of Aβ fibrils
while addressing some intermediates or oligomerized states that can be retained under nonphysiologically relevant conditions. Owing to the vast heterogeneity and high aggregation
propensity, however, the low molecular weight (low-MW) Aβ oligomers are not amenable to
NMR or X-ray crystallography. Along a similar vein, atomic force microscopy (AFM) visualizes
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morphology of the aggregates but provide no site specificity. More recently, Bowers et al. 15
implemented high resolution AFM to provide insight into Aβ1-42 and Aβ1-40 oligomers formed at
early stage. The results with respect to the morphology is clear, but the process used to evaporate
the droplet of Aβ solution before the visualization is not free of ambiguity.
Fluorescence may be the most widely adopted approach to follow Aβ aggregation, offering a
solution medium that affords more physiological relevance. The signature measurement for
amyloid formation is the fluorescence-based Thioflavin T (ThT) labeling assay that shows two
regions or stages of aggregation separated by a sigmoid (Figure 2.3)16. Recently, Frieden et al.17
labeled Aβ with tetramethylrhodamine (TMR) as a novel fluorescent reporter for
oligomerization. This method reports more details, showing a lag and growth phases in amyloid
formation. Although those fluorescence-based methods inform on the states of aggregation, only
low structural resolution data is available. Despite their ease of use, they require either adding a
dye molecule, which affects the accuracy in measuring amyloid-ligand interactions because antiamyloid compounds such as polyphenols with strong absorption and fluorescence properties can
significantly bias the fluorescence readout,18 or pre-modifying Aβ, a perilous approach given that
addition or subtraction of one amino acid changes significantly the properties of Aβ.
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A

B

Figure 2.3. Thioflavin T (ThT) fluorescence assay for monitoring amyloid fibrilization. (A)
Structure of ThT. (B) A typical ThT fluorescence curve representing two stages in amyloid
formation, including a lag phase and a growth phase. Adapted from ref 16.

Mass spectrometry is now playing a role in understanding Aβ oligomerization, principally via
measurements of the ion mobility of the gas-phase species.3 Most ion-mobility work reports on
small oligomers and short Aβ fragments, whereas the full protein and its very large soluble
oligomers (n~100) likely hold the secret of its debilitating role in the human brain.
Contemporaneously with the application of the TMR fluorescence method, we applied MS-based
pulsed hydrogen-deuterium exchange (HDX)19 and obtained similar results as Frieden et al.
Although pulsed HDX avoids the problem of pre-modifying Aβ, the application of sophisticated
proteomics for downstream protein analysis must be constrained to minimize the back-exchange
resulted from hydrogen/deuterium scrambling.20 As an alternative, Axelsen et al.21 applied a
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synchrotron-based hydroxyl radical footprinting to study Aβ1-40 fibril and compared the outcome
with those of multiple NMR structural studies. Despite all these efforts, the techniques we have
currently, however, do not fully address the intermediate conformational transitions of Aβ1-42
during aggregation. Thus, the transient aggregates of oligomerization remain insufficiently
characterized, and our tools to characterize the oligomerization are temporarily exhausted.
In this report, we describe a new platform based on fast hydroxyl-radical footprinting (FPOP)
and mass spectrometry to follow the aggregation of Aβ1-42, which is regarded to be the most
pathologically relevant Aβ isoform in AD. Unlike Aβ1-40, the folding and assembly of Aβ1-42 are
highly complicated and multi-step process,2-3,

6-7, 13-14, 22

(Figure 2.2A). Here, we seek an

informative, time-dependent approach that not only follows oligomerization but also can be
extended to test the effects of other proteins, lipids, and potential drugs on the monomer/solubleoligomer transitions. The cutting-edge approach builds on proteomics measurements and MSbased footprinting. It utilizes hydroxyl radical-mediated irreversible reactions23 initiated on a
FPOP platform24 to footprint Aβ1-42 as it undergoes oligomerization. FPOP allows various Aβ1-42
oligomeric species to be footprinted rapidly and irreversibly on amino-acid side chains. To locate
the modified regions, we implemented Lys-N rapid digestion and LC-MS/MS to characterize Aβ1-42

fragments. Our hypothesis is that FPOP modifications sensitively respond to the solvent

accessibility changes of Aβ1-42 upon self-association (Figure 2.4). This approach uses
downstream sample processing independent of protein conformational changes occurring post
footprinting to report changes on the Aβ1-42 side chains at the global, peptide regional, and even
amino-acid levels.
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Figure 2.4. Schematic of using FPOP to probe Aβ aggregation. As Aβ (blue sphere)
undergoes self-association, its decreased solvent accessibility is reflected by changes in FPOP
modification (green sphere). The FPOP-modified Aβ are denatured for measuring the averaged
modification extent of the peptide using LC-MS.

2.3 Materials and Methods
2.3.1 Materials
Synthetic wild type human amyloid beta 1-42 (Aβ1-42) was from AnaSpec (San Jose, CA). Lys-N
protease was from Seikagaku Corporation (Tokyo, Japan). Hexafluoroisopropanol (HFIP),
sodium hydroxide (NaOH), L-glutamine, L-methionine, catalase, hydrogen peroxide (H2O2),
phosphate buffer saline (PBS, 10 mM phosphate, 138 mM NaCl, 2.7 mM KCl), urea, formic acid
and trifluoroacetic acid were from Sigma Aldrich (St. Louis, MO).

2.3.2 Formation of Aβ1-42 aggregates
The purchased Aβ1-42 was dissolved in HFIP at 1 mM and incubated at room temperature for 1 h
to disrupt any pre-existing aggregates. The resulting solution was then aliquoted into tubes, and
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the HFIP was evaporated in a fume hood. After solvent evaporation, a clear film of Aβ1-42
remained at the bottom of the tube. HFIP treatment was then repeated two more times. Samples
were then frozen in -80 ⁰C for future experiments. Prior to incubation for aggregate formation,
HFIP-pretreated Aβ1-42 was dissolved in 3 mM NaOH (pH 11.7) and incubated without stirring at
room temperature for 3 min followed by sonication for 1 min. Aggregation was initiated upon
diluting the Aβ1-42 NaOH solution by 20 fold (v/v) with PBS buffer (pH 7.4). The final Aβ1-42
concentration after dilution was 10 μM. Different extents of aggregation were achieved by
varying the incubation time from 0 to 48 h in PBS buffer (25 oC or 37 oC). For each time point,
the incubation and analysis was done in triplicate.

2.3.3 FPOP labeling of Aβ1-42
At the various incubation times, Aβ1-42 was immediately submitted to FPOP labeling. FPOP was
performed as previously described.25 Briefly, a KrF excimer laser (GAM Laser Inc., Orlando,
FL, USA) generated laser beam with an excitation wavelength of 248 nM initiated H2O2
photolysis to give hydroxyl radicals. The Aβ1-42 in PBS was mixed with 20 mM glutamine
(scavenger) and 20 mM H2O2 just prior to injection into the flow tubing for FPOP. The flow rate
was adjusted according to the width of the laser irradiation window to ensure 20% irradiationexcluded volume and to

minimize repeated laser exposure. The total time for one sample to

pass through the silica tubing was ~2 min. After laser irradiation, the sample was collected in a
tube containing 10 mM catalase and 20 mM methionine to decompose leftover H2O2 and prevent
oxidation-artifacts during storage. For each aggregation time point, Aβ1-42 was incubated
independently in triplicate and subjected to FPOP. In addition, control samples of Aβ1-42 were
handled in the same manner in triplicates, but not laser-irradiated. Each FPOP-labeled sample
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was transferred into aliquots for intact Aβ1-42 characterization and enzymatic digestion,
respectively.

2.3.4 Proteolysis
Urea was added to each 20 μL aliquot of the FPOP-labeled Aβ1-42 sample to give a final
concentration of 6 M. Lys-N was then added with an enzyme to protein ratio of 1:10 (w/w). The
concentrated urea facilitated rapid digestion and prevented hydrophobic peptides from selfassembly during digestion. Samples were incubated at 45 oC for 30 min. The digestion was then
quenched by adding trifluoroacetic acid to a final concentration of 1% (by volume).

2.3.5 Mass spectrometry
For intact Aβ1-42 characterization, 20 μL of the FPOP-labeled sample was directly submitted to
an Agilent 1100/1200 separation system at a flow rate of 200 μL before being admitted to a
MaXis 4G quadrupole-time-of-flight (Q-ToF) mass spectrometer (Bruker Daltonics, Billerica,
MA). Solvent A was water + 0.1% formic acid, and solvent B was 80% acetonitrile + 0.1%
formic acid. The gradient started from 5% B and increased to 15% B in 0.3 min, ramped to 50%
B in 5.2 min, increased to 100 % B in 0.5 min, held at 100 % B for 0.5 min, returned to 5% B in
0.1 min and equilibrated at 5 % B for 2 min. The mass spectrometer was operated in the positiveion electrospray ionization mode at a mass resolving power of 30,000 (m/z 400).
For peptide and residue level analysis, 5 μL digested sample was submitted to LC-MS/MS
analysis. Samples were pre-concentrated on an Acclaim PepMap C18 column (Thermo
Scientific, 100 µm × 2 cm, 5 μm, 100 Å) and desalted for 15 min before elution. Separation was
performed on a 15 cm custom-packed C18 column (Magic, 75 µm × 15 cm, 5 μm, 200 Å)
maintained at 65 oC by using a Nano UltiMate 3000 Rapid Separation system (Dionex, Co.).
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Solvent A and B were the same as above. Peptides were eluted at a flow rate of 700 nL/min with
the following gradient: 2% B to 20% in 1 min, ramped to 70% B in 10 min, increased to 90% in
1 min, held at 90% for 3 min, returned to 2% B in 1 min, and equilibrated at 2% B for 4 min. LC
separation was directly coupled to online detection using a Q Exactive Plus hybrid quadrupole
orbitrap mass spectrometer with a Nanospray Flex ion source (Thermo Fisher, Santa Clara, CA).
The top ten abundant ions seen in the mass spectrum were subjected to higher energy collision
dissociation (HCD) for identification and characterization of possible FPOP modifications. The
mass resolving power was 70,000 (m/z 400) for MS1 and 17,500 (m/z 400) for MS/MS.

2.3.6 Data analysis
Whole protein-level analysis with the custom program afforded the fraction of unmodified Aβ1-42
after FPOP for all samples. Signal intensities for the modified (Iox) and unmodified species (I)
were integrated from the raw data files, either with the custom program for the intact Aβ1-42 or
Thermo Xcalibur for the digested peptide and residue-level analysis. The extent of modification
was calculated by using the following equation, as previously described,25
Eq. 2.1

% 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 = Σ𝐼

Σ𝐼𝑜𝑥

𝑜𝑥 +∑ 𝐼

× 100

For analysis of Aβ1-42 digested peptides, product-ion spectra obtained with the orbitrap mass
spectrometer were searched for peptide identification by using Mascot (Matrix Science, London,
UK) software. Mass of unmodified peptides and assigned modifications validated by manual
inspection were input into an inclusion list to afford better sampling and identification of FPOP
modifications.
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Figure 2.5. An example of FPOP identification. (A) Mass spectra of peptide 16-27 (doubly
charged), unmodified peptide (top), and modified peptide (bottom). (B) Product-ion spectra
(MS/MS) of the unmodified (top) and modified (bottom) peptide 16-27. The MS/MS spectra of
the modified peptide was integrated over the signal with the retention time of 10.2 min and
indicates FPOP oxidation on F20 of Aβ1-42.
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Modification sites on the peptide were assigned on the basis of product-ion (MS/MS) spectra
(Figure 2.5). In a few cases, the location of a modification to a single residue was not possible
owing to limited fragmentation information from MS/MS or to the presence of interference from
co-elution of peptide isomers. In that case, the modification was indicated to occur on a set of
possible residues. For any specific residues, the fraction modified was calculated by the
following equation as the ratio of the signal of each peptide modified at that residue
( Σ𝐼𝑜𝑥 𝑜𝑛 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑋 ) to the total intensity of modified and unmodified peptide signal spanning this
residues.26
Eq. 2.2

For amino-acid residue, % 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 =

Σ𝐼𝑜𝑥 𝑜𝑛 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑋
Σ𝐼𝑜𝑥 +∑ 𝐼

× 100

2.3.7 Kinetic Modeling
The fraction of FPOP modified molecules was modeled on the basis of Scheme 2.1 by using six
rate constants as model parameters (see “Fitting Parameters” in SI). The overall FPOP fraction
modified F(t) was computed as shown in Eq. 2.3 from the species concentrations ([D], [D*],
[D**]), which varied with time, and the species fraction-modified (𝐹0, ΔFD, ΔFD*, ΔFD**) that
are also model parameters. 𝐹0 is the fraction modified for Aβ1-42 monomer. The monomer
concentration [M] is implicated by the experimental starting concentration of the monomer MT.
Eq. 2.3

𝐹(𝑡) = 𝐹0 − (

𝛥𝐹𝐷∙2[D]
𝑀𝑇

+

𝛥𝐹𝐷 ∗ ∙2[D∗ ]
𝑀𝑇

+

𝛥𝐹𝐷 ∗∗ ∙2[𝐷 ∗∗ ]
𝑀𝑇

)

The model curve fractions modified F(t) were calculated by solving differential equations (see
“Fitting Parameters” in SI) representing each reaction in Scheme 2.1 with are time-dependent
species concentrations and the postulated species fractions modified (𝐹0, ΔFD, ΔFD*, ΔFD**).
The quantities of ΔFD, ΔFD*, ΔFD** are properties (in term of fraction modified) of the
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proposed Aβ1-42 species in various oligomeric states (monomeric Aβ1-42 as the reference). Note
that the definition of the fraction modified (Eq. 2.1) should not be interpreted in terms of intrinsic
reactivities with the hydroxyl radical; that is, the differences in the fraction modified signaled the
presence of different Aβ1-42 species with a characteristic protection level.
The process for determining the model parameters and the kinetic curve was implemented in
Mathcad v.14.0 M020 (Parametric Technology Corp.). The "Nonlinear Quasi-Newton" mode
was used in the "Minimize" function in a search for the solution model parameters. In each trial,
the postulated normalized rate constants were converted to their physical values by
multiplication by the initial physical rate constants to accommodate the numerically large range
of rate constants. The adaptive step-size fourth order Runge-Kutta "Rkadapt" function was then
used to solve the system of ordinary differential equations corresponding to Scheme 2.1 with
initial conditions that all concentrations were zero except [M] = MT = 10 μM.
Generally, all ten model parameters were varied in a search to minimize the root-mean of the
squares of the residuals between experiment data and model curve as shown in Figure 2.8 for
Aβ1-42 and the solid curves shown in Figure 2.10 and Figure 2.11. For the dashed curves in
Figure 2.10 and Figure 2.11, all rate constants were fixed to the values obtained from the model
whose curve is shown in Figure 2.8A for Aβ1-42 while the four postulated species fractions
modified were varied.
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2.4 Results and Discussion
2.4.1 Aggregation of Aβ1-42 at the global (protein) level
Given that Aβ1-42 aggregation is time-sensitive and continues after footprinting, it is important to
utilize an irreversible footprinting “snapshot” to capture accurately the oligomerization
intermediates. In our triplicate experiments, formation of Aβ1-42 aggregates begins with
incubating Aβ1-42 monomers in PBS buffer for up to 48 h (Figure 2.6), followed by footprinting
of the protein occurring after irradiation by a labeling laser pulse in a flow system. MS analysis
gives representative mass spectra of intact Aβ1-42 labeled by hydroxyl radical. The oxidative
labeling occurs at solvent-accessible Aβ1-42 side chains to give variously labeled proteins
observed as isotopic clusters (Figure 2.7).
▪ Dilute with PBS (pH 7.4)
▪ Initiate aggregation

▪ Dissolve in 3 mM
NaOH (pH 12)

▪ Mix with H2O2 and
scavenger
Unmod.

t1

mix
sonicate

t2

FPOP

LC-MS

t3

+16Da
+32Da
+48Da

Mass/charge

solid Aβ1-42

monomeric
Aβ1-42 solution

Aβ1-42 aggregates of
various oligomeric
orders

FPOP-modified Aβ1-42

FPOP modification profile
(5+ charged of Aβ1-42 )

Figure 2.6. Preparation of Aβ1-42 aggregates for LC-MS analysis.

Owing to its intrinsically disordered structure, 77% of unfolded Aβ1-42 monomers undergo
modification (Figure 2.7B) at short times. As Aβ1-42 adopts some conformational order by
folding into higher-order oligomers, it loses solvent accessibility, gains protection, and
undergoes correspondingly decreased FPOP modification (Figure 2.7C-E). At the longest
incubation times, Aβ1-42 becomes highly resistant to modification, indicating formation of mature
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aggregates, presumably with beta-sheet bundles (Figure 2.7F).10,

27

The FPOP modification

pattern for various charge states of Aβ1-42 produced in the electrospray ionization are consistent,
as expected, with a relative error of less than 2% for the calculated extent of modification of
various charge states.
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Figure 2.7. Mass spectra showing extents of FPOP modification for intact Aβ 1-42 (5+
charged) as a function of incubation time. (A) Aβ1-42 monomer as a control with all reagents,
including H2O2, added and flowed through the FPOP tubing but without laser irradiation, (B)
extensively hydroxyl radical-modified, unstructured Aβ1-42 monomers, (C-E) decreasing FPOP
modification extents of Aβ1-42 aggregates, reflecting increasing structural protection to FPOP
modification, (F) minimal Aβ1-42 modification, reflecting solvent-inaccessible, highly ordered
core structure of the fibrillar aggregates that resist FPOP modification. In B-F, t represents the
time of incubation.

45

We calculated the fraction modified of the full-length Aβ1-42 and its digested peptide (as
discussed later) from the ratio of the signal of the modified peptide (Iox) to that of the total
amount of the modified and unmodified peptides (I) (Eq. 2.1), as described in the experimental
section. By adopting this metric, we can pursue the change in the amount of modified species
raised from Aβ1-42 conformational change, regardless of the intrinsic reactivity or reaction
kinetics of the peptide with hydroxyl radical. The use of the above metric for quantifying the
level of modification is not unusual (see Xie and Sharp28). Here the fraction unmodified is
directly inferred as one minus fraction modified, and for a given peptide or residue it increases
monotonically (because it is the product of the fraction unmodified at each reaction site) as the
reactivity of the overall peptide or specific residue decreases owning to Aβ1-42 association. The
sensitivity of this metric to increasing reactivity diminishes, however, as the percent unmodified
becomes very small. For small proteins like Aβ1-42 and, more importantly, for amino-acid
residues, the relative amount of the unmodified species remains high; thus, this is of minor
concern under the conditions of our footprinting.
Another possible concern for processing modified peptides is that some residues can decrease in
reactivity while others increase. One might suggest as a solution to this concern a metric in
which the intensities of oxidized species are weighted by the number of oxygens.29 This would
be analogous to the centroid calculation often used as an algorithm for HDX footprinting of
proteins. This proposed solution does not always address the issue30 and has the potential to
magnify uncertainties arising from signals with low signal-to-noise ratio.31 A similar problem
applies to centroid calculations (i.e., weighing the intensities by the number of modifications) in
hydroxyl radical footprinting. Therefore, we choose the metrics (Eq.1) that does not compromise
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the accuracy in quantification and meanwhile sufficiently provides insights in reporting the
conformational change of Aβ1-42 as it associates.
The oxidation patterns of Aβ1-42 at various incubation times in the FPOP experiment follow a
Poisson-distribution;25 that is, the signal of unmodified Aβ1-42 is the most intense, followed by
those corresponding to the oxidized species with the mass shifts of +16, +32, +48 Da etc. in a
sequentially descending manner. The patterns of various extents of oxidation follow this manner
as the overall oxidation level decreasing owning to the folding of Aβ1-42.

2.4.2 Structural Rationalization of Multiple Kinetic Phases
The hydroxyl radicals are comparably sized as water molecules, allowing them to modify
solvent-accessible side chains and report on the transient states of soluble aggregates. We chose
to model the Aβ1-42 aggregation kinetics, observed at 25 oC (Figure 2.8A), on the basis of the
nucleation-autocatalytic growth mechanism proposed by Finke et al.32 with modifications that
address the transient stages observed in the present case.3, 33 This modeling approach is perhaps
the simplest model that accounts for the various stages of aggregation. Two nucleation and two
autocatalytic reactions, as shown in Scheme 2.1, were used to describe the time-dependent
aggregation of Aβ1-42, one more stage than seen by fluorescence and pulsed HDX.
With kinetic modeling (see experimental section) based on Scheme 2.1 and support from other
published work,3, 14, 33 we can follow the aggregation through five stages: AB, BC, CD, DE, and
EF (Figure 2.8A), instead of the four observed previously by pulsed HDX and fluorescence. 17, 19
In the modeling, our assumption is that the monomer concentration at time zero is 10 μM, which
is the concentration upon diluting Aβ1-42 into the PBS buffer, and the solution at that time is free
of oligomers.
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A

B

Figure 2.8. Characterization of Aβ1-42 aggregation on the global (full-polypeptide) level by a
kinetic simulation. (A) points represent experimental data (10 μM, 25 oC, pH 7.4, no agitation),
and the solid curve is a model fit based on two autocatalytic reactions. The inset in (A) shows a
comparison of the fitting with and without the consideration of the 2-min FPOP dead time. (B)
Time-dependent concentrations of the various Aβ1-42 species from the solution to the differential
equations of the fitted model in (A). M-monomer; D-dimer; D*-product of 1st catalytic reaction,
D**-product of 2nd catalytic reaction. For each species, the concentration is of monomeric Aβ1-42
equivalents.
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The stage resolved additionally by FPOP is represented by transition from D to F, which leads to
the formation of lateral protofibrillar and then to fibrillar aggregates, whereas the transition is a
single growth phase in the pulsed HDX and fluorescence platforms. In Figure 2.8A, the first
stage corresponds to (1) Aβ1-42 monomers assembling rapidly to form dimers and small
oligomers. As the monomers continue to oligomerize, their solvent accessibility and concomitant
FPOP reactivity decrease in a fast, exponential-like manner (AB). (2) The early-formed small
oligomers cooperatively nucleate to provide paranuclei-like “seeds” for subsequent aggregation
(transition BC). During this time, the oxidation extent cannot significantly change because the
monomers have almost ceased to disappear. (3) As the concentration of “seeds” reaches a critical
threshold, larger oligomers form in an autocatalytic fashion (transition CD).34 (4) Lateral
oligomers

likely

with

the

beta-strand

structure

associate,

elongate

into

large

aggregates/protofibrils presumably with in-register beta sheets (transition DE),33, 35 and (5) large
aggregates/protofibrils further associate and catalyze the reorganization of other Aβ1-42 species
into mature fibrils presumably with the well-defined beta-sheet structure (transition EF).10

Transition A-B.

M+M⇌D

(dimerization)

Lag stage B-C.

D → D*

(1st nucleation)

Transition C-D.

D + D* → D*+D*

(1st autocatalytic reaction)

Lag stage D-E.

D* → D**

(2nd nucleation)

Transition E-F.

D*+D** → D** + D**

(2nd autocatalytic reaction)

M- monomer
D- dimer

D*- product of 1st catalytic reaction
D**- product of 2nd catalytic reaction

Scheme 2.1 Proposed kinetic scheme for Aβ1-42 aggregation.
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We chose Scheme 2.1 to support the observation that there are additional stages reported in the
aggregation kinetic curve while applying the principle of parsimony in modeling. The monomer
to dimer transition (reaction A-B) is illuminated by the work of Frieden et al17, in which early
changes in their kinetic curves with different starting Aβ concentrations behaved consistently
with a model of dimer and trimer formation. Here we have not deployed the trimer formation
component because we argue that the amount of additional protection afforded by the trimer over
the dimer is not sufficiently large to justify the additional parameters that the trimer would
require in the scheme. Visual inspection of the kinetic curves shows two steps; each step is
characteristic of a slow nucleation phase (reaction B-C and D-E) followed by a rapid
autocatalytic growth phase (reaction C-D and E-F). Given there are two steps, we invoked the
Finke-Watzky two-step mechanism twice in succession, which might be described as double
autocatalytic.36
The use of the Finke-Watzky two-step mechanism does have limitations. It does not account for
the equilibrium between the Aβ1-42 monomer and other species.37 An alternative and still minimal
model that addresses this issue is by Crespo et al38. In addition, nucleation and autocatalysis
models augmented with fibril growth and fragmentation fail to match correctly the lag time
scaling as a function of monomer concentration for a number of fibrilizing protein systems.39
The time for the each Aβ1-42 passing through the FPOP workflow is 2 min; thus, for each
experimental time point, the FPOP fraction modified quantifies an assemble average of Aβ1-42
conformations over that 2 min in addition to the reported aggregation time. Although this “dead
time” in FPOP will have a minor influence on the samples with long-time incubation, it may
affect the early-stage characterization of the curve as the monomer will aggregate to some extent
in this short period of time. To test, we repeated the simulation by shifting the actual time of
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aggregation by 2 min as a maximum and extrapolated the curve to the actual start point. We
found the overall fitting of the aggregation curve is not significantly affected by considering the
FPOP dead time. In a zoom-in view of the first 60 min (inset in Figure 2.8A), the “-2 min” on the
time axis of the solid grey curve is regarded as the actual starting point of the aggregation that
modeled in the testing trial. The outcomes overlap well with curve neglecting the 2 min (dashed
blue) even for the early aggregation stage as one can think it as the aggregation curve is rightshifted by 2 min. According to the kinetics revealed by TMR fluorescence, which does provide
clearer time resolution for the first a few minutes of Aβ1-42 aggregation, the initial exponential
decrease in fluorescence intensity representing the monomer-dimer-trimer transition proposed
happens over 30-45 min for the Aβ1-42 with concentrations ranging from 0.5 μM up to 4 μM with
stirring the solution.17 From the pulsed HDX results, although the initial phase is not well
defined, it shows a burst tendency of increasing protection over 30 min for Aβ1-42 of 50 μM
without any stir.19 Taken these observations together, we believe that it is unlikely that the dead
time from the FPOP labeling has a substantial influence on the aggregation kinetics. If a burst
phase occurred so rapidly in the 2 min prior to laser irradiation to initiate FPOP such that we no
longer can explain transition AB, the kinetics will need to be addressed by involving a model
justifying the additional conformation change in the burst phase as well as transition AB tandem
to it.
Although we calculated the reaction rate constants for each stage by solving the differentialequation for each reaction in Scheme 2.1, we are not quoting them because they do not directly
relate to the actual rate constants. Each rate constant in the model is condensed and simplified as
a summary of many underlying reaction steps.32 The “dimer” species, for example, is expected to
be made up of many species, each formation with its own rate constant. Others noted that
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nucleation rate constants for the lag phase are unreliable.39 Reliable rate constants associated
with the growth phases require representation of the maximum slopes during the growth phase,
which are not present in the data. Nevertheless, we can specify the species concentrations as a
function of the time obtained from the model and describe the disappearance of Aβ1-42 monomers
(M) and the formation of various oligomer including paranuclei (D), protofibrils (D*) and fibrils
(D**) (Figure 2.8B). In the experiment, the initial concentration of Aβ1-42 monomers is 10 μM.
In the early oligomerization, ~30% of the monomers rapidly assemble into low-MW oligomers
(solid black curve), followed by a lag phase during which low-MW oligomers slowly accumulate
until the concentration is sufficient to catalyze (seed) the formation of larger oligomers (dashed
black curve). As the amount of large aggregates/protofibrils reaches a concentration
corresponding to ~80% consumption of the original monomer equivalents (dashed grey curve), a
structural reorganization occurs to deplete the monomers and form rapidly mature fibrillar
aggregates (solid grey curve). At the end of the aggregation, equilibrium is nearly achieved for
fibrils and persistent, leftover monomers (~10%). At this stage, the rapid second autocatalytic
reaction almost shuts down the first autocatalytic reaction, and, as a result, the monomer
concentration becomes relatively stable.
A previous study shows that Aβ1-42 and Aβ1-40 have distinct aggregation pathways.6 The assembly
of Aβ1-42 involves formation of several distinct transient structures to form paranuclei that
assemble further to form superstructures similar to early protofibrils, whereas Aβ1-40 mainly
forms low-MW oligomers at a much slower rate than that of Aβ1-42 at similar concentration.3, 19
We have preliminary results from the FPOP study of Aβ1-40 under the same conditions (10 µM,
pH 7.4, 25 oC, no agitation) as for Aβ1-42 that this proteoform shows extensive but relatively
constant FPOP modification over the time scale we investigated (0~48 h) (Figure 2.9A),
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indicating that it is considerably less reactive than Aβ1-42 in term of the aggregation propensity.
Further, we examined the aggregation of Aβ1-42 at 37 oC (Figure 2.9B). The higher temperature
accelerated Aβ1-42 aggregation substantially without showing any lag or intermediate phases.
Within the first 8 h of incubation, the FPOP fraction modified decreases sharply and then levels
off, suggesting either the nucleation process happens so rapidly that no apparent lag phase is
observed or the oligomerization pathway changed from a self-catalytic seeding mechanism.
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Figure 2.9. Aggregation of Aβ1-40 at 25 oC and of Aβ1-42 at 37 oC. (A) Mass spectra of Aβ1-40
(5+ charged) with 0 min and 45 h incubation, 10 μM, 25 oC, pH 7.4, no agitation. (B) Aβ1-42
aggregation curve, 10 μM, 37 oC, pH 7.4, no agitation.
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2.4.3 High Resolution View of Oligomerization
The FPOP approach permits a high-resolution view of the oligomerization down to even the
amino-acid level for some residues. To interrogate the conformational changes at a regional
level, we proteolyzed the irreversibly footprinted protein and analyzed the resulting peptides by
LC-MS/MS. Normally, this is a straightforward process for soluble proteins, but Aβ1-42 and its
hydrophobic C-terminal proteolytic fragments continue to associate during the digestion,
resulting in appreciable resistance to long-term proteolysis, a loss in mass spectral signals, and a
possible bias towards those regions that are less prone to association.19, 27 These compounded
issues motivate a kinetic study that targets high structural resolution by effective and rapid
digestion of Aβ1-42 aggregates. We used Lys-N protease under optimized digestion conditions to
address successfully this issue. Taking advantage of Lys-N maintaining its high enzymatic
activity in 6 M urea,40 we reconstituted a post-labeling aliquot of Aβ1-42 in 6 M urea and
incubated it with Lys-N (enzyme: protein ratio of 1:10 (w/w)) at 45 oC to digest the Aβ1-42 as
quickly as 30 min. The high-concentration of urea present in the digestion not only affords rapid
proteolysis by denaturing Aβ1-42, but minimizes non-covalent association of the hydrophobic
peptides. More importantly, Lys-N cleaves Aβ1-42 at the amino side of lysine residues, leaving
the hydrophilic residue K28 on the highly hydrophobic C-terminal proteolytic fragment, thereby
increasing the sensitivity by two orders of magnitude for the peptide covering this region
compared to the corresponding peptide formed when trypsin is used (data not shown), improving
quantification and accuracy.
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2.4.4 Aggregation of Aβ1-42 at the Peptide and Residue Levels

A

B

C

Figure 2.10. Time-dependent FPOP labeling of Aβ1-42 incubated at 25 oC, pH 7.4, no
agitation and kinetic simulations for Lys-N digested Aβ1-42 peptides. Oligomerization of (A)
N-terminal region 1-15, (B) middle region 16-27, and (C) C-terminal region 28-42. Solid curves
are simulations that afford rates constants for each peptide treated independently, whereas the
dashed curves are simulations constrained by global rates.

We characterized further the conformational changes in aggregation for the regions represented
by the three peptides resulting from Lys-N digestion (N-terminal region 1-15, middle domain 1627, C-terminal region 28-42). We simulated the kinetics for each region by using the model
described above (Figure 2.10), both independently and constrained by the outcome of the global
(protein)-level rate constants. As discussed above, we expect regions that undergo
conformational changes and serve as oligomerization interfaces to exclude solvent and show
decreased oxidative modification. The different scales of fraction modified for each peptide is
related to the distinct reactivities of the corresponding Aβ1-42 sub-regions. The reactivity is a
function of: 1) the intrinsic reactivity of those sub-regions as contributed by the amino acid
residues with respect to its primary sequence, and 2) the protection from the secondary and/or
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ternary structure of Aβ1-42 for that sub-region. Given that FPOP modification of the N-terminal
peptide does not change significantly as a function of aggregation time, this region must remain
structurally flexible with little self-association and little loss of solvent accessibility as Aβ1-42
associates. This is in accord with solid state-NMR data, indicating that the N-terminal region
remains disordered in various Aβ1-42 oligomers and fibrils.2, 9 In contrast, the extent of FPOP
modification significant decreases (protection increases) over time for the middle domain peptide
16-27 and the C-terminal peptide 28-42 (6 and 2.5 times decreases in rate from Aβ1-42 monomers
to fibrils, respectively). This indicates convincingly the importance of those two regions in Aβ1-42
aggregation whereby the central region must play a prominent role and serve as the selfassociation interface to drive aggregation. This is key experimental evidence that the middle
region is a nucleation interface, as suggested by molecular dynamics studies.35, 41
The peptide-level results are better modelled by allowing the rate constants for each peptide
region to be independent (Figure 2.10, solid curves). When the modeling is restricted by the rate
constants from fitting for the whole protein, we find relatively pronounced discrepancies
between the results and the simulated curves (Figure 2.10, dashed curves). Assuming the
discrepancy is not solely contributed by any structural bias in the digestion, we suggest that
regions of Aβ1-42 act nearly independently in the oligomerization of Aβ1-42 and that the local
(regional) rates are not predictable from the kinetic results for the whole protein. Notice that in
the pulsed HDX, the “half lives” of the peptide-level transitions are also different19 and show that
the center and C-terminal regions are more important in the oligomerization than is the Nterminus.
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Figure 2.11. FPOP results for Aβ1-42 amino acid residues and kinetic simulations. (A) H6
showing little participation in the oligomerization, (B) H13 showing slightly increasing
modification initially and then level off, (C) and (D) F19/F20 and M35 showing large changes of
solvent accessibility along with oligomerization (FPOP modifications on F19 and F20 were
summed to improve accuracy in quantification).

Furthermore, measuring the modification at the amino-acid level allows characterizing
aggregation tendencies for Aβ1-42 at that level at least for some of the amino-acid residues
(Figure 2.11). The oxidative modification on the residue level was assigned by using the production spectra of the modified peptide precursor ion. Their aggregation curves are generated based
on measuring the ratio of the signal abundance from that specific oxidized residues to the total
amount of the peptide observed that contained that residue (see experimental section). The
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modification for H6, H13, F19, F20 and M35 are well resolved chromatographically with
quantifiable extent of oxidation at better than a signal-to-noise ratio of 10:1. We also identified
FPOP modifications on H12, L17, V18, V39/V40/I41. The extent of modification for those
residues, however, is of very low abundance (less than 1%) and not well sampled; and thus in the
present case not quantified.
Residues H6 and H13 show an overall constant extent of FPOP modification during aggregation,
indicating that few conformational changes occur for these two residues (Figure 2.11).
Interestingly, for H13 despite showing little change in the fraction modified, this residue shows a
clear trend of an initial increase in FPOP modification within the first 30 min, suggesting this site
becomes relatively solvent-exposed and could be a critical nucleation site either to promote or
delay the next transition. Note that the absolute FPOP modification extents for residues of the
same type are only related to the surrounding steric environment and protection.

The

modification extent of H6 is 40% and of H13 is 19%, whereas that of H12 is too low to
characterize accurately. These results suggest that, although the N-terminal region remains
structurally disordered during aggregation, the solvent accessibilities of these residues represent
different microenvironments. H6 is the most solvent-exposed among the three, followed by H13
and then H12. For F19 and F20 we summed the FPOP modifications before plotting those
values. These two residues show a decrease in FPOP modification extent by 4.5 times in going
from monomers to fibrils, and M35 from the C-terminal region showed a similar decrease of 2.5
times (Figure 2.11). For the middle domain of Aβ1-42 represented by peptide 16-27, the
difference in modification largely occurred on F19/F20, because not only is phenylalanine highly
reactive to hydroxyl radical compared to other nearby residues42, but their high hydrophobicity
potentially driving the oligomerization. We envision that the ability of FPOP to reveal the site58

specific aggregation can be applied to understand interactions of Aβ with other molecules,
especially drug candidates that affect oligomerization.

2.4.5 Results from Complementary Biophysical Tools
Many available biophysical tools provide complementary results in tracking Aβ assembly. We
are limiting our comparison to those that can follow the time course of aggregation under
physiologically relevant condition. We are not considering the many approaches that view Aβ as
its initial, largely low-MW oligomers (e.g., solution NMR) or in its final aggregated state (e.g.,
solid state NMR). Among the methods tracking aggregation, ThT dye fluorescence is regularly
used to follow amyloid formation. The dye undergoes a large enhancement in fluorescence upon
binding to amyloid fibrils, making it a particularly powerful and convenient tool. A typical ThT
fluorescence curve reports a single sigmoid including a lag phase and a rapid growth phase to
form fibrils. Because ThT primarily interacts with β-sheet structure, this method is less suitable
to study the amorphous oligomers lacking well-defined β-strand structure. ThT does not give
site-specific information on the oligomerization. Furthermore, because ThT bears structural
similarities to many amyloid inhibitors, it is possible that ThT can influence the fibril structure
and the formation kinetics.18
The recent development of TMR, as an alternative fluorescence dye, affords a more informative
sigmoidal curve. In this experimental design, Aβ was pre-modified to carry an extra lysine
residue that was covalently linked to the TMR molecule at the N-terminus of Aβ.17 Unlike in the
ThT assay, fluorescence quenching due to the proximity of the TMR molecules was detected as
Aβ associates. This assay characterized the early-stage oligomer formation by showing an initial
exponential drop in TMR fluorescence intensity before the emergence of the first lag phase.
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This, like all the fluorescence methods, however, suffers from the need to modify the Aβ, a
polypeptide whose aggregation is highly sensitive to its length and size (consider the difference
between Aβ1-42 and Aβ1-40).
We found similar results with pulsed HDX as with TMR. In the pulsed HDX method, the
hydrogen on Aβ backbone amide is in exchange with the deuterium in the solvent, and the level
of deuterium-uptake within a certain short time window reflects changes in the conformation of
the polypeptide backbone.19 This approach, although yielding regional information, is not highly
sensitive.
More recently, using high resolution AFM, Buratto, Bowers, and co-workers15 found that Aβ1-42
hexamer- and dodecamer-sized structure become dominant in as short as 5 min, and the density
of large spherical aggregates termed preprotofibrils grows considerably by 20 min. This result
brings new insight, but it may be confounded by surface effects because a subset of protein
aggregates may be preferentially deposited on the surface for AFM and the interactions between
the protein and the sample surface can affect aggregate morphology and formation kinetics.43-44
Therefore, comparisons of solution measurements by fluorescence and MS footprinting with
measurements from using sample deposition will require careful interpretation. The former
approaches map co-populated species in a mixture, and report Aβ1-42 conformation quantitatively
as an assemble average of structural protection in bulk solution without pointing to individual
oligomers; the latter provides a visualization of the oligomer morphology at certain oligomeric
orders (e.g. hexamer and dodecamer). Note, as we discussed above, the initial burst phase of the
early oligomerization is represented by an exponential decrease in fluorescence intensity in the
TMR assay and a rapid increase in the structural protection in pulsed HDX experiment. This
phase occurs over a time scale of 30-60 min, with our outcome from the FPOP experiment
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falling in the same range. Considering the vast complexity and high sensitivity of Aβ1-42
oligomerization towards external conditions, experimental phenomena observed in various
approaches are not necessarily proportionate in terms of the time scale, and it is sensible for us to
the set our sights on the general trends.
More importantly, caution is needed to correlate the “phases” observed using various available
tools. The molecular-level mechanisms of the probes used in each method discussed above,
including FPOP, differ significantly. The aggregation of Aβ, especially of Aβ1-42 under study, is a
process highly sensitive to buffer conditions, concentration, temperature, pH, agitation etc.
Therefore, the observed phases uncovered by these methods can be different. For example, using
an equivalent Aβ1-42 system, the growth phase indicated by ThT fluorescence comes later than
that observed in the TMR assay.17 In addition, we do not expect the fluorescence and HDX data
to fit into Scheme 2.1 because we invoked the double-catalytic reactions to address the five
distinct stages revealed uniquely by FPOP. In the FPOP approach, the footprinting reagent, here
a hydroxyl radical, is comparably sized to water molecules and directly modifies the solventaccessible amino-acid side chains of Aβ1-42. The probe is sensitive to subtle conformational
changes involving the transient states, especially those in which Aβ1-42 side chains are involved
(e.g., several protofibrillar filaments twist to form bundles of mature fibrils, in which case the
polypeptide backbone stays relatively unchanged.10-11).

2.5 Conclusions
FPOP footprinting provides new, in-depth insights into Aβ1-42 conformational changes and its
aggregation by affording structural resolution even down to the amino-acid residue level. It not
61

only defines the early oligomerization stages but also reports subtle conformational changes that
occur after early beta-strand formation, allowing the intermediate transitions to be effectively
resolved to reveal the multi-step nature of oligomerization. We chose to model the aggregation
curve by two autocatalytic reactions based on a modified Finke-Watzky mechanism, being
attracted by the simplicity of this model. The successful fit of the observed aggregation kinetics
to two-sigmoid model provides more insight on the molecular mechanisms involved in Aβ1-42
self-assembly.
The FPOP approach overcomes most of the weaknesses of other methodologies used to study the
time-dependent amyloid formation by affording a direct, real-time, fast, and accurate
measurement of the solvent accessibility of Aβ. Moreover, applications of the platform can be
extended to address the effects of pH, concentration, agitation, and Aβ modification on
aggregation. We expect this measurement strategy to be utilized further to guide the design of
optimal compounds that inhibit Aβ aggregation and/or toxicity, and to be extended to the
evaluation of other amyloidogenic proteins.
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Chapter 3: Fast Photochemical Oxidation of
Proteins Characterizes the Interaction of a
Small Molecule Inhibitor on Amyloid Beta 142 Aggregation
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3.1 Abstract
Significant evidence has linked aggregation of amyloid beta (Aβ) to the pathogenesis of
Alzheimer's disease, motivating the development for small molecules that prevent aggregation.
Study of anti-amyloid compounds suggest that many small molecules may re-direct the
aggregation cascade rather than completely inhibiting it. Here, we describe an application of Fast
Photochemical Oxidation of Proteins (FPOP) to evaluate the effect of a polyphenolic compound
derived from curcumin in remodeling the aggregation pathway of Aβ1-42. We find that the small
molecule inhibits aggregation by maintaining Aβ1-42 in LMW oligomers, resulting in an extended
lag phase prior to the rapid formation of fibrils. The compound presumably interacts with the Nterminus of Aβ1-42, “caps” oligomers, and slows down stacking of oligomers, as evidenced by the
reduced solvent accessibility of the N-terminal region in the remodeled Aβ1-42. The compound
also destabilizes the middle region, which has been hypothesized to serve as the nucleation
interface, whereas the C-terminal region is minimally affected. FPOP effectively reveals the
effect of the compound on aggregation by accurately reporting the solvent accessibility changes
of Aβ1-42 with peptide and even some amino-acid readouts, providing insights into the pathway
of Aβ1-42 aggregation and the mechanism of inhibition of anti-amyloids. Our approach
overcomes major limitations of the widely-used Thioflavin T fluorescence assay for monitoring
amyloid formation, including low spatial resolution and biased readout due to presence of
exogenous inhibitors with intrinsic fluorescence (e.g., polyphenols).
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3.2 Introduction
Accumulation and aggregation of Aβ peptides in the brain are critical pathogenic events in
Alzheimer's disease. The exact pathway of Aβ aggregation, however, is not fully understood. A
general view of Aβ aggregation involves formation of dimers and soluble oligomers followed by
growth into protofibrils and fibrils via a complex multistep-nucleated polymerization.1-3 From
previous studies in the aggregation mechanism of Aβ as well as from the insights described in
Chapter 2, this process involves the following features: (i) nucleation dominated by a fast, short
initial phase to form soluble, low-molecular-weight (LMW) oligomers, (ii) assembly of the
LMW oligomers into larger oligomeric states with defined beta-sheet structure, (iii) association
and elongation of the β-sheet-rich oligomers into higher-order protofibrillar aggregates, and (iv)
reorganization of the higher-order intermediate aggregates to form mature fibrils.
Initially, fibrils were considered to be the molecular culprit in AD. The accumulation of amyloid
plaque, however, does not correlate well with AD pathogenesis.4 More recent evidence has
supported that the soluble Aβ oligomers or prefibrillar aggregates are the causes of synaptic loss
and cognitive impairment.5-6 Although precise relationships between the oligomeric states of Aβ
aggregates and the disease remain to be established, the connection between Aβ aggregation,
cellular dysfunction, and AD suggests that anti-AD drugs targeting soluble Aβ oligomers could
hold considerable promise and ultimately lead to therapeutics that prevent and/or treat AD.
Over the past decade, significant research effort was made toward discovering and developing of
compounds that inhibit aggregation of amyloid proteins. These compounds, known as antiamyloids, show efficacy in preventing amyloid formation, disaggregating pre-formed fibrils and
reducing amyloid-induced cytotoxicity.7-8 Natural polyphenols, a class of compounds abundant
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in wine, tea and spices have captured considerable attention owing to their effective suppression
of amyloid formation.9 Inhibitory effects of several natural polyphenols, such as (-)epigallocatechin-3-gallate (EGCG), resveratrol, and curcumin (Figure 3.1) have been extensively
studied.10-13 Polyphenol inhibitors exhibit different interaction patterns and inhibition
mechanisms, but presumably remodel aggregation by interacting with the β-sheet, maintaining
the protein in a non-aggregated, soluble form or yielding nontoxic, off-pathway oligomers or
high-molecular-weight (HMW) aggregates.
The heterogeneity of Aβ aggregates, however, represent important challenges in structural and
functional characterization. In vitro aggregation assays require tools for detecting Aβ
oligomers/fibrils and monitoring the dynamic process in real time. In Chapter 2, we described the
development of the FPOP platform to monitor Aβ1-42 self-association by probing the solvent
accessibility change of the peptide. In this chapter, we describe an extension of the platform by
evaluating the effect of a curcumin derivative on Aβ1-42 aggregation. Curcumin (diferulomethane)
(Figure 3.1), found in the spice turmeric, is a potent antioxidant possessing anti-inflammatory
activities. It has been shown that curcumin directly binds to small Aβ species, prevents
oligomerization, and protects against Aβ-induced neurotoxicity.13-14

70

curcumin

resveratrol

EGCG

1
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Figure 3.1 Structure of curcumin, EGCG, resveratrol, compound 1, and compound 2.

Curcumin, however, does not have good therapeutic perspective owing to its poor metabolic
stability and limited blood–brain barrier penetration.15 Here, we studied two novel curcumin
derivatives,

(4aR,9R,9aR)-7-hydroxy-9-(4-hydroxy-3-methoxyphenyl)-8-methoxy-4,4a,9,9a-

tetrahydro-1H-fluorene-1,3(2H)-dione (compound1) and (4aR,9R,9aR)-7-hydroxy-9-(4-hydroxy3-methoxyphenyl)-6-methoxy-4,4a,9,9a-tetrahydro-1H-fluorene-1,3(2H)-dione (compound 2)
(Figure 3.1), on Aβ1-42 aggregation. Compound 1 and compound 2 are structural isomers
obtained from acid-catalyzed cyclization of curcumin. Our collaborator, Dr. George Mathai,
hypothesized that treating curcumin in acid would mimic the condition when curcumin is
ingested into the stomach. In our study, we first performed Thioflavin T (ThT) fluorescence
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assays to identify preliminarily in vitro the most potent inhibitors among curcumin and its two
derivatives. We then applied MS-based FPOP to investigate the effect of compound 1, the most
potent inhibitor among the three, on Aβ1-42 aggregation and reveal changes in the behavior of
Aβ1-42 sub-regions in the presence of compound 1. This study, together with that detailed in
Chapter 2, demonstrates the capability of the FPOP platform as a sensitive tool to monitor
amyloid formation and to evaluate crucial factors affecting the aggregation.

3.3 Materials and Methods
3.3.1 Materials
Synthetic human amyloid beta 1-42 (Aβ1-42) was from AnaSpec (San Jose, CA). Curcumin,
compound 1 and compound 2 were synthesized by our collaborator, Dr. George Mathai.
Hexafluoroisopropanol (HFIP), sodium hydroxide (NaOH), ThT, L-glutamine, L-methionine,
catalase, hydrogen peroxide (H2O2), phosphate buffer saline (PBS, 10 mM phosphate, 138 mM
NaCl, 2.7 mM KCl), urea, formic acid and trifluoroacetic acid were from Sigma Aldrich (St.
Louis, MO). Lys-N protease was from Thermo Scientific (Waltham, MA).

3.3.2 ThT fluorescence assay
To investigate the effect of the test compounds on Aβ1-42 fibrilization, 5 μL HFIP-pretreated Aβ142

dissolved 3 mM NaOH was sequentially mixed with 1 μL containing the test compounds in

PBS (or 1 μL PBS only for the control) and 1 μL ThT (1.5 mM in water), followed by a 1:20
dilution with PBS buffer to initiate aggregation. The final concentration of Aβ1-42 and ThT after
dilution were 20 μM and 15 μM, respectively. For each compound, two molar ratios, including
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1:1 and 1:5 of Aβ1-42 to the small molecule were examined. ThT fluorescence was measured in
duplicate using a SpectraMax M2e plate reader (Molecular Devices, San Jose, CA). Excitation
and emission wavelengths were 440 and 485 nm, respectively.

3.3.3 Sample preparation for FPOP
HFIP-pretreated Aβ1-42 was dissolved in 3 mM NaOH and incubated without stirring at room
temperature for 3 min followed by sonication for 1 min. Aggregation was initiated upon diluting
Aβ1-42 by 10 fold (v/v) with compound 1 in PBS (pH 7.4). The final concentrations of Aβ1-42 and
compound 1 after dilution were 20 M and 100 M, respectively. The solution mixture was then
incubated at 25 °C without stirring. For each time point, the incubation and analysis were done in
duplicate.

3.3.4 FPOP
At the various incubation times, Aβ1-42 was immediately submitted to FPOP labeling. FPOP was
performed as previously described,16 except no scavenger was added. This is because compound
1 is a hydroxyl radical-reactive polyphone and serves as the radical scavenger in FPOP. Briefly,
a laser beam from a KrF excimer laser (GAM Laser Inc., Orlando, FL, USA) of wavelength 248
nM was used to initiate H2O2 photolysis to give hydroxyl radicals. The Aβ1-42 in PBS was mixed
with 20 mM H2O2 just prior to injection into the flow tube for irradiation with the laser. The flow
rate was adjusted according to the width of the laser irradiation window to ensure 20%
irradiation-excluded volume and to minimize repeated laser exposure. The oxidatively modified
sample was collected in a tube containing 10 mM catalase and 20 mM methionine to decompose
leftover H2O2 and prevent oxidation-artifacts during storage. Control samples of Aβ1-42 in the
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presence of compound 1 were handled in the same manner as the experimental ones, but not
laser-irradiated.

3.3.5 LC-MS/MS
Digestion of the FPOP-modified Aβ1-42 and the subsequent LC-MS/MS analysis were adopted
from the previous established protocols described in 2.3.4 and 2.3.5 in Chapter 2.

3.3.6 Data analysis
Quantification of the FPOP modification was adopted from the previous established protocol
described in 2.3.6 in Chapter 2.

3.4 Results and Discussion
3.4.1 Potency of compounds active for inhibition of Aβ1-42 aggregation
ThT is a benzothiazole dye that undergoes enhanced fluorescence upon binding to amyloid
fibrils. It is the most commonly used probe for monitoring fibrillization kinetics in vitro. Using
fluorescence spectroscopy with ThT, we performed a global examination of the effects of
curcumin, compound1 and compound 2 on the aggregation of 5 μM Aβ1-42 incubated at 25 °C,
pH 7.4 (Figure 3.2). In our measurement, the fluorescence intensity at long times decreases
owing to precipitation of mature fibrils. Despite this, all the ThT fluorescence curves of Aβ 1-42
incubated under our conditions follow a characteristic sigmoidal curve representing a lag phase
and a growth phase in aggregation, consistent with the nucleation-dependent polymerization. In
the presence of curcumin or compound 1, the ThT fluorescence at the final equilibrium level are
lower than that in the ligand-free sample (Figure 3.2A and B), presumably due to the effective
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inner quenching of the ThT fluorescence by curcumin and compound 1 upon binding and
stacking in fibrils. This is, however, not observed in samples incubated with compound 2 (Figure
3.2C).

ThT florescence intensity

A

5 μM Aβ1-42
+ 5 μM Cur
+ 25 μM Cur

200

5 μM Aβ1-42
+ 5 μM Cpdm 1
+ 25 μM Cpdm 1

B 200

C

150

150

150

100

100

100

50

50

50

0

0
0

1000

2000

Time (min)

3000

4000

5 μM Aβ1-42
+ 5 μM Cpdm 2
+ 25 μM Cpdm 2

200

0
0

1000

2000

3000

4000

0

1000

Time (min)

2000

3000

4000

Time (min)

Figure 3.2. ThT fluorescence analysis of Aβ1-42 (5 μM) at 25 °C, pH 7.4. Aβ1-42 was incubated
in the absence and presence of 5 μM or 25 μM (A) curcumin, (B) compound 1, and (C)
compound 2. Data points are the mean of two independent measurements.

Despite the reduced fluorescence intensity at equilibrium owing to binding, curcumin did not
significantly affect the length of the lag phase prior to fibrilization. This observation is consistent
with the previous ThT study on the effect of curcumin on remodeling Aβ aggregation13. For the
inhibitory effect of curcumin, controversies arise as some results shows curcumin inhibits both
oligomers and fibrils formation14, whereas others found that curcumin inhibits oligmerization but
not fibrilization20. These variable results are likely to result from the different conditions (e.g.,
concentration of Aβ, agitation) used in the experiments.
In contrast, Aβ1-42 incubated with a 25 μM solution of compound 1 at high stoichiometry (1:5
molar ratio of Aβ1-42 to compound 1) displays a prominently extended lag phase compared to
those in the ligand-free sample and the sample incubated with 5 μM compound 1 (1:1 molar
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ratio) (Figure 3.2B). This suggests that compound 1 is effective in stabilizing soluble oligomers
in a dose-dependent manner, resulting in a longer lag phase to achieve fibrilization, but
eventually allowing conversion of Aβ1-42 into fibrils. In addition, Aβ1-42 incubated with 5 μM or
25 μM of compound 2 also undergoes a delay in fibrilization (Figure 3.2 C), but a high
concentration of compound 2 at 25 μM does not result in an extension of the lag phase that is as
pronounced as that for compound 1 does at the same concentration.
ThT fluorescence, however, is not highly suitable for mechanistic studies primarily owing to its
inability to report on early steps of oligomerization that occur prior to fibril formation. 17 In
addition, problems arise when relying on ThT fluorescence to assess the anti-amyloid activity of
the polyphenol compounds. Polyphenols can be chromophoric or even intrinsically fluorescent
because they have strong π-π* electronic transitions via conjugation of the phenolic aromatic
rings upon binding to amyloids.18 Actually, the spectroscopic properties of curcumin
significantly interferes with the fibril-associated ThT fluorescence by absorbing both the
excitation an emission lights of ThT.19 We thus turned to FPOP for an accurate characterization
of the inhibitory effect, taking advantage of the ability of FPOP to follow Aβ in-vitro without
requiring binding of a fluorophore. The method provides a sensitive, clear readout on the
changes in Aβ solvent accessibility in the presence or absence of a ligand or inhibitor.

3.4.2 Characterization of the effect of compound 1 on Aβ1-42 aggregation by
FPOP
Preliminary results from ThT fluorescence indicate an apparent delay in Aβ1-42 fibrillation in the
presence of compound 1 at 1:5 molar ratio of Aβ42: compound 1. We, thus, chose to characterize
the effect of compound 1 at this ratio by FPOP. To allow formation of aggregates, 20 µM Aβ1-42
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was incubated with 100 µM compound 1 for various times. Upon completion of the incubation,
Aβ1-42 was immediately mixed with H2O2 and submitted to FPOP. The modified Aβ1-42 was then
digested using Lys-N, the aggregation was followed using the measured modification levels of
the three peptide fragments as determined by LC-MS/MS (Figure 3.3 A-C).
The aggregation 20 μM Aβ1-42 in the presence of compound 1 (Figure 3.3 A-C) shows
significantly different characteristics than in the absence of compound 1 (data taken from our
previous FPOP study for a concentration of 10 µM, Figure 3.3 D-F, adapted from Chapter 2).
There are two variables, a higher starting concentration of Aβ1-42 at 20 μM, which should
accelerate the aggregation and shorten the time required for fibrillation. For ease of comparison,
we “normalized” the plots to have the same width although the time scales are different in Figure
3.3.
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Figure 3.3. Changes in the FPOP modification of Aβ1-42 sub-regions as a function of
incubation time. Aggregation at 25 °C in the presence (A-C) and absence (D-F) of compound 1
in PBS solution (pH 7.4) without stirring. Three peptide fragments, 1-15, 16-27 and 28-42,
obtained from Lys-N digestion of the full-length Aβ1-42 are colored in red, blue, and green on the
Aβ1-42 sequence, respectively. (A-C) Aβ1-42 incubated in the presence of compound 1, with initial
concentrations of Aβ1-42 and compound 1 at 20 µM (equivalent to monomeric Aβ1-42) and 100
µM, respectively. (D-F) Aβ1-42 incubated in the absence of compound 1 (adapted from Figure 2.5
in Chapter 2), with an initial concentration of Aβ1-42 at 10 µM (equivalent to monomeric Aβ1-42).

There are modest variations in the parameters of FPOP (e.g., laser energy, focusing lens) and
between the two experiments conducted in the presence and absence of compound 1. We first
considered to incorporate a reporter into the FPOP experiment to evaluate the dosage of hydroxyl
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radicals in each sample. This would provide a mean to normalize the extents of modification
between different samples. The method requires spiking in a fixed amount of a short peptide
(e.g., Leu-enkephalin) into each protein sample prior to the laser irradiation (for an example of
using a reporter peptide to assist FPOP quantification, referred to 5.4.2 in Chapter 5). Adding a
reporter peptide into the sample may influence Aβ self-association. Additionally, the reporter
peptide exhibits poor reproducibility in terms of its signal intensities in LC-MS and the
modification levels, presumably because the reporter peptide interacts and possibly coaggregates with Aβ1-42 and its oligomers. The outcome indicates incorporation of a reporter is not
feasible in study of an extremely hydrophobic peptide like Aβ1-42.
Despite the small variations in FPOP parameters, we conclude that the modification levels of the
C-terminal fragment (peptide 28-42) are nearly the same in the presence and absence of
compound 1 (Figure 3.3 C and F). Specifically, the C-terminal region of the compound 1remodeled Aβ1-42 shows nearly the same extent of change in solvent accessibility as in the ligandfree sample during the monomer-to-fibril transition (both showing an absolute decrease of ~ 35%
in modification extent from monomers to fibrils) (Figure 3.3 C and F). Those results indicate that
the C-terminal region of Aβ1-42 is unaffected or only affected to a modest extent by compound 1.
In contrast, the modification extent of the N-terminal region (peptide 1-15) is considerably
reduced in the presence of compound 1. This dramatic decrease is likely due to 1) compound 1
binding to the N-terminal region, leading to protection from free-radical reactions, 2) compound
1 interaction of Aβ1-42 at sites other than the N terminus, causing remote conformational changes
that reduced its flexibility or solvent accessibility, leading to protection, or 3) a combination of
these effects. Although the aggregation curves are remarkably displaced, their shapes as Aβ 1-42
transitions from monomers to fibrils are nearly identical in the presence and absence of
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compound 1 (in both showing an absolute decrease of ~ 20% in modification). This phenomenon
is more likely if compound directly binds to the N-terminal region of the monomer. This
proposed mode of action is similar to that of its precursor curcumin as revealed by atomic force
microscopy21.
On the other hand, the middle domain (peptide 16-27) exhibits an opposite trend as the Nterminus. It shows a significant increase in FPOP modification in the compound 1-remodeled
Aβ1-42, indicating that binding of compound 1 results in increasing solvent exposure, flexibility
and possibly decreasing oligomerization involving this central region.
Moreover, the FPOP aggregation curves indicate that the lag phase for nucleation of LMW
oligomers is prominently extended in the presence of compound 1, which is observed for all
three regions (Figure 3.3). After an initial decrease in modification during the first 60 min of
incubation, the modification extent, a measure of the solvent accessibility of Aβ1-42, becomes
nearly constant, displacing a long plateau (60 ~ 1100 min) stage. Finally, a sharp decrease in
modification takes place at long times, indicating a rapid transition of LMW oligomers to fibrils
(Figure 3.3). During this process, there is little evidence for a clear phase of formation of HMW
protofibrillar aggregates prior to fibrillation. Thus, we propose that compound 1 remodels Aβ1-42
aggregation by stabilizing LMW oligomeric conformers.
We note that these results do not inform us on the exact conformation or biochemical properties
of the compound-1-remodeled oligomers, or if those aggregates are on- or off-pathway. This
means those oligomers could be similar to or different from the small oligomers formed in the
absence of compound 1. In addition, FPOP indicates that under our condition and in the presence
of compound 1, Aβ1-42 eventually matures structurally as fibrils. This is consistent with the
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outcome from the ThT fluorescence (Figure 3.2 B), and the relatively rapid oligomerization is
due to the high concentration of Aβ1-42 used in those in-vitro assays.

3.5 Conclusions
Compound 1 is capable to remodel Aβ1-42 aggregation by maintaining Aβ1-42 in LMW oligomers,
presumably via interacting with the N-terminal region. Binding of compound 1 also results in
deprotection and destabilization of the central domain, which was previously proposed to play an
important role in Aβ1-42 self-association by serving as a folding nucleus or interface for
oligomerization.22-23 The C-terminal region is minimally influenced by compound 1.
In terms of methodology development, we have extended the FPOP platform for monitoring
amyloid formation (Chapter 2) to evaluate the effect of a polyphenolic inhibitor on Aβ1-42
aggregation and reveal changes in the behavior of Aβ1-42 sub-regions modulated by the inhibitor.
This study demonstrates that FPOP is an effective and sensitive tool for probing the effect of
potential therapeutic agents on Aβ aggregation in vitro. In addition, FPOP can be combined with
other biophysical tools (e.g., atomic force microscopy, fluorescence spectroscopy) and
biochemical assays (e.g., SDS-PAGE, immunoblotting) to obtain a comprehensive understanding
of the properties of Aβ species and the mechanism of amyloid inhibition. For example, a
previous study indicates that small, aromatic compounds lead to remodeling of Aβ soluble toxic
oligomers into alternative conformers with reduced toxicity.24 For our work, neurotoxicity of the
intermediate LMW oligomers remodeled and stabilized by compound 1 can be further assessed
by using the cytotoxicity assay. Last but not the least, we speculate that our FPOP approach
would be applicable for studies of many amyloid inhibitors, not only small molecules, but also
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peptides and antibodies against Aβ, providing valuable insights for the rational design of antiamyloids therapeutics.
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Chapter 4: Orthogonal Mass SpectrometryBased Footprinting for Epitope Mapping and
Structural Characterization: The IL-6
Receptor upon Binding of Protein
Therapeutics*

_____________________
* This chapter is based on the following publication: Li, K. S.; Chen, G.; Mo, J.; Huang, R. Y.
C.; Deyanova, E. G.; Beno, B. R.; O’Neil, S. R.; Tymiak, A. A.; Gross, M. L., Orthogonal Mass
Spectrometry-Based Footprinting for Epitope Mapping and Structural Characterization: The IL-6
Receptor upon Binding of Protein Therapeutics. Anal. Chem. 2017, 89 (14), 7742-7749.
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4.1 Abstract
Higher order structure (HOS) is a crucial determinant for the biological functions and quality
attributes of protein therapeutics. Mass spectrometry (MS)-based protein footprinting approaches
play an important role in elucidating the relationship between protein biophysical properties and
structure. Here, we describe the use of a combined method including hydrogen-deuterium
exchange (HDX), fast photochemical oxidation of proteins (FPOP) and site-specific carboxyl
group footprinting to investigate the HOS of protein and protein complexes. The work focuses
on implementing complementary solution-phase footprinting approaches that differ in time scale,
specificity for protein residue side chains vs. backbone as well as selectivity for different residue
types to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins
with distinct affinities (Kd, Adnectin1 ~ 6.2 pM vs. Kd, Adenctin2 ~ 46 nM), and evaluate the resultant
conformation/dynamic change of IL-6R. The suggested epitope, which is conserved for
adenctin1 and adenctin2 binding, is a flexible loop that connects two β-strands in the cytokinebinding domain (DII) of IL-6R. We also found that adnectin1, the more strongly binding ligand,
induces structural perturbations on two unstructured loops that are distally located beyond the
epitope. Those changes are either attenuated or not detected for the case of adnectin2 binding. In
addition to providing credibility in epitope determination, utilization of those combined
approaches reveals the structural effects that can differentiate protein therapeutics with similar
apparent biophysical properties.

86

4.2 Introduction
In Chapter 2-3, we focus on the development and application of hydroxyl radical footprinting,
specifically FPOP to follow protein aggregation. In this chapter, and the following chapter 5, we
implement FPOP with another two commonly used footprinting approaches, HDX and carboxyl
group footprinting, to gain complementary insights into protein-ligand interaction and protein
higher order structures.
Protein higher order structures describes the three-dimensional arrangement of a protein structure
required for biological function. Monitoring protein higher order structures is critical for
understanding the impact of molecular conformation on biotechnological applications in the
protein-discovery pipeline.1-2 Furthermore, maintaining protein higher order structures presents
one of the key challenges for achieving robust and stable formulations of therapeutic proteins. 3
For the design of monoclonal antibodies (mAbs) and other therapeutic protein products, protein
higher order structures is essential because binding of the therapeutic to the target is based on the
specific recognition of the epitope on the protein. This is not only related to the primary
sequence but also to conformation and post-translational modifications.4
Although atomic-level mapping of a protein or a protein complex can be achieved by highresolution X-ray crystallography, the resulting static structure may have limited biological
relevance and not reveal solution phase dynamics or long-range protein-protein interactions.5-6
The complexity and low-throughput of X-ray crystallography restrict its application in the initial
research stages where many potential therapeutic protein candidates may be of interest.
Spectroscopy-based approaches including circular dichroism (CD),7 infrared (FTIR)8 and
fluorescence spectroscopy9 provide quick, global measurements of protein conformation, but the
profile obtained from those methods often contains no local or regional structural information. In
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contrast, protein footprinting, an evolving bioanalytical tool in structural biology, can reveal
coarse-grained structural information relevant to proteins and their complexes. High sensitivity
and fast data acquisition recommend MS-based footprinting for characterization of protein
structure and macromolecular interactions at regional and even residue-specific levels of
detail.10-12
Here, we describe a combination of MS-based protein footprinting methods, including hydrogendeuterium exchange (HDX), fast photochemical oxidation of proteins (FPOP) and carboxyl
group footprinting for mapping the extracellular region of human interleukin-6 receptor α-chain
(referred as IL-6R hereafter) interacting with adnectins. Interleukin-6 (IL-6) plays critical roles
in the pathogenesis of multiple myeloma, autoimmune diseases, and prostate cancer, appearing
in abundant IL-6/IL-6R complexes.13 Inhibition of the IL-6/IL-6R complex is a primary goal to
antagonize the action of IL-6 in vivo.14 The interacting partners of IL-6R selected for this study,
adnectins, belong to a class of therapeutic proteins designed based upon the 10th human
fibronectin type III domain.15 The two adnectins (adnectin1 and adnectin2) bind to IL-6R with
picomolar and nanomolar affinity, respectively. X-ray structures of the IL-6R/adnectin
complexes are not available, however, further motivating protein footprinting.
Among the methods to footprint IL-6R in this work, HDX is already well-established for protein
HOS characterization.16-17 HDX occurs via formation of covalent bonds in a reversible manner.18
Its sensitivity to structural change is high provided there is little back exchange due to the labile
nature of the N-D bond. HDX may be insensitive to subtle differences in conformation or
dynamics when the exchange at the local region is low or rapid with respect to the HDX
timescale.19
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As an alternative to HDX, footprinting by incorporating irreversible modifications is emerging
because it provides site-specific information by targeting amino acid side chains. Unlike HDX,
irreversible labeling can survive extensive sample treatment and digestion. Footprinting by the
hydroxyl radical, a common approach, involves irreversible oxidation of surface-accessible
amino acid side chains as the primary product formation pathway. The radical probe has high
reactivity with many residues, particularly those with sulfur-containing, aromatic, and aliphatic
side chains.20 FPOP, the method used to generate hydroxyl radicals in this work, utilizes pulses
of 248 nm KrF laser radiation to induce photolysis of hydrogen peroxide.21 As discussed in
Chapter 1, the lifetime of labeling with primary hydroxyl radicals can be controlled within
microseconds by introducing a radical scavenger.22 To date, FPOP has been implemented for
protein higher order structures characterization of several therapeutic targets23-26 (referred to
1.4.3 in Chapter 1 for more details), showing its suitability for proteins of interest in drug
discovery.
As a complement to free-radical footprinting, a variety of chemical reagents that target amino
acid residues in a site-specific manner (e.g., N-ethylmaleimide27 and diethylpyrocarbonate28-29)
can also provide information on site-specific solvent accessibility but react with protein
substrates more slowly than do free radicals.30 In this work, we performed carboxyl group
footprinting with glycine ethyl ester (GEE) to corroborate the findings from HDX and FPOP,
taking advantage of the presence of the many Asp/Glu residues in the flexible loops of IL-6R.
The chemical modification occurs for solvent-accessible Asp/Glu side chains (and the Cterminus) as a result of activation by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
through formation of an O-acylisourea intermediate, which is subsequently displaced by the
amine group of a GEE molecule via nucleophilic attack.31 The labeling product, which is stable
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and remains intact in post-sample handling and digestion processes, can be quantified to
determine the solvent accessibility at various carboxylic acid sites.32-33
In practice, application of protein footprinting to structural characterization projects including
epitope mapping requires careful consideration of time and resource allocation because, at this
stage, experiments still require considerable instrument and interpretation time. Questions arise
whether time is better spent doing many replicates or time points with one approach or instead
employing other complementary approaches each in a less rigorous manner.

Although an

exhaustive evaluation by one approach will often provide an answer, we have chosen an
integrative course, and the results presented here demonstrate the value of applying that approach
for epitope mapping and HOS characterization.

4.3 Materials and Methods
Recombinant human IL-6R alpha extracellular region (residue 20-358, referred as IL-6R below)
was purchased from R&D systems (Minneapolis, MN). Adnectin1 (Kd ~ 6.2 pM) and adnectin2
(Kd ~ 46 nM) were expressed and purified at BMS as previously described.34 All surface
plasmon resonance (SPR) experiments for binding affinity measurement were performed using a
Biacore T100 instrument (GE Healthcare) (details of SPR can be found in SI Materials and
Methods). To form the IL-6R/adnectin complex, bound state IL-6R was prepared by mixing 50
μM IL-6R with adnectin1 or adnectin2 at a 1:1 molar ratio and incubated at room temperature for
1 h.
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4.3.1 H/D exchange
HDX was performed by following a standardized protocol (see SI Materials and Methods).
Briefly, a mapping experiment of IL-6R peptic peptides was performed under non-denaturing
condition, and the common peptides identified were further monitored for their deuterium uptake
levels with a Synapt G2 High Definition mass spectrometer (Waters). HDX was initiated by
mixing the labeling buffer (10 mM phosphate buffer in D2O, pD 6.99) with the protein solution.
The labeling reaction was allowed for different periods of times: 20 s, 1 min and 10 min.

4.3.2 FPOP
Prior to injection into the FPOP tubing, the protein sample in PBS was mixed with 20 mM H2O2
and 500 μM histidine. The final concentration of IL-6R for FPOP labeling was 10 μM. No
dosimeter or reporter peptide was used (see SI for explanation). To avoid repeated laser
exposure, the flow rate was adjusted to give ~20% irradiation-excluded volume. The laser beam
was from a KrF excimer laser (GAM Laser Inc.), providing an excitation wavelength of 248 nM
to initiate H2O2 photolysis into hydroxyl radicals. After laser irradiation, the sample solution was
collected in a tube containing 10 mM catalase and 20 mM Met to remove leftover H2O2 and
prevent post-labeling oxidation artifacts. Control samples of IL-6R with all the reagents added
(including H2O2) were handled in the same manner, but not laser-irradiated. Samples of each
state were subjected to FPOP in triplicate.

4.3.3 Carboxyl Group Footprinting
For carboxyl group labeling, glycine ethyl ester (GEE), 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) stock solutions were prepared freshly in PBS buffer. GEE was added to
each pre-equilibrated sample to a concentration of 200 mM, followed by adding EDC to a
concentration of 50 mM. The final concentration of IL-6R was 10 μM. In this reaction regime,
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the by-products of the reaction (e.g., Lys-Asp/Glu cross-links) were essentially eliminated
because the excessive amount of GEE dominates the cross-linking reactions.35-36 Timedependent labeling was carried out at room temperature and quenched at 1 min, 3 min and 10
min by adding an equal volume of 1 M ammonium acetate. Samples were further desalted using
a Zeba column (Thermo Scientific, Rockford, IL).

4.3.4 Mass Spectrometry
FPOP or GEE-labeled protein was deglycosylated using PNGas F (New England Biolabs,
Ipswich, MA) and digested using Trypsin/Lys-C or chymotrypsin (Promega, Madison, WI). In
LC-MS/MS analysis, peptide fragments were separated on a custom-packed C18 column (CSH,
75 µm × 15 cm, 3.5 μm, 130 Å) using a Nano UltiMate 3000 Rapid Separation system (Dionex
Co.) and analyzed with a Q Exactive Plus Orbitrap mass spectrometer (Thermo Scientific). The
relative FPOP or GEE modification fraction was calculated by dividing the intensity of modified
peptide/residue (Iox) by the summed intensity of modified and unmodified peptides (Iu) (i.e.,
fraction of modified = Iox/(Iox + Iu)). A detailed description of MS methodology and data analysis
of FPOP and GEE footprinting is given in SI Materials and Methods.

4.4 Results and Discussion
4.4.1 HDX mapping
HDX is a widely used method for exploring protein conformation and monitoring protein-ligand
interactions based on mapping the hydrogen bonding of protein backbone amide; a number of
examples of using HDX MS for epitope mapping were reported.37-40 We first applied HDX to
probe the structure of IL-6R and its complexes with the adnectins and found modest changes in
the region 130-141 (Figure 3.1A). Although there is usually a more significant change in
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protection (reduction in HDX rates) of the amide backbone with epitope binding37-39, the results
clearly suggest an epitope at this site. At this point, we considered repeating the HDX study and
extending it over longer times with improved sequence coverage (78% residues mapped by
peptic peptides (Figure 3.2)) by using other acid-insensitive proteolysis enzymes.41 We reasoned,
however, that more time points or higher coverage would not alter our conclusion about the 130141 region or address the distinctive affinities of adnectin 1 and adnectin 2. In fact, HDX kinetic
curves often show convergence at longer times owing to fast off rates, suggesting that extending
the time for HDX is not productive.24,

37, 39

Furthermore, all other detected regions follow

identical HDX kinetics for the apo and holo forms (see Figure 3.1B as an example). We were
thus motived to seek orthogonal footprinting methods to provide corroborating evidence for the
epitope determination as well as to uncover conformational effects that may impact the binding
of the two adnectins.

B

111-123

Relative Uptake (Da)

130-141

Relative uptake (Da)

A

Exposure time (min)

Exposure Time (min)

Figure 4.1. Representative HDX kinetics for IL-6R. (A) Region 130-141 shows reduced rates
or extents of exchange in the holo (bound) states. (B) Region 111-123 shows no difference
providing an example of a region that is not involved in or affected by adnectin binding.
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Figure 4.2. Sequence coverage of IL-6R in HDX.

4.4.2 FPOP mapping
FPOP is capable of reporting on protein transient dynamics, including fast folding42 and
alteration in side-chain flexibility43. We also showed that FPOP reveals fast fluctuations
occurring remotely upon ligand binding, which is undetectable by slower footprinting methods 24.
Thus, we applied FPOP as a probe with high sensitivity to monitor changes in structure and
dynamics of IL-6R. To obtain structural resolution spanning the IL-6R sequence, we chose two
separate proteolysis experiments with Lys-C/trypsin and chymotrypsin. In the LC-MS/MS
analysis, peptides and their modifications were identified by relying on their accurate (< 5 ppm)
mass and the product-ion spectra (see Figure 4.3 for an example). In the bottom-up strategy, all
tryptic peptides, including those with one missed cleavage site, provide > 90% sequence
coverage of IL-6R. By contrast, chymotryptic cleavage is less specific. We found that
chymotryptic digestion of IL-6R provides a better overall regional resolution by yielding
peptides with shorter average length, the signal intensities for some regions are dispersed among
94

a greater number of overlapping chymotryptic fragments. With 80% sequence coverage from
chymotrypsin digestion, we observed loss in the signal intensities for some chymotryptic
peptides. This phenomenon is particularly pronounced for modified peptides of low abundance.
Nevertheless, performing two sets of digestion experiments afforded a combined coverage of
96% of IL-6R sequence (Figure 4.4), permitting a detailed investigation into the local structure
of IL-6R. In the data analysis, we only selected representative peptides that were relatively short
and had desirable signal-to-noise ratios for accurate, label-free quantification (Table 4.1).
Unmod.

A
253DLQHHCVIHDAWSGLR268

W264

W264
W264

W264
23

24

25

26

27

28

29

30

31

32

33

Retention time (min)

B

95

H256/H257
34

35

36

37

Figure 4.3. Representative LC-MS/MS identification of the peptide and its FPOP
modification. (A) Extracted ion chromatogram of the unmodified peptide 253-268 (top, m/z =
486.7378) and its mono-oxidized (+15.9949 Da) form (bottom). Labels on the chromatogram
indicate signal of site-specific oxidation determined by the product ions. (B) Product-ion spectra
of the unmodified peptide 253-268 (top) and its modified form with oxidation identified on
Trp264 (bottom).

FPOP clearly shows differential modification of peptides from regions in IL-6R (Figure 4.5A
and B). Some regions (e.g., 61-65, 119-126, 232-237) are “FPOP-silent”; that is, we could detect
no FPOP modification even though we saw signals from the unmodified peptides. We found
small modification extents for other regions that are either shielded in the inner core of IL-6R
(PDB: 1N26) and not solvent-accessible, or mainly composed of residues less reactive to
hydroxyl radicals (e.g. Glu, Ser, Lys and Thr). By contrast, we observed high levels of
modifications (modified fraction > 50%) for the C-terminus (288-296 and 301-319), because this
region not only contains highly reactive Met292, Trp296 and Met312 residues but also diversified
loops and random coils that are inherently flexible and expected to be reactive with short-lived
radicals.

96

Tryptic
Chymotryptic

Combined coverage 96%

Figure 4.4. Sequence coverage of IL-6R in FPOP. Tryptic peptides are shown in green and
chymotryptic peptides are shown in blue.
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Peptide

Sequence

5-13

RCPAQEVAR

17-26

TSLPGDSVTL

27-41

TCPGVEPEDNATVHW

45-54

KPAAGSHPSR

55-60

WAGMGR

61-65

RLLLR

66-79

SVQLHDSGNYSCYR

80-104

AGRPAGTVHLLVDVPPEEPQLSCFR

105-118

KSPLSNVVCEWGPR

119-126

STPSLTTK

127-132

AVLLVR

135-148

QNSPAEDFQEPCQY

133-154

KFQNSPAEDFQEPCQYSQESQK

156-168

SCQLAVPEGDSSF

170-183

IVSMCVASSVGSKF

186-210

TQTFQGCGILQPDPPANITVTAVAR

214-231

WLSVTWQDPHSWNSSFYR

232-237

LRFELR

245-252

TFTTWMVK

253-268

DLQHHCVIHDAWSGLR

269-274

HVVQLR

274-284

RAQEEFGQGEW

288-296

SPEAMGTPW

301-319

SPPAENEVSTPMQALTTNK

320-327

DDDNILFR

Table 4.1. Peptides from IL-6R digest selected for FPOP quantification.
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A

70

% FPOP Modified

60
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20
10
0

IL-6R peptide

B

C
25

**
**

% FPOP Modified

20

**
**

DI

**

15

DII

10
5

DIII
0

27-41

135-148

274-284

IL-6R peptide

Figure 4.5. FPOP modification extents of IL-6R peptide regions and the locations of the
regions showing altered solvent accessibility. (A) Regions of IL-6R without significant change
in their extent of FPOP modification. (B) Regions of IL-6R with significantly decreased (**Δrel.
> 40%, p < 0.005) FPOP modification, indicating reduced solvent accessibility upon
adnectin1/adnectin2 binding. (C) Regions in (B) mapped onto IL-6R (PDB: 1N26) are colored
blue. The three domains of IL-6R are referred as DI, DII and DIII on the structure.

Regions 27-41, 274-284 and 135-148 in adnectin1-bound IL-6R, and regions 274-284, 135-148
in adnectin2-bound IL-6R show remarkably decreased FPOP modification (relative difference >
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40%, p < 0.005 in Student’s t-test) (Figure 4.5B), suggesting those regions undergo major
conformational changes introducing reduced solvent accessibility upon adnectin binding (Table
4.2 summarizes the FPOP modifications of those regions exhibiting statistically significant
differences in solvent accessibility upon adnectin binding). We also observed minor differences
in FPOP modification for region 301-319 in the adnectin1-bound state, which is likely attributed
to minor structural or dynamical perturbation on this region upon adenctin1 binding. The 3D
structure of IL-6R consists of three domains including the N-terminal Ig-like domain (DI) and
two cytokine-binding domains (DII and DIII). All the regions for which solvent accessibility is
significantly altered in FPOP adopt a flexible loop structure (Figure 4.5C). In addition, we found
the overlapping tryptic and chymotryptic peptides (e.g., tryptic peptide 133-154 and
chymotryptic peptide 135-148) reveal correlated trends of FPOP modification change (Figure
4.6). This indicates that the observed difference is due to structural changes of IL-6R in the holo
states, instead of structure-based proteolytic bias caused by the FPOP modification.

Sequence

Relative
difference
(%)

p-value

27-41

TCPGVEPEDNATVHW

67

0.001

274-284

RAQEEFGQGEW

61

0.004

135-148

QNSPAEDFQEPCQY

50

< 0.001

135-148

QNSPAEDFQEPCQY

54

0.001

274-284

RAQEEFGQGEW

42

0.004

IL-6R
Ligand
peptide

Adnectin1

Adnectin2

Table 4.2. Summary of the regions showing significant changes in conformation and/or
dynamics identified by FPOP.
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10

0

0
14-44

17-26

27-41

0
133-154

135-148

275-300

274-284

Figure 4.6. Correlation in FPOP quantification for overlapping peptides. The overlapping
regions covered by tryptic (red triangle) and chymotryptic (blue diamond) fragments show
correlated trend in term of the change in the FPOP modification. For example, region represented
by tryptic fragment 14-44 are covered by two chymotryptic fragment 17-26 and 27-41, whereas
FPOP quantification on the shorter chymotryptic fragments indicates the decreased solvent
accessibility upon adnectin binding is attributed to region 27-41, with the solvent accessibility of
region 17-26 remains unchanged.

A significant advantage of FPOP is that it provides residue-level information (Figure 4.7). His40
and Trp41 are the residues that are predominantly modified by FPOP in region 27-41
(TCPGVEPEDNATVHW). The two residues are located at the front end of a β-stand connected
to the loop. The side chain of His40 is exposed on the protein surface, and the aromatic side chain
of Trp41 is largely protected inside the protein core. Note that the amino acid residues from the
sequence that compose the loop (30GVEPEDNAT38) on region 27-41 are much less reactive than
His and Trp, with the most reactive Val and Pro being ~ 20X and 6X less reactive compared to
Trp and His, respectively.20 Therefore, the hydroxyl radical preferentially modifies His40 and
Trp41 rather than the less reactive ones from the loop. The local selectivity is also pronounced for
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some Met containing regions (e.g., 245-252 and 288-296). Moreover, the product-ion spectrum
does not definitively indicate what residue is modified on region 274-284, but it does show that
the FPOP modification occurs on either Pro138, Phe142, Pro145 or Tyr148.
80

% FPOP modified

70
60
50
40
30

20
10
0

Figure 4.7. FPOP modification level for IL-6R residues.

Although peptide regions in Table 4.2 undergo significantly reduced FPOP modification in the
holo states, one should be cautious in interpreting the data because the change in FPOP extent
may result either from the epitope binding, or from decreased dynamics and flexibility induced
remotely from the adnectin binding site. For the residues with high intrinsic reactivity with the
hydroxyl radical, a relatively modest change in their solvent accessibility in response to the
dynamic motion can result in a dramatic difference in their FPOP modification. 44-45 Our
hypothesis is that dynamic motions occurring within the sub-second time range will be
differentiated by fast labeling but not by slow labeling that presents an averaged view over
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seconds, and applying orthogonal footprinting can distinguish binding from remote dynamics
change.
There are ways to improve the confidence in the FPOP experiment.

For example, the

footprinting can be done as a function of time to give outcomes similar to those typically
obtained for HDX. Assigning differences can be elaborated further with kinetic curves46 (e.g.,
five time points) rather than single point, but this requires considerable investments in
LC/MS/MS analysis time, data processing, and interpretation as well as more sample. At this
point, we decided to turn instead to another type of footprinting.

4.4.3 Carboxyl group footprinting
The effectiveness of protein footprinting to map the epitope and conformational changes depends
on whether the reagent-active residues are located on those regions.12 Although residue-speciﬁc
labeling provides less structural information due to limited numbers of target residues on the
protein surface, fortuitously, the regions of IL-6R with significant changes in the solvent
accessibility mapped by FPOP (27TCPGVEPEDNATVHW41,
135

274

QNSPAEDFQEPCQY284 and

RAQEEFGQGEW148) are rich in Asp/Glu as potential GEE modification sites, and we expect

carboxyl group footprinting, as an orthogonal approach to provide more site-specific insights for
those acidic regions.
In the GEE reaction, carboxyl groups of Asp/Glu located on the surface are readily modified,
whereas ones surrounded by hydrophobic amino acids or buried in the interior of the structure
undergo less or even no modifications (assuming there is no additional steric restrictions
prohibiting the access of EDC and the GEE molecules).33, 47 To investigate the kinetics of the
labeling, we performed sparse, time-dependent GEE footprinting (1, 3 and 10 min) on the apo
and adnectin-bound IL-6R. Given that for 16 Asp/Glu-containing chymotryptic peptides, 17-26,
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109-134, 247-254, 255-264 and 297-315 have no detectable modification, we performed
quantification for the other 11 peptides.
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Figure 4.8. GEE labeling kinetics for selected IL-6R peptides in the ligand-free (gridded
circle), adnetin1-bound (triangle) and adnetin2-bound state (diamond) state. (A) Region
135-148 shows decreased GEE incorporation upon adnectin1/adnectin2 binding, whereas (B)
region 274-284 shows increased GEE modification upon adnectin1 binding. (C) A representative
peptide region without differentiable GEE modification extent between apo and holo as the
control. Dashed trend curves in (A), (B) and (C) are generated by linear or 2nd-degree polynomial
fitting. (D) Region 135-148 and 274-284 mapped onto IL-6R. (E) Microenvironments of Glu140,
Asp141 and Glu144.
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From the time-dependent GEE footprinting, we found two regions 135-148 on DII and 274-284
on DIII show a clear difference upon binding of either adnectin1 or adnectin2 (Figure 4.8A and
B). The two regions are mapped onto the IL-6R structure in Figure 4.8D. The rates of GEE
incorporation for region 135-148 in the two holo states decrease significantly with a relative
change of 30% at 10 min of labeling, and the differences are made more apparent by the timedependent results, indicating prominently decreased solvent accessibility of the region upon
adnectin binding. Region 135-148 contains Glu140, Asp141 and Glu144 as possible GEE
modification sites, but we found the modification is exclusively on Glu140. The structure of IL6R indicates that the GEE-modified Glu140 is on the surface of a loop with a flexible carboxyl
group amenable to EDC/GEE reaction (Figure 4.8E). By contrast, Asp141 is involved in the front
end of a β-strand with its side-chain hydrogen bonded to Arg132, and Glu144 is also located on the
same β-strand with its side chain occluded by surrounding residues Phe142, Gln158 and Leu159.
The GEE labeling reaction requires activation of the carboxyl group by EDC, and the sizes of
EDC and GEE are larger than the small reagents in FPOP and HDX, suggesting steric
requirements for the reaction. We reason that although Asp/Glu as charged residues are often
prone to be on the protein surface, their solvent accessibility can be largely diminished or even
completely blocked by their microenvironments.
We found region 247-284 to be slightly deprotected in the adnectin1-bound state (Figure 4.8B)
as reported for the acidic residues. Due to a steric effect similar to that described above, Glu283,
which is located on the unshielded surface loop, is readily modified by GEE. Glu277 and Glu278,
however, which are located on or close to the end of a β-strand, remain unmodified owing to the
protection from the surrounding loops and hydrogen bonds. The increased solvent accessibility
can thus be attributed to the side chain of Glu283. Interestingly, residue-level analysis of FPOP
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modifications on the same region shows that the Phe279/Trp284 side-chain solvent accessibilities
are reduced (Figure 4.7), and the analysis and interpretation for the motion of the region will be
discussed later in section 4.4.4.
By contrast, a majority of peptides, as represented by 27-41, show nearly identical labeling
kinetics for bound and unbound states, supporting their role as controls and suggesting their local
conformations remain unchanged upon adnectin binding (Figure 4.8C and Figure 4.7). The
labeling extents of those regions at 10 min, at which time the difference in modification is
expected to be greatest, are not differentiable (Figure 4.10). Unlike FPOP labeling, which is
often performed over a single exposure time, kinetic curves of GEE labeling provide statistical
weight by tracking the labeling over a time course. We also found the GEE modification extent
generally increases with the reaction time, but the labeling of some peptide regions can occur
very rapidly. For example, regions 1-16, 288-296 and 316-326 show bursts in their GEE
incorporation at the first 1 min of the reaction (Figure 4.9), indicative of their flexible loop or
coil secondary structures.
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Figure 4.9. Representative GEE labeling kinetics for selected IL-6R peptides without
differentiable GEE modification extent. Ligand-free (gridded circle), adnetin1-bound
(triangle) and adnetin2-bound state (diamond).
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GEE exposure time = 10 min

25

20

% GEE yield

15

10

5

0
1-16

65-75

91-103

156-168
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Figure 4.10. Regions without appreciable difference in their modification extent between
the ligand-free and adnectin1/adenctin2-bound IL-6R. Samples are labeled with GEE for 10
min.

4.4.4 Structural features from complementary footprinting
HDX rates of exchange of labile amide hydrogens are characteristic of local backbone
conformations and related to its hydrogen-bonding pattern and solvent accessibility, which are
affected by protein binding. In highly dynamic, unstructured regions, the exchange reaction
proceeds on the millisecond to second timescale, whereas amides that are hydrogen bonded will
exchange more slowly (minutes to days).48 With comparable reaction rates to HDX, GEE targets
solvent-accessible carboxyl group side chains. Labeling by FPOP, however, is considerably
faster than HDX and GEE because the lifetime is microseconds for the primary hydroxyl radical
and milliseconds for all radicals.22,

49

Hydroxyl radicals react with a variety of amino acid

residues, and the labeling extent of a particular residue site is a function of the inherent reactivity
and solvent accessibility of the amino acid side chain. Clearly the approaches are complementary
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in location of footprinting (protein backbone vs. side chain), residue specificity, and rate of
reaction. The more rapid approaches offer an opportunity to understand protein dynamics and
minor structural fluctuations.43
The epitope and critical contacting residues
In FPOP and GEE footprinting, region 135-148 becomes significantly protected upon binding of
adnectin1 or adnectin2, whereas HDX focuses on region 130-141 (region 142-147 does not
change). Taken together, the integrated outcome strongly suggests the short segment
135

QNSPAED141 to contain the critical binding epitope. The suggested epitope is conserved for

adnectin1 and adenctin2 binding. Mapping the proposed epitope onto the IL-6R structure
highlights a loop on the DII domain of IL-6R (Figure 4.11).
A closer examination of the residue-specific data may reveal the contacting residues. Generally,
FPOP modification on a residue is assigned when a +15.9949 Da shift is observed in the production series of the modified peptide. For peptide 135-148, each of FPOP modified residues
Pro138/Phe142/Pro145/Tyr148 produces multiple +16 Da products as structural isomers (e.g., by
o-/m-/p- oxidation of Phe). Those isomers of peptide 135-148 cannot be distinguished by mass
and give very slightly different retention times. The complicated chromatogram for oxidized
peptide 135-148 makes FPOP quantification of a specific residue difficult. As for the suggested
epitope 135-141, however, we identified Pro138 to be the modified residue responsible for the
changes in FPOP. Carboxyl group footprinting also slows for the proposed epitope, but the
information is restricted to Glu140 as it is the only residue modified in region 135-148. Although
there are Asp141 and Glu144 as potential GEE modification sites in this region, no modification is
detected for the two residues owing to shielding of their microenvironments as discussed above.
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Summarizing the information from the complementary methods, we posit that

135

QNSPAED141

represents the region containing the epitope of IL-6R, with Pro138 and Glu140 being possible
binding residues or closely adjoining the critical binding residues (Figure 4.11 shows Pro138 and
Glu140 in the surface presentation with side chains extruding). At this time, we cannot rule out the
residues on region 135-141 that are not mapped by the hydroxyl radical or GEE probe (e.g., Gln
135

, Asn 136, Ser137 and Ala139), but we can potentially identify some key interacting residues as

well as narrow down the epitope to a short segment by FPOP and GEE-reactive residues that are
involved in binding. Note that HDX fails to report the backbone solvent accessibility of Pro 138
owing to its lack of an amide hydrogen atom, which may account for why the putative epitope
region 130-141 only shows a modest protection in HDX, despite the two adnectins both being
high-affinity ligands against IL-6R.

A

B

E140

E140

P138

P138

90

Figure 4.11. Structural change of IL-6R (PDB: 1N26) upon adnectin binding in the surface
representation. IL-6R consists of three domains. DI, DII and DIII are located from the top to
the bottom on the structure. (A) Front view and (B) side view of the regions that undergo
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conformational change in structure or dynamics upon adnectin binding. Close-up views of the
region in (A) shows the secondary structure of the region and the side chain orientation. Region
135-141 as the proposed epitope for adentin1/adnectin2 binding are colored in blue with Pro138
and Glu140 highlighted in cyan. Region 27-41 and 274-284 (located on DI and DIII respectively)
whose conformation is affected by adnectin binding are colored in coral.
Conformational dynamics and side-chain motion of IL-6R loop regions
Protein structure fluctuations will be affected by protein binding.50 If the sampling time of a
footprinting reaction is long with respect to the protein dynamics, differences will be averaged
and no effect seen. FPOP is capable of reporting on regions showing fast dynamics because its
sampling time is short with respect to local motions.19, 42, 51 In the adnectin1-bound IL-6R, the
decreased solvent accessibility reported by FPOP for region 27-41 is not observed by HDX or
carboxyl group footprinting, indicative of fast changes in the conformational dynamics of region
27-42 upon adenctin1 binding. Region 27-41 is located on the DI domain of IL-6R as a surfaceexposed loop (Figure 4.11B) where changes in dynamics are likely to happen.
For amino-acid residues with high intrinsic reactivities with the hydroxyl radical, drastic changes
in their modification occur in response to modest change in the solvent accessibility,45 whereas
differences in modification extent of less reactive residues (e.g., Leu, Pro and Val) is expected to
be observed for large conformational changes. His40 and Trp41 are the only two residues
modified by FPOP in region 27-42, and they do exhibit dramatic differences in FPOP
modification with a relatively decrease of 67% in the adenctin1-bound state. The observed
protection on the two residues with high susceptibility to the hydroxyl radical suggests relatively
modest changes in the structure or dynamics upon adnectin-1 binding. Considering the binding
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strength of adnectin1 (Kd ~ 6.2 pM) is greater than that of adnectin2 (Kd ~ 46 nM), we posit that
the binding of adnectin1 stabilizes IL-6R more by reducing the local flexibility of region 27-41.
Interestingly, in contrast to the decreased FPOP modification of residue Phe279/Trp284 in region
274-284 in adnectin1 bound IL-6R, the GEE labeling of Glu283 increases slightly for the
adnectin1-bound state, but not for adnectin2, whereas no difference in HDX occurs for this
region. This suggests that region 274-284 undergoes minor structural perturbation in dynamic
and/or sidechain reorientation upon adnectin binding, which may not cause changes in the amide
hydrogen-binding pattern. Considering the hydrophobicity of Phe/Trp and the polarity of Glu, it
is possible that the binding causes side-chain motions involving inward rotation of Phe279/Trp284
with its solvent accessibility decreasing, whereas the side chain of Glu283 rotates outward and
becomes relatively solvent exposed. These solution-state motions would not be reflected in a
single static 3D-structure. Furthermore, region 274-284 spans a flexible loop, where side-chain
rotation is more facile than for a more rigid α-helix or β-sheet. This may have implication in the
low-affinity binding of IL-6 to IL-6R that precedes the binding to a signal-transducing molecule
gp130 to form high-affinity functional complex.52-53 An investigation into the structure of the IL6R/IL6/gp130 complex (PDB: 1P9M) further reveals that the loop region represented by peptide
274-284 serves as one of the interfaces with IL-6 in this biologically-relevant complex (Figure
4.12). The structural changes adopted by this region may be inferred by the therapeutic efficacy
of the adnectins to block IL-6-mediated signal transduction through inhibiting the binding of IL6 to IL-6R.
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135-148

IL-6

IL-6R
DII

274-284

IL-6R
DIII

gp130

Figure 4.12. Cocrystal structure of IL-6R/IL6/gp130 complex. Region 135-148 and 274-284
(magenta) on IL-6R (blue) both closely interact with IL-6 (cyan) as shown in the 3D-structure of
the biologically-relevant human IL-6/IL-6R/gp130 (2:2:2 stoichiometry) hexameric complex.
The complex consists of two IL-6, IL-6R, and gp130 hetero-trimers (PDB: 1P9M, only one copy
of the hetero-trimer is shown for clarity). IL-6 and the signal transducer glycoprotein 130
(gp130) is in cyan and red respectively. Domain DI of IL-6R is absent in this 3D-structure.

4.5 Conclusions
Solution-state protein-protein interactions and related conformational changes can be
interrogated with high spatial resolution by using orthogonal footprinting and structural mapping.
We proposed the epitope of IL-6R is in the region 135-141 and concluded that adnectin binding
affects fast dynamics and side-chain reorientation of some of IL-6R’s flexible loops. Those
“hidden” motions in structure and/or dynamics are invisible to a relatively slow footprinting
method like HDX. The results support a more comprehensive understanding of IL-6R HOS and
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highlight the sensitivity of FPOP towards fast structural changes owing to the short half-life of
hydroxyl radicals and higher coverage compared to HDX and site-specific carboxyl group
footprinting. Their combined use not only serves to categorize and interpret changes in
footprinting as due to protection from binding or to remote structural changes occurring with
binding, but also adds confidence to assign the epitope where any stand-alone method has
uncertainty. This integrated approach shows great utility for charactering protein and protein
complex, which can be applied efficiently to assist understanding and optimizing the design of
protein therapeutics.
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Chapter 5: Mapping Hydrophobic
Interactions of Human Bromodomain with a
Small Molecule Inhibitor by HydrogenDeuterium Exchange and Hydroxyl Radical
Footprinting Mass Spectrometry
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5.1 Abstract
Mass spectrometry-based protein footprinting, a valuable structural tool in mapping proteinligand interaction, has been extensively applied to protein-protein complexes, showing successes
in mapping large interfaces. Here we compared hydrogen-deuterium exchange (HDX) and
hydroxyl radical footprinting using fast photochemical oxidation of proteins (FPOP), as a proofof-concept study, to characterize the interaction of human bromodomain-containing protein 4
(BRD4) with a hydrophobic benzodiazepine inhibitor. HDX does not provide strong evidence for
the location of the binding interface, presumably because the shielding of solvent by the small
molecule is not large. Instead, HDX suggests that BRD4 appears to be stabilized by showing a
modest decrease in dynamics caused by binding. In contrast, FPOP points to a critical binding
region in the hydrophobic cavity, also identified by crystallography, and, therefore, exhibits
higher sensitivity than HDX in mapping the interaction of BRD4 with compound 1. In the
absence of or under low concentrations of the radical scavenger, FPOP modifications on Met
residues are significantly different with respect to a minor change in protein conformation. This
problem can be avoided by using a sufficient amount of proper scavenger, as suggested by the
FPOP kinetics directed by a dosimeter of the hydroxyl radical.

5.2 Introduction
Despite the rapid development of protein-based therapeutic biologics, small molecules are still
remarkably dominant in development pipelines of the biopharmaceutical industry, making up
over 90 percent of the therapeutics in use.1 Small-molecule drugs have relatively stable chemical
property and are mostly non-immunogenic. Their tiny size and chemical composition make them
easy to penetrate cell membranes and reach desired delivery destinations. Generally, design of
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small-molecule drugs is based on specific macromolecules as targets for inhibition or
modulation. Thus, characterization of the interaction between a small molecule and its target
macromolecule is important for drug development, as knowledge in their interaction is essential
for understanding the mechanism of action. Compared to Chapter 4 discussing protein-protein
interaction, this chapter is focused on evaluating MS-based protein footprinting, including FPOP
and HDX to probe protein-small molecule interaction. From a method development perspective,
this is also the first example of applying FPOP to investigate the direct binding interface of a
protein with its small molecule ligand.
MS-based protein footprinting is a valuable tool to characterize protein structure and dynamics.
Hydrogen-deuterium exchange (HDX) and hydroxyl radical footprinting are the two most
commonly applied protein footprinting methods. HDX reports the stability and structural
protection of the protein by measuring the exchange of amide hydrogens with deuterium on the
protein backbone.2 Its utility has been established by extensive applications in studying proteinprotein, protein-DNA, protein-membrane interactions,3-4 showing successes in probing large
interfaces in protein-ligand complexes. Using HDX to probe protein-small molecule interfaces is
challenging, however, possibly owing to the relatively small protection afforded to the protein by
the small molecule. Hernychova et al.5 applied HDX to the interaction of the protein MDM2
with a small molecule, Nutlin3, and observed reduced HDX kinetics upon ligand binding in
regions surrounding the pocket only at relatively high protein-to-ligand ratio (1:4). Wang et al.

6

used HDX with ligand titration to obtain the affinities of a small molecule drug with
Apolipoprotein E3 at the peptide-level, obtaining convincing changes in HDX at the binding
sites. Despite these successes, direct mapping of a small molecule interaction when the binding is
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hydrophobic may be particularly difficult because the binding interface does not involve
hydrogen bonding of the protein backbone, explaining the lack of sensitivity in HDX.
By contrast, hydroxyl radical footprinting reports changes in solvent accessibility of amino-acid
side chains via covalent and irreversible oxidative modification. Here differences in bound vs.
unbound states are less dependent on H bonding. Furthermore, hydrophobic side chains (Phe,
Leu, Ile, Val) are reactive with •OH, leading to potentially sensitive indications of binding.7
Here we describe the implementation of fast photochemical oxidation of protein (FPOP), which
uses laser-induced hydrolysis of hydrogen peroxide to generate hydroxy radicals. 8 Using a
radical scavenger, we varied the time scale of labeling, determined by the lifetime of the radical,
is tuned to be faster than protein conformational change or unfolding induced by modification. 9
Although FPOP has been applied to protein folding, protein aggregation,10-12 protein-ligand
interactions including epitope/paratope mapping,13-16 to our knowledge, FPOP, and hydroxyl
radical footprinting in general, have not yet been applied to protein-small molecule interactions.
Thus, we want to explore this opportunity and test the capability of the method for this
application.
We chose to evaluate HDX and hydroxyl radical-based FPOP to characterize binding of a
benzodiazepine

inhibitor,

benzyl

(1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-

a][1,4]diazepin-4-yl)carbamate (referred to as compound 1 hereafter), to human bromodomaincontaining protein 4 (BRD4). BRDs are protein interaction modules that specifically recognize
acetylation motifs, a key event in the reading process of epigenetic marks. 17 Inhibitors targeting
BRD

have

therapeutic

efficacy

as

anti-inflammatory,

antiviral,

and

anticancer

agents.18 Compound 1 is a potent (nM) inhibitor that disrupts the function of the bromodomain
family (BRD2, BRD3, and BRD4). A cocrystal structure of the bromodomain 1 of BRD4 and
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compound 1 shows that the inhibitor occupies the central hydrophobic cavity of the protein used
for acetyl-lysine recognition, thus directly antagonizing the interaction between the
bromodomain and the acetylated histone peptides by steric competition.18 The outcome of this
comparative study is not only valuable for understanding the principles of HDX and FPOP but
also should provide insights into the analytical capabilities of the methods, guiding the choice of
suitable MS-based footprinting methods for investigating protein structure and interactions.

5.3 Experimental
5.3.1 Materials
The bromodomain 1 (residue 41-168) of human BRD4 (refereed to as BRD4 hereafter) and
compound 1 were provided by Bristol Myers Squibb. L-Glutamine, L-methionine, catalase,
hydrogen peroxide (H2O2), trifluoroacetic acid (TFA), formic acid (FA), phosphate buffer saline
(PBS, 10 mM phosphate, 138 mM NaCl, 2.7 mM KCl), urea, dithiothreitol and iodoacetamide
were from Sigma Aldrich (St. Louis, MO). Trypsin and chymotrypsin were from Promega
(Madison, WI).

5.3.2 HDX
To prepare compound1-bound BRD4, the protein solution and compound 1 were combined to
form a 40 µM:48 µM concentration ratio and incubated at 25 °C for 30 min to allow formation of
the complex. Aliquots of 3 µL of 40 µM BRD4 with and without the complex were then
continuously labeled in 37 µL of 1 × PBS in 99.9% deuterium oxide (pD =7.4), at 25 °C, at 10 s,
30 s, 1 min, 2 min, 15 min, 1 h, 2 h, 4 h, and 6 h time points. The reaction was quenched by
adding 60 µL of 3 M urea and TFA (final pH = 3.0). Samples were then flash frozen in liquid
nitrogen and stored at -80 ⁰C. Control samples were prepared in like fashion by using 1 x PBS in
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water in place of deuterium oxide.

Each sample was thawed immediately prior to LC-MS

analysis. The protein was digested by pepsin by using a custom-packed pepsin column (2 mm x
20 mm) at a flow rate of 100 µL/min. The resulting peptic peptides were then trapped on a
Zorbax Eclipse XDB-C-8 trap column (2.1 x 15 mm, 3.5 µm) and desalted for 3 min, followed
by separation of the peptides on a Hypersil Gold C-18 analytical column (2.1 x 50 mm, 2.5 µm)
by using a gradient of 4-80 % acetonitrile with 0.1% formic acid at a flow rate of 100 µL/min.
Peptides were detected using a LTQ XL Orbitrap mass spectrometer (Thermo Fisher Scientific),
at a mass resolving power of 100000 at m/z 400. The capillary temperature and voltage for ESI
were 275 °C and 49 V, respectively. All experiments were performed in duplicate.

5.3.3 HDX data analysis
To identify the peptic peptides generated from the protein and to provide a list of peptides to be
followed during HDX, peptide mapping with a non-deuterated protein sample was conducted.
The product−ion mass spectra were acquired in a data-dependent mode, with the six most
abundant ions from each scan selected for MS/MS. Peptides, as identified using Mascot (Matrix
Science, London, UK), were used to guide the HDX setup. The HDX mass spectra were
analyzed with HDX Workbench (Scripps, Jupiter, FL). All experiments were performed in
duplicate.

5.3.4 FPOP
A complex of bound BRD4 with compound 1 was prepared by incubating 20 μM BRD4 with
compound 1 in a 1:1 molar ratio for 30 min at 25 °C in PBS. Unbound BRD4 was prepared as a
20 μM stock solution in PBS. Just prior to injection into the flow tube for FPOP, H2O2 was
added to a final concentration of 20 mM. FPOP was performed as previously described8, expect
that for each state of the protein, FPOP was conducted in duplicate each for four different
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concentrations of His (0, 0.3, 3, 30 mM) as the radical scavenger. The final concentration of
BRD4 for FPOP labeling was 10 μM. After laser irradiation, the sample was collected in a tube
containing 10 mM catalase and 20 mM Met to react with any leftover H2O2 and prevent
oxidation artifacts. In addition, control samples of BRD4 with all the reagents (including H2O2)
added were handled in the same manner in duplicate, but not laser-irradiated.

5.3.5 LC-MS/MS
For each 20 μL aliquot of the FPOP sample, urea was added to a final concentration of 6 M to
denature the protein. Cysteines of the protein were reduced by adding dithiothreitol to a final
concentration of 5 mM, and samples were incubated at 37 oC for 30 min. Iodoacetamide was
subsequently added to a concentration of 15 mM to alkylate the free cysteines. Samples were
incubated in the dark at room temperature for 30 min. PBS was added to dilute the urea to 1 M.
Samples were digested overnight with trypsin or chymotrypsin at 37 oC with a protease-toprotein ratio of 1:25 (w/w). The digestion was terminated by acidifying the sample with 1%
trifluoroacetic acid. The sample was then vacuum-dried on a speedvac, and each peptide digest
was reconstituted with 60 μL 0.1% FA in water for LC-MS analysis.
An aliquot of 5 μL of protein digest was submitted to LC-MS/MS analysis. For the elution,
solvent A was water with 0.1% (v/v) FA, and solvent B was 80% (v/v) acetonitrile with 0.1%
(v/v) FA. Peptides were pre-concentrated on an Acclaim PepMap C18 column (Thermo
Scientific, 100 µm × 2cm, 5μm, 100 Å) and desalted for 10 min at a flow rate of 4.5 μL/min by
using solvent A. Separation was performed on a custom-packed C18 column (CSH, 75 µm × 15
cm, 3.5 μm, 130 Å) at a flow rate of 400 nL/min with a gradient of 2-65 % solvent B in 90 min
using a Nano UltiMate 3000 Rapid Separation system (Dionex, Co.). The solution flow was
directed with a Nanospray Flex source coupled for online detection using a Q Exactive Plus
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orbitrap mass spectrometer (Thermo Scientific) with a spray voltage of 2.5 kV and a capillary
temperature of 250 oC. In the data-dependent mode, the 15 most-abundant ions were submitted to
higher energy collision dissociation (HCD) with an isolation window of m/z 1.5 and a
normalized collisional energy of 30%. Resolving power was 70,000 (at m/z 400) for MS1 and
17,500 (at m/z 400) for product ions in MS/MS.

5.3.6 FPOP data analysis
Identification of the unmodified peptides and assigned modifications were done by using
Byologic (Protein Metrics) and further validated by manual inspection. Modification sites were
identified based on MS/MS. Signal intensities of the unmodified peptide (Iu) and its modified
species (Iox) were integrated using Byologic (Protein Metrics) from the extracted ion
chromatograms (XICs). The FPOP modification level of a peptide was calculated using the
following equation: % modified = Iox/(Iox + Iu)×100. Quantification of the modified species was
based on the dominant FPOP products with oxygen addition/substitution(s) (+15.9949 Da, +
31.9898 Da, etc.).

5.4 Results and Discussion
5.4.1 Mapping by HDX
In our model system, benzyl (1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin4-yl)carbamate (compound 1) (Figure 5.1A) is a BRD competitive inhibitor that possesses a
binding cavity for acetyl-lysine recognition (Figure 5.1B).18 The structure of bromodomain
adopts a left-handed four-helix bundle topology. Overlapping the compound 1-bound BRD4
(bound) with the ligand-free protein (unbound) shows the two structures are nearly identical
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(Figure 5.2C), indicating no significant structural rearrangement of the protein that is caused
compound 1 binding.
A

C

B

90

Figure 5.1. Binding of BRD4 to compound 1. (A) Molecular structure of compound 1. (B)
Crystal structure of BRD4 in complex with compound 1 (PDB 2YEL), referred as “bound”
hereafter. Secondary structures and surface presentation of the protein are shown in cyan and
white, respectively. (C) Bound BRD4 in cyan is overlaid with the ligand-free BRD4 in orange
(PDB 4LYI), referred as “unbound” hereafter.
In the HDX experiment, the hydrophobic core of BRD4 is expected to show very slow rate of
deuterium uptake owing to its solvent accessibility. Thus, we extended the time course of D2O
exposure to 6 h to allow exchange to occur in the hydrophobic cavity. In accord with the nearly
identical structures of BRD4 in the unbound and bound states, most regions in BRD4 shows no
change in HDX kinetics upon compound 1 binding, as represented by peptides in Figure 5.2A-C.
By way of contrast, we found some regions exhibit slightly reduced rates and extents of
exchange in the bound state (Figure 5.2E-J). The differences in those regions, however, are still
too modest compared to what we would typically expect for a binding interface.19-21 Instead,
HDX shows that BRD4 only undergoes a slight decrease in H-bonding and flexibility upon
compound 1 binding, and we conclude that the overall structures of the unbound and bound
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BRD4s are very similar. Indeed, we are seeking a binding scenario such as this to test whether
protein footprinting is sensitive to small-molecule binding.
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Figure 5.2. HDX kinetics of BRD4 upon binding of compound 1. Comparison between the HDX of
unbound (blue) and bound (orange) BRD4 reveals representative peptide regions (A-D) that do not show
changes in HDX upon binding, and regions (E-J) showing small changes upon binding to compound 1.
Amino-acid numbering and charge state of the peptide from pepsin digestion of BRD4 are shown above
each plot.

Given the small changes in HDX resulting from binding, we turned to FPOP to probe the
interaction of BRD4 with compound 1. Compared to HDX that interrogates the structure and
dynamics of backbone amide, we expect FPOP to show higher sensitivity in mapping the binding
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cavity of BRD4 with the compound 1, because the binding interface may involve sidechain
interactions and, moreover, many of the hydrophobic residues are reactive with the OH radicals
used for footprinting.

5.4.2 Mapping by FPOP using a reporter peptide strategy

A

Unmod.
+16 Da
+32 Da
+48 Da

0 mM His

B

0.3 mM His

C

3.0 mM His

D

30 mM His

E

control 1
(no laser)

F

1080

control 2
(no FPOP)
1085

1090

1095

1100

m/z

Figure 5.3. Global FPOP modification of BRD4 as a function of the scavenger concentration.
Mass spectra of unbound BRD4 (+14 charged). FPOP was done without addition of the
scavenger in the protein sample (A), and with 0.3, 3, 30 mM His used as scavenger (B-D). (E)
Control sample of BRD4 (with addition of H2O2) submitted to the same FPOP workflow as the
experimental group except the laser was turned off. (F) starting state of BRD4 in PBS buffer.
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To obtain FPOP kinetic curves of the unbound and ligand-bound BRD4, we performed the
labeling experiment with various concentrations (0, 0.3, 3, 30 mM) of histidine as the radical
scavenger to give different timescales of labeling. Mass spectra of the intact BRD4 shows that
the extent of FPOP modification gradually attenuates in respond to increased amount of the
scavenger (Figure 5.3). To track the lifetime of the hydroxyl radical in the sample, we used Leuenkephalin (YGGFL) as a peptide reporter for the hydroxyl radical22 by mixing each protein
sample with a fixed amount of Leu-enkephalin prior to FPOP. Upon laser irradiation, the reporter
is competitively labeled with BRD4 by the hydroxyl radical under the same condition, and thus
the reporter-% modified can be used to follow the hydroxyl radical lifetime in the sample.
Compound 1, a polyphenol molecule, is likely to be reactive with the hydroxyl radical, and if so
this ligand will quench some of the radicals. Thus, there may be a different overall oxidation
potential for the bound-sample solution compared to that containing the unbound. The
modification of compound 1 will not compromise our efforts to locate the binding provided the
count of radicals available to the protein can be normalized for the unbound and bound states. In
fact, the “unintended” quenching effect of compound 1 is negligible under high concentrations of
scavenger (3 and 30 mM His) as indicated by the equal modification extents of the reporter for
the unbound and unbound samples when submitted to FPOP (Table 5.1). In absence of the
scavenger (His = 0 mM), however, the reporter for the bound sample is significantly less
modified than for the unbound BRD4 (relative difference 32%). In the presence of 0.3 mM His, a
small variation in the reporter-% modified is observed. Those results demonstrate that in these
FPOP experiments, the modification extent is well-controlled because the dominating chemistry
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that controls the lifetime of the hydroxyl radical is the reaction of the radical with the largeexcess scavenger rather than that with the protein or ligand.
Averaged % modified ± S.D.
His
of the reporter
(mM)
Unbound hBRD4

Bound hBRD4

0

22.40 ± 0.12

15.31 ± 0.53

0.3

14.92 ± 0.05

12.40 ± 0.11

3

6.69 ± 0.01

6.60 ± 0.36

30

1.85 ± 0.08

1.88 ± 0.02

Table 5.1. FPOP modification levels of the reporter peptide. Extent of modification of the
reporter in the unbound and bound BRD4 sample. Scavenger concentrations of His are 0, 0.3, 3
and 30 mM respectively. FPOP labeling was done in duplicate.

To obtain comprehensive coverage across the BRD4 sequence in the bottom-up proteomics
strategy used for analysis, we performed digestion with trypsin and chymotrypsin separately.
Plotting the % modified of BRD4 peptide as a function of the reporter-% modified provides a
“time-course” for the FPOP modification. The curves are similar to the HDX kinetic curves
characterized by deuteration extents at different deuterium exposure times (Figure 5.4), curves
that are commonly viewed in the field.
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Figure 5.4. FPOP kinetic curves of BRD4. The x-axis of each curve is the % modified of the
reporter peptide, which correlates with the lifetime of the hydroxyl radical. The y-axis is the %
modified of the peptide from the FPOP-modified BRD4 in unbound (blue) and bound (orange)
states, respectively. Numbering and sequence of the peptide from digestion of BRD4 are shown
above each plot. Identified residues with FPOP modification are highlighted in red on the peptide
sequence.
We find that for peptide regions not containing Met, the % modified for the protein shows a
linear correlation with that of the reporter (Figure 5.4 A-F, I and K). Among those regions, 76-83
clearly exhibits reduced modification in the bound state. Therefore, this region is likely part of
the binding site.
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In contrast, FPOP modifications of peptide regions that contains one or more Met (e.g. 99-114,
100-112, 121-133 and 149-156) saturate and decrease as the lifetime of the hydroxyl radical
becomes longer. (Figure 5.4 G, H, J and L). Because the modification on those regions occurs
nearly exclusively on Met residue(s), we first hypothesized saturation and turnover of the
modification extent are due to a switch of the Met oxidized products to higher oxidation states
(e.g., + 32 Da, + 48 Da) as the labeling time increases (peptides with multiple oxidation are very
rare, so they are generally not considered in the algorithm for peptide-level quantification). By
manual search of the data, we found no detectable signals in LC-MS/MS for FPOP products in
higher oxidation states (e.g., +32, +48). Although the reasons for such trends observed for Metcontaining peptides is unclear, we are considering two explanations: 1) As the lifetime of the
hydroxyl radical becomes longer, oxidation by FPOP on Met produces oxidized species that are
not yet known. 2) Met-containing regions in the protein have affinity with H2O2, and thus the
radicals are generated in the immediate vicinity of Met. In the latter case, the reactions of Metcontaining regions with the hydroxyl radical is no longer limited by diffusion of the radical, but
by the local concentration of H2O2 that surrounds the Met.

5.4.3 Correlating HDX and FPOP mapping with BRD4 structures
A co-crystal structure of the complex indicates that compound 1 binds to the acetyl-lysine
recognition pocket of BRD4. Using proximity of hBRD4 residues with compound 1 as a
criterion, we considered that residues of the protein within 4 Å from compound 1 could be key
contacts. Using this criterion, we identified W81 (3.6 Å), P82 (3.9 Å), F83 (3.7 Å), L92 (3.7 Å)
and N140 (3.3 Å) as key residues that directly interact with compound 1 from the crystal
structure (Figure 5.5A).
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F83
N140
P82

W81
L92

B
124-136

98-117
149-153

137-145
72-88

Figure 5.5. Correlation of the footprinting results with BRD4-compound 1 interaction. (A)
Key contacts (magenta) of the protein (cyan) in contact with compound 1 (blue) according to the
X-ray structure. The distance criterion for a contact was chosen to be 4 Å. (B) Peptide regions
that showing reduced rates of HDX in the bound state (Figure 2 E-J) mapped onto the BRD4
structure (PDB 2YEL). Regions with low and intermediate extents of HDX (i.e., relative HDX of
the peptide in the bound or unbound state instead of the difference in HDX between the two
states) are colored in green and salmon, respectively.
5.4.3.1. HDX: Mapping the peptide regions that show reduced HDX in the bound (Figure 5.2EJ) onto BRD4-compund 1 complex indicates that those regions span the binding pockets and the
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surrounding sequence (Figure 5.5B). As discussed earlier, the differences in HDX, however, are
subtle and do not provide high confidence that a binding pocket has been identified. This may
because 1) the protein only undergoes subtle structural change upon compound 1 binding, as
indicated by the nearly identical crystal structures of the unbound and bound protein, 2) the size
of the ligand is too small to provide efficient shielding from the solvent at the binding interface,
and 3) the binding is not significant involved with peptide bonds but rather with side-chain
interactions.
Despite these uncertainties, the kinetics of HDX provides information on the secondary structure
elements of the region based on their effects on HDX. For example, regions 124-136 and 149153 that are comprised of a two α-helix bundles that are structurally rigid (Figure 5B) resist
solvent contact and show low extents of HDX (Figure 5.2 G, H and J). By contrast, region 119124 is a loop located on the surface of the protein. Its flexible structure and solvent exposure
allow the region to uptake rapidly deuterium and undergo extensive HDX even at short times
(Figure 5.2C). Regions represented by peptides 72-88 and 137-145 cover both fast and slow
exchangers and show intermediate rates of HDX (Figure 5.2E and I).
5.4.3.2. FPOP: Differential labeling by FPOP shows that region 76-83, containing key contacts
W81, P82 and F83 is decreased for the bound state (Figure 5.4D), clearly indicating a binding
interface. Further residue-specific analysis of this region indicates the FPOP modification occurs
only on W81, which is at the entrance of the binding pocket and accessible to the solvent (and
H2O2) (Figure 5.2A). No modifications were detected on P82 and F83 presumably because the
two residues are buried deep in the hydrophobicity pocket and have low solvent accessibility
(Figure 5.5A). Actually, the three residues W81-P82-F83 constitute the conserved WPF shell
motif in the bromodomain family; this domain plays an important role in positioning inhibitors
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through hydrophobic van der Waals interactions.23-24 Our finding confirms that role of W81 is
critical for substrate recognition and binding.
In addition, for L92 and N140 that have also been identified to be in contact with compound 1
based on the crystal structure, regions covering the two residues (84-92 and 138-148) show
overlapping FPOP kinetic curves in unbound and bound (Figure 5.4 E and K). Although
modification was detected on L92, we found no difference in its modification levels between
unbound and bound protein. This is likely due to the insufficient solvent protection from
compound 1 and the structural flexibility of L92 in a dynamic loop (Figure 5.5A). Meanwhile,
owning to the low intrinsic reactivity of Asn with the hydroxyl radical, N140 did not undergo
modification in FPOP. Instead, modification was detected on K141 and P142 nearby (Figure
5.4K). In this case, we lack information on N140 because the residue is not reactive with the
hydroxyl radical probe.
Interestingly, all the covered Met residues of the protein (e.g., M105, M107, M132 and M149)
show reduced rates of FPOP modification in the bound state (Figure 5.4G, H, J and L).
According to the x-ray structure, there is no significant alteration in their conformation or side
chain orientation upon compound 1 binding (Figure 5.1C). Thus, we indicate that the difference
in FPOP labeling associated with those Met residues should NOT be attributed to a major change
in protein structure or protection caused by compound 1 binding. Instead, given the similar
unbound and bound structures of BRD4, the decreased modifications on Met in the ligand-bound
state are more likely to result from the increased stability of the protein upon compound 1
binding, as revealed by reduced HDX in regions containing M105, M107, M132 and M149
(Figure 5.2F, H and J). Those changes in protein dynamics are not necessarily reflected by
crystal structures that capture only a single low-energy state of the protein.
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Furthermore, previous studies showed that Met tends to exhibit large change in FPOP
modification in response to a minor structural perturbation, presumably owing to its high
intrinsic reactivity with the hydroxyl radical.14, 25 Therefore, caution is needed when interpreting
changes in modification extents on Met and associating it with a major structural effect.
Furthermore, although FPOP can potentially result in a “false positive” in suggesting a
conformational change associated with Met, this problem can be avoided by performing the
experiment under a high concentration of the scavenger (e.g., ~ mM His), because at short
labeling times the modification extents on the Met for unbound and bound are more modest and,
importantly, are identical (Figure 5.4G, H, J and L). More research is required to understand this
effect of Met on FPOP yields.

5.5 Conclusions
In this chapter, we applied two most commonly used protein footprinting methods, HDX and
hydroxyl radical footprinting to interrogate the epitope of BRD4 for a small molecular inhibitor.
Results from HDX show very similar kinetics for the unbound and compound-1 bound BRD4,
indicating the sensitivity of the method is not sufficient in this case to map directly the
intermolecular interface between the protein and small molecule ligand presumably because the
shielding of solvent by the small molecule is ineffective. In FPOP, the region containing the
conserved WPF shell and residues nearby show a clear decrease in FPOP modification upon
compound 1 binding, consistent with the predicted interactions at the binding interface
determined by crystallography. Although there may be other residues in the vicinity of the
binding, they do not variations in their solvent accessibility reported by FPOP.
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In addition, regions containing Met residues display distinct chemical kinetics in FPOP,
including saturation in the modification at extended labeling time and a relatively large
difference in modification as an effect of a modest change in protein dynamics. Those
differences seem to be false positives and require further evaluation.
Although the interactions of the protein BRD4 with the small molecule (compound 1) are
difficult to decipher by FPOP and particularly by HDX, the small differences nevertheless
provide valuable constraints of how the small molecule is poised with respect to the protein.
Those constrains can be used to guide molecular dynamics simulation to pinpoint the binding site
especially in the early stages of research or when a high-resolution structure from X-ray/NMR
cannot be obtained.
In addition to providing insights into protein structure and properties, this chapter, together with
Chapter 4 gives us a better understanding in the sensitivity, spatial resolution, applicability and
limitation of each protein footprinting method for protein structure characterization.
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Chapter 6: Identify Key Salt Bridges
Controlling the Gating of Major Facilitator
Superfamily Transporters Using Mass
Spectrometry-Based Live-Cell Footprinting
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6.1 Abstract
The major facilitator superfamily (MFS) transporters move a wide range of substrates across
biological membranes. They function through an alternating access motion, during which the
protein progresses through a series of conformational states to accomplish substrate translocation.
Those conformational changes are mainly orchestrated by salt-bridge interactions between the Nand C-terminal domains of the transporter. Even with a structure from X-ray crystallography,
however, identification of the key salt bridges of MSF transporters remains challenging. Here,
we report the development of a MS-based live-cell footprinting approach, combined with
suspension cell expression, green florescence protein (GFP) tagging and optimized in-gel
proteolysis to probe the structures of MFS transporters in their native cellular environment. As a
proof of concept, we applied carboxyl group footprinting to probe the formation and breakage of
the salt bridges of human glucose transporters (GLUTs) during the transportation cycle.
Substrates/inhibitors stabilizing the inward- or outward-open conformations generate distinct
modification patterns, revealing the key salt-bridge interactions that control the gating of those
transporters. We identified key salt bridge interactions in GLUT1 and GLUT5 on both its
intracellular and extracellular sides. Remarkably, mutations disrupting the salt bridges located at
the two opposite sides of membrane have opposite effect to the transporter activity. Mutants (at
the cytosolic side) disputing the outward-facing conformation are inactive, suggesting that this
conformation need to be stabilized. Conversely, mutants (at the extracellular side) disrupting the
inward-facing conformation are hyperactive, suggesting that this alternative conformation needs
to be maintained transient, because removal of the salt bridges normally stabilizing this state
facilitates the transporter motion. Thus, the rocker-switch motion is asymmetrical in time, a
mechanism probably adopted by most MFS transporters. This structural mechanism has evaded
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extensive structural investigation of MFS transporters for decades, demonstrating again the
powerful capability of our method to investigate the conformations, interaction and dynamic
motion of membrane proteins in live cells.

6.2 Introduction
The major facilitator superfamily (MFS) is the largest group of secondary active transporters
found in nearly all living organisms. This superfamily represents about one quarter of known
membrane

transport

proteins,1-3

with

85

subfamilies

being

identified

to

date

(http://www.tcdb.org).4 Each functionally characterized subfamily transports a certain set of
substrates, including ions, sugars, nucleotides, amino acids, peptides, vitamins, and drugs. This
broad range of substrates are transported across the membrane via structural motions of MFS
proteins.
Crystal structures and functional analysis show that MFS proteins mediate substrate transport by
an alternating-access mechanism. These transporters share a canonical MFS fold consisting of 12
transmembrane helices (TM); the N- and C-terminal halves of the proteins, each containing 6
TMs, form two pseudo symmetrical domains surrounding a translocation pore. The substrate is
bound at a single site in this pore, and is transported through a rocker-switch rotation of the two
protein halves that alternatively exposes the substrate to promote its binding or release at each
side of the membrane. Thus, inward-open and outward-open occur as two major conformations
during the transport cycle, with substrate-occluded conformations as intermediate states.
Formation and breakage of critical salt bridges controls the rocker-switch rotation and the gating
of the translocation pore.5 In proton-coupled transporters, such as LacY6-7, GlpT5 and POT8, the
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protonation state of key residues and changes in their salt bridges were proposed to induce
significant structural rearrangements. The salt bridges provide part of the driving force, or even
act as the pivot, to flip the transporters between inward- and outward-facing conformations. In
GLUT5,9 a glucose uniporter, an outward-facing conformation is stabilized by interdomain salt
bridges between Glu and Arg residues, which are strictly conserved as part of the sugar porter
signature. These residues, however, in the inward-facing conformation are too far apart to form
salt bridges. Conversely, disruption of a salt bridge by a Glu329Gln mutation in GLUT1
stabilizes its inward-facing conformation, permitting the determination of its crystal structure.10
MFS transporters still hold specific challenges in structural biology compared to soluble proteins.
For example, the conformation of MFS transporters is sensitive to extraction, solubilization and
purification. Obtaining the crystal structure of the MFS transporters, particularly for eukaryotes
is primarily limited by their hydrophobic surface, intrinsic flexibility, and lack of stability.
Despite advances in X-ray crystallography11, identification of alternating salt bridges during the
rocker-switch motion remains a challenge. Until 2013, none of the MFS proteins had structure
captured in more than one conformational state. Today, structures of 15 MFS proteins are
available, including a handful of eukaryotic proteins (mostly glucose transporters), among which
GLUT5 is the only one determined in the two alternating conformations. Additionally, crystal
structures capture only a single low-energy state, which heavily depends on the crystallization
conditions, such as pH12, mutation (e.g., conformationally restricted E329Q in hGLUT1)10,
presence of an antibody, and crystal packing, all of which may perturb the native state of the
protein. Furthermore, the surrounding lipids in their native environment are likely to affect the
function, kinetics, or even thermodynamics of the transporter. Owing to these limitations, one
can turn to molecular-dynamics simulation to rationalize the formation and breakage of salt
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bridges implicated in biochemical studies.13 Direct evidence of such subtle changes, however,
especially in a native cellular environment, remains enigmatic for MFS transporters.
Recently, MS-based methods are showing potential for membrane protein characterization.
Membrane proteins and their complexes can be interrogated in gas-phase under non-denaturing
condition by intact mass analysis (native MS). The method allows membrane protein complexes
to be released from detergents, bicelles or nanodiscs after collisional activation in the gas phase
for MS detection. The approach provides insights into the subunit composition and lipid
interactions of membrane protein complexes.14-15 Native MS can also be coupled with ion
mobility to obtain information on membrane-protein conformation and dynamics.16 As an
alternative, MS-based “bottom-up” proteomics identifies the proteolytic peptides of a membrane
protein.17 This approach, used with chemical footprinting are usually performed on purified
protein in buffer solution, as exemplified by Chapter 2-5. For study of membrane proteins, the
protein is usually stabilized by detergent or nanodiscs in buffer for characterization. In this
chapter, we develop a novel way to apply protein footprinting by using it to label live cells. This
should give results on the structure of the membrane protein and its modifications in the native
cellular environment with high spatial resolution detailed to sub regions or even amino-acid
residues.
Because salt bridges are formed or broken between basic and acidic residues, the study and
identification of exposed carboxyl side chains can be achieved by chemical reactions
(footprinting) with a nucleophilic compound, glycyl ethyl ester (GEE). This carboxyl group
footprinting approach has been applied and discussed in Chapter 4, and showed its simplicity to
be performed as a bench-top method. This is advantageous for studying a complicated biological
system like the cell. In the footprinting reaction, the small chemical probe (GEE) irreversibly
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modifies Glu and Asp residues, made more quantitative with isotopic encoding.18 Although the
GEE method was originally developed for soluble proteins in vitro,19 we are motivated to
conduct this labeling under mild conditions that we find compatible with human cells. Here we
describe an in cellulo GEE footprinting method using mass spectrometry (MS), with GFP-aided
enrichment, to obtain nearly complete sequence coverage of these membrane proteins analysis.
This enables us to identify key salt bridges in both GLUT1 and GLUT5, including some missed
by crystal structures. Substrates and inhibitors stabilizing the inward- or outward-open
conformations generate distinct modification patterns, indicating specific changes of salt bridges.
The native cellular state of GLUT1 and GLUT5 appears to contain both conformations. The
results demonstrate that GEE MS-based footprinting is a novel and effective approach to study
alternating salt bridges, in living cells, that govern the transport of numerous MFS proteins.

6.3 Methods
6.3.1 Cell culture and virus transfection
GLUT1/GLUT5 knockdown HEK293 cells were cultured in MEM medium added with 3mg/L
puromycin dihydrochloride from Streptomyces alboniger, 10% FBS, 1% Pen/Strep, 1% Lglutamine (fresh) and 1% non-essential amino acids. Cells were grown at 37 oC, 5% CO2,
followed by adding 5% (v/v) virus GLUT1/GLUT5 after the density of cells reached 90%. After
8 h incubation, 0.5% (v/v) Na-butyrate was added, and the cells were incubated for another 36 h
at 30 oC in 5% CO2. Cells were plated into 25 μg/mL PEI (in 150 mM NaCl)-treated 24 wells
plate, with 400,000 cells in each well. Cells were then incubated for 24 h at 37 oC, 5% CO2 for
cells adhesion onto the bottom of the plate.
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6.3.2 Live-cell membrane protein footprinting
For each sample, 250 mL suspension cells are required. Cell suspension was centrifuged at 200×
g, 4 oC for 5 min resulting in a cell pellet. After removal of the supernatant, the pellet was
resuspended in 10 mL culture media. In separate experiments for the substrate-bound hGLUT,
D-glucose, D-maltose or cytochalasin B were added to the cell media to final concentrations of
200 mM, 200 mM and 100 μM, respectively. Cell suspensions were incubated at 37 oC for 30
min for substrate binding. Control sample (unbound) was prepared in the same manner as above
except no substrate was added. A subsequent centrifugation at 200×g for 5 min resulted in a cell
pellet. The pellet was washed with 20 mL ice-cold PBS (10 mM, pH 7.4) and resuspended in 3
mL PBS containing 0.025% (w/v) digitonin. To drive the binding equilibrium and maintain
GLUT in its bound form, the substrate was again added to the PBS solution to the same
concentrations as above.
For protein footprinting, 500 μL light and heavy GEE mixture (1:1 molar) stock solutions were
added to the cells to a total concentration of 300 mM, followed by adding 300 µL EDC to give a
final concentration of 50 mM. Cells were labeled (footprinted) for 20 min at 25 oC while the
sample tube was rotated. The reaction was then terminated by adding 3 mL 1 M ammonium
acetate to quench the GEE footprinting, and samples were incubated at 25 oC for 10 min. This
quench step simultaneously diluted the concentration of digitonin and allowed the permeabilized
plasma membrane to “heal”.

6.3.3 Post-labeling protein purification
Immediately after footprinting, GLUT1/GLUT5 were solubilized with 1% (w/v) n-dodecyl β-Dmaltoside (DDM) in PBS and incubated for 1 h at 4 oC. The mixture was centrifuged at 20000×g
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for 10 min, and the supernatant containing the solubilized membrane protein was collected.
Cobalt affinity resin (300 µL) was added to the supernatant and the mixture was incubated for 30
min at 4 oC. The cobalt resin bound with the target membrane protein was then loaded onto a
pre-equilibrated chromatographic column and washed at 4 oC with a buffer containing 10 mL
PBS and 0.04% (w/v) DDM. The resin was immediately subjected to reducing SDS-PAGE to
enrich further the protein. The green florescence of the GFP-tagged GLUT was excited under
UV irradiation to reveal the corresponding gel band of the GFP-tagged protein, which was
excised for in-gel digestion.

6.3.4 In-gel digestion
Two sets of enzymatic digestions, with chymotrypsin and trypsin, were performed separately to
yield complementary sets of peptides, affording high sequence coverage of the membrane
protein in LC-MS/MS analysis. Digestion was performed as previously described20 with
modifications. Briefly, gel pieces were digested for 8 h at 37 oC with 0.02 µg/mL chymotrypsin
(Promega) in a buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM CaCl2 and 0.1% RapiGest
SF surfactant (Waters), or with 0.025 µg/mL trypsin/Lys-C mix (Promega) in a PBS buffer (pH
7.4) and 0.1% RapiGest SF surfactant. The digestion was quenched by adding formic acid to a
final concentration of 1% (by volume). The solutions of peptides released by digestion were
directly used for MS and MS/MS bottom-up proteomic analysis.

6.3.5 Mass Spectrometry
Mass spectrometry analysis was performed on an Orbitrap Q Exactive plus mass spectrometer
(Thermo Fisher Scientific) coupled to a Nano UltiMate 3000 Rapid Separation system (Thermo
Fisher Scientific). The peptides were pre-concentrated on an Acclaim PepMap C18 column
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(Thermo Scientific, 100 µm × 2cm, 5μm, 100 Å) and desalted for 10 min. Peptides were then
loaded on to a custom-made column (75 μm × 200 mm) packed with reversed-phase C18
material (Symmetry, 100 Å,5 μm) and separated at a flow rate of 500 nL/min by a gradient from
2 to 60% B in 80 min. Solvent compositions for solutions in channels A and B were water with
0.1% (v/v) formic acid and 80% (v/v) acetonitrile with 0.1% (v/v) formic acid, respectively. Full
mass scans were performed at a resolution of 70,000 after accumulation to an automated gain
control (AGC) target value of 3 × 106 or a maximum injection time of 150 ms. In the datadependent mode, the 15 most-abundant ions were isolated by using a quadrupole mass filter with
an isolation window of 3 m/z and an isolation offset of 1 m/z and submitted to “higher energy
collisional dissociation” (HCD) at a normalized collision energy (NCE) of 30% of the maximum.
Dynamic exclusion was set to be 8 s for the selected ions.

6.3.6 Data Analysis in LC-MS/MS
Unmodified peptides and assigned modifications on the peptide were identified by Byonic
(Protein Metrics) based on the accurate m/z of the peptide and the product-ion spectra (MS/MS)
and further validated by manual inspection. Reaction of GEE with the side chain of Asp/Glu
results in primary products with a mass shift of +85.0527 Da (light, +C4H7NO) or +88.0527 Da
(heavy, +C213C2H715NO). For some modifications, the ester bond in the primary products
underwent hydrolysis under the acidic conditions, resulting in secondary products with a mass
shift of +57.0214 Da (light, +C2H3NO) or +60.0251 Da (heavy, +C13CH315NO).
Peptide signals represented by the peak area from the extracted ion chromatogram (XIC) based
on the accurate mass were integrated by Byologic (Protein Metrics). In the quantification, total
signal (Atotal) of a certain peptide includes the unmodified form (Au), the primary (Apri) and
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secondary (Asec) products on all modified D/E residues (namely x, y, … if more than one D/E
present) in that peptide (i.e., Atotal = Au + Σ (Apri,x + Asec,x + Apri,y + Asec,y +…). For a certain
residue x, signals of its primary (Apri) and secondary (Asec) products, each including the light and
heavy forms were summed to count as the total modified signal of residue x. The fraction
modified of residue x was then calculated by the following equation: fraction modified = (Apri,x +
Asec,x)/Atotal where A refers to an integrated signal intensity.

6.3.7 Substrate uptake assay
The medium for cell culture was first removed from the plate wells, followed by rinsing and
resuspending the cells by using glucose/fructose-free HEPES (pH 7.3). Cells were starved for 30
min at 37 oC. To monitor GLUT1 and its mutant uptake activity, 2-Deoxy-D-glucose (2DOG,
cold) and 3H-2DOG (hot) mixture were added to final concentrations of 0.5 mM and 13 μCi/mL,
respectively. To monitor the uptake activity of GLUT5 and its mutants, D-fructose (cold) and
3H-D-frucose (hot) were added to final concentrations of 0.5 mM and 13 μCi/mL, respectively.
The plate was incubated for 4 and 2 min, respectively, before measuring the uptake levels of
GLUT1 and GLUT5, respectively. The substrate uptake levels of GLUT1/GLUT5 were then
measured at 0, 10 s, 20 s, 40 s, 1 min, 2 min, 4 min, 8 min. In the kinetic assays, a series of
concentrations of 2DOG/D-fructose (0, 0.625, 1.25, 2.5, 5.10, 20, 40, 80 mM) were added to
GLUT1/GLUT5. After incubation of the cells with the substrate, the plate was washed with cold
PBS several times and gently knocked to remove the remaining solution. Triton X-100 (1%) in
PBS was added to each well. The plate was shaken at room temperature for 20 min for cell lysis.
The supernatant was transferred into scintillation-counter fluid for measuring the uptake activity
of GLUT1/GLUT5.
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6.4 Results and Discussion
6.4.1 Footprinting design of MFS transport in living cells
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Figure 6.1. The alternating access model of MFS transporters. (A) The overall structure of
MFS transporters, exemplified by human GLUT3 (PDB 4ZW9). The N- and C-domain TM
bundles are colored in orange and yellow, respectively. The intracellular helical (ICH) domain
on the cytoplasmic side is not shown for clarity. The substrate, D-glucose is bound in the central
cavity formed by residues from both N- and C- domains, and shown by stick structure in red. (B)
A schematic illustration of the alternating access (rocker-switch) model of MFS transporters. The
motion and conformational change of the N- and C-domain of the protein translocate the
substrate (red sphere) across the biomembranes (depicted by black lines).
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The structures of MFS transporters are comprised of the N-domain and C-domain, each
containing 6 TM helices, centered on a rotation axis that crosses the central substrate-binding site
at the interface of the two half domains (Figure 6.1A).11 Substrate translocation of MFS transport
is mediated by an alternate access mechanism known as the ‘rocker-switch’ rotation. This model
incorporates alternate movements of the N-domain and C-domain to create access on two sides
of the membrane, allowing uptake of the substrate from one side of the membrane to the binding
pocket and then release of the substrate to the other side of the membrane (Figure 6.1B).2, 21 This
alternative-accessing mechanism prevents simultaneous opening of both sides, preserving
essential electrochemical gradients across biological membranes. During the transportation cycle
enabled by alternating access, the inward-open and outward-open conformations occur as two
major conformations, with the ligand-bound occluded conformations as intermediates. The
inward-open and outward-open conformations are characterized by interactions, particularly of
salt bridges, between the N-domain and C-domain of the transporter.2,

5, 21

Formation and

disruption of salt bridge upon substrate binding may play a role in controlling the conformational
change required for substrate translocation in several MFS transporters, including Lac Y, GlpT
etc.5-6
Choosing the human glucose transporters (hGLUTs) as models to evaluate the effectiveness of
MFS transporter footprinting, we designed a MS-based living-cell footprinting approach to probe
the structure of MFS transporters in the native cellar environment and to identify the key salt
bridges controlling their rocker switch motion. The GLUT family, exemplified by GLUT1-5
belong to the solute carrier 2 family (SLC2). GLUT proteins translocate glucose and other
monosaccharides including fructose, myo-inositol, and urate across the biological membrane in
mammalian cells.22 All GLUT proteins appear to share a similar structure, one that typically
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contains 12 TM helices for MFS transporters. Recently, a number of crystal structures of GLUTs,
including GLUT1 in the inward-open conformation10,

23

, GLUT3 in the outward-open and

outward-occluded conformations24, and GLUT5 in both outward-facing and inward-facing
conformations9 were determined. Those structures serve as valuable models for understanding
MFS transporters as well as for bench-marking our protein footprinting results. Among
eukaryotic MFS transporters, GLUT5 is the only protein whose structures have been reported in
two alternating confirmations.
In our design, we carried out live-cell protein footprinting with MFS protein over-expressed in
HEK293 cells (Figure 6.2). The MFS transporter (e.g., GLUT) was engineered to carry a green
florescence protein (GFP) tag followed by a poly-His tag on the C-terminus of the protein. The
outward- or inward-facing conformation of the protein in solution is favored by binding of a
ligand (e.g., substrate or inhibitor), allowing us to interrogate the protein conformation in
different functional states. Prior to chemical footprinting, we permeabilized the cell plasma
membrane of by treating cells with a low concentration of digitonin. Digitonin is a nonionic
detergent that reversibly permeabilizes the plasma membrane of mammalian cells without
significantly affecting their functional integrity.25 Permeabilization of cells allows the chemical
reagents for protein footprinting to diffuse passively into the cell and modify the cytoplasmic
portion of the membrane protein.
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Figure 6.2. Schematics of the MS-based live-cell footprinting of membrane transporters.
The MFS protein (e.g., GLUT) is over expressed in HEK293 cell. The protein is engineered to
carry a GFP tag followed by a poly-His tag at the C-terminus. For protein footprinting, the
plasma membrane of HEK293 cells is permeabilized by treating cells with digitonin, followed by
modification of Asp/Glu side chain via the EDC-mediated GEE reaction using an isotopic
mixture of a 1:1 molar ratio of “light” and “heavy” GEE. The protein after GEE footprinting is
purified and enriched by Co-affinity and SDS-PAGE. Proteolytic peptides of the protein from ingel digestion are analyzed by LC-MS/MS to quantify the modification extent of the labeled
Asp/Glu residues. These extents are compared between protein samples in different functional
states.
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In protein footprinting, we submitted the cells to chemical modification with an isotopic mixture
of “light” and “heavy” (1:1 molar) GEE (Scheme 6.1). GEE labels the acidic residues (Asp and
Glu) that may involve a salt bridge. In the reaction, the carboxyl side chain of the acidic residue
is first activated by forming an O-acylisourea intermediate with EDC. This intermediate quickly
reacts with GEE to produce the primary labeling product with a chemical tag of + C 4H7NO
(+85.0527 Da for “light”, or +88.0564 Da for “heavy”).26-27 In the downstream sample handling
procedures, hydrolysis of the ester bond in the product may occur, which results in a secondary
product with a chemical tag of + C2H3NO (+57.0214 Da for “light”, or + 60.0251 Da for
“heavy”).

Primary product (R’= CH2CH3)
Light: + 85.0527 Da
Heavy: + 88.0564 Da

hydrolysis

Secondary product (R’= H)
Light: + 57.0214 Da
Heavy: + 60.0251 Da

Scheme 6.1. EDC-mediated GEE carboxyl group footprinting. GEE reacts with Asp and Glu
side chains to produce the primary products with a stable chemical tag. Some of the primary
products undergo hydrolysis in the down-stream sample handling to produce the secondary
products. Both primary and secondary products are encoded by the reaction with a 1:1 mixture of
“light” and “heavy (C13×2 and N15×1)” GEE. The locations of the “heavy” isotopes are
highlighted in red circles.
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After quench of the reaction and dilution of digitonin, we extracted the membrane proteins from
the plasma membrane of the cell into a buffer solution for purification and enrichment using Coaffinity and gel electrophoresis (SDS-PAGE) (Figure 6.2). Based on the fluorescence of its GFP
tag, the target protein in the gel was immediately visualized by UV irradiation. We digested the
proteins in the gel spots and submitted the proteolytic fragments to LC-MS analysis.
Identification of the GEE-modified peptide is made as certain as possible by using the accurate
mass of ions encoded with characteristic isotopic patterns. By comparing the modification
extents of Asp/Glu in distinct functional states of the protein, we are able to determine the
solvent accessibility changes regions containing Asp and Glu and map the motion of those
residues.
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Figure 6.3. Morphology and viability of the cells exposed the carboxyl group footprinting
reagents. (A) HEK293 cells exposed to 50 mM EDC and 300 mM GEE in PBS buffer. The cell
morphology is depicted by the green fluorescence of the GFP-tagged GLUT on the plasma
membrane. (B) Viability of HEK293 cells exposed to 50 mM EDC and 300 mM GEE in PBS
buffer. Cell viability was normalized to the control sample in PBS buffer without the addition of
EDC and GEE.
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The chemical reagents, EDC and GEE are potentially toxic to cells as determined by their
concentration and resident time in the cell. Thus, we investigated whether the integrity and
viability of the cells are affected during protein footprinting. We treated the HEK293 cells with
various concentration of the footprinting reagents, and we found the morphology of cells remain
intact in 50 mM EDC and 300 mM GEE for up to 25 min (with observation of fluorescence
photobleaching in the sample owing to long-term excitation) (Figure 6.3A). This length of time
is sufficient for completing the GEE footprinting. In addition, the viability assay shows that
despite a 25% decrease in viability owing to the addition of 50 mM EDC and 300 mM GEE, a
majority (75%) of the cells remain alive for up to 25 min (Figure 6.3B). This ensures that the
protein conformation and cell activity that we are probing are biologically relevant.

6.4.2 Proteomics strategy for high sequence coverage of MFS in structural
analysis
“Bottom-up” proteomics analysis affords high structural resolution by providing details on subregions or even amino-acid residues of the protein. Difficulties in characterization of MFSs
transporters, however, arise from their high hydrophobicity, a common problem for membrane
proteins. MFS transporters have 12 α-helical TM domains, making them poorly soluble in
aqueous solution and immune to proteolysis, thus limiting the sequence coverage in “bottom-up”
proteomics.
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A

70 kDa

B

Figure 6.4. Post-labeling purification and proteolysis of hGLUT1. (A) SDS-PAGE separation
shows a band near 70 kDa visualized by the inherent fluorescence of the GFP-tagged hGLUT1
under UV irradiation. (B) The tryptic (green bar) and chymotryptic (blue bar) peptides of
hGLUT1 detected in LC-MS/MS. The twelve TM domains are indicated in the GLUT1 sequence
above. Asp and Glu are in red on the sequence.

We used SDS–PAGE separation and multi-enzyme digestion to improve the sequence coverage
of GLUTs in bottom-up proteomics. SDS-PAGE, in addition to Co-affinity purification, provides
enrichment of the protein, and removes salts and detergents that interfere with downstream
proteolysis and LC-MS analysis. Meanwhile, SDS-PAGE strongly denatures the membrane
protein, enhancing its solubility and making the protein more susceptible to proteolysis. Taking
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advantage of the GFP tag, we can directly visualize the gel band containing the target MFS
transporter (Figure 6.4A).
In a previous LC-MS study, hydrophilic peptides of the membrane protein were not adequately
covered.28 The outcome usually suffers from a lack of cleavage sites (e.g., Arg or Lys for trypsin
in the TM regions) and the tendency of hydrophobic peptides to aggregate in aqueous solution
after removal of detergents. In our LC-MS analysis, we see some lengthy peptides (> 40 residues)
from the TM regions of GLUTs. They are not selected for label-free quantification owing to their
poor reproducibility in reversed-phase chromatography and/or the low signal intensity in MS and
MS/MS. Proteolysis of the protein with chymotrypsin, which cleaves at Tyr, Phe, and Trp,
significantly favors proteolysis in the TM regions due to the frequent presence of hydrophobic
residues. Thus, proteolysis of GLUTs, as well as other membrane proteins using trypsin and
chymotrypsin offers the advantage of creating overlapping peptides throughout the membrane
protein sequence. We found that digestion with Lys-C/trypsin and chymotrypsin separately on
the GLUTs generates properly-sized peptides that maximize the sequence coverage of hGLUT1
and hGLUT5 to 95% (Figure 6.4B) and 93%, respectively (Figure 6.5).
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A

B

Figure 6.5. Sequence coverage of hGLUT5 achieved in LC-MS/MS analysis. Peptide
fragments from digestion with (A) trypsin and (B) chymotrypsin.

167

6.4.3 Isotope-encoded MS identification of GEE-modified peptides
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Figure 6.6. Representative LC-MS/MS analysis for GEE footprinting. The tryptic peptide
459

TFDEIASGFR468 of hGLUT1 is shown as an example. (A) Extracted ion chromatograms

(EICs) of (from top to bottom) the unmodified peptide (m/z = 571.7774), mono-modified
peptides with the GEE tag on either Asp461 or Glu462 (primary product of m/z = 614.3038;
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secondary product (*) of m/z = 600.2882), and doubly-modified peptide with GEE tags on both
Asp461 and Glu462 (primary product of m/z = 656.8302; the secondary product has low signal,
comparable to the noise). All m/z values are for [M + 2H]2+ ions, and the sites of modification
were identified by MS/MS, and the fragment series is labeled above each signal peak. The
“heavy” labeled peptides co-elute with their “light” equivalent and are not shown. (B) The
mono-modified peptide (top) shows an isotopic doublet of 1:1 ratio in their intensities, and the
doubly-modified peptide (bottom) shows an isotopic triplet with 1:2:1 ratio in their intensities.
(C) The product-ion (MS/MS) spectrum of the precursor ion of m/z = 614.3038 indicates a mass
shift of + 85.0527 Da on Asp461 that designates the GEE modification onto that site.

Labeling by GEE on Asp and Glu is covalent and stable (irreversible). Thus, the modification
made on the protein in live cells is preserved in the downstream sample handling processes of
purification, proteolysis and LC-MS analysis. This insures that the modification readouts from
MS analysis report on the structure of the protein in its native cellular environment. In LC-MS
analysis, a GEE-modified peptide is separated with the unmodified form (i.e., have different
retention times (Figure 6.6 shows the LC-MS analysis of peptide region

459

TFDEIASGFR468 in

hGLUT1 as an example). This region contains Asp461 and Glu462 as two potential acidic sites for
GEE modification. We found the modified forms of the region include peptides with one GEE
tag on both Asp461 and Glu462, and a peptide with double GEE tags on both sites (Figure 6.6A).
Peptides of GLUT from the digestion contains a high content of hydrophobic peptides from the
protein TM domains. Those hydrophobic peptides generally exhibit low solubility in the aqueous
solution and poor ionization efficiency in electrospray ionization (ESI). Those problems lead to
difficulties in identification of the GEE-modified peptide, because the modified forms of those
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peptides are even less abundant. To identify unambiguously and to quantify accurately the GEE
modification, we employed isotope encoding to enhance the delectability of the low-abundance
modified peptide. Carboxyl group footprinting using a mixture of “light” and “heavy” GEE in
1:1 molar ratio produces labelling products that display isotope-encoded signals in MS.

6.4.4 Intracellular salt-bridge interaction stabilizes GLUT1 in the outwardfacing conformation
GLUT1 specifically translocases glucose across biomembranes in mammals. We performed livecell GEE footprinting on hGLUT1 in the ligand-free state as the control, and then in three ligandbound states with D-glucose, maltose and cytochalasin B, respectively. Maltose, a condensation
of two D-glucoses (Figure 6.7A), functions as an exofacial and competitive inhibitor for glucose
transport by GLUTs.29 The crystal structure of GLUT3 in complex with maltose shows that the
one of the constituent glucoses is sufficient to occupy the glucose-binding pocket, causing the
interactions between GLUT3 and maltose to be nearly identical to those of D-glucose.24
Therefore, maltose binding, similar to that of glucose, favors the outward-facing conformation
that allows substrate binding. In contrast, cytochalasin B (Figure 6.7A), a cell-permeable
mycotoxin, binds to GLUT1 in the inward-open state and favors the inward-facing
conformation.23, 29
LC-MS/MS analysis of the post-labeling hGLUT1 reveals that 28 of 31 Asp/Glu residues are
covered in peptide mapping. GEE modification is detected on 19 Asp/Glu residues (Figure 6.7B,
D and Figure 8). GEE modification dominantly occurs on residues occupying the periphery of
the protein, because Asp and Glu, as polar residues, tend to appear on the protein surface in
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contact with aqueous solution. The only acidic residue in the TM domains of hGLUT1 is E380
(TM10), and it is not modified.
In hGLUT1, we found two residues, E299 and E329, that show differential modifications in
distinct functional states of hGLUT1 (Figure 6.7B and D). We identified from the crystal
structure an intracellular salt bridge between E329 and R333, and an extracellular one between
E299 and K38, both located near the translocation pore (Figure 6.7C and E). The outward-facing
conformation, favored by glucose or maltose binding, is stabilized by inter-TM bundle salt
bridging on the intracellular side involving E329 (TM9), R333 (TM9) on the C-domain and the
backbone of G154 (TM5) of the N-domain (Figure 6.7C). Formation of the salt bridge results in
decreased GEE modification consistent with increased protection on E329 (Figure 6.7B). As
GLUT1 adopts the inward-facing conformation, initiated by cytochalasin B binding, the saltbridge interactions on the intracellular side are disrupted, E329 becomes more solvent accessible,
and it undergoes increased modification (Figure 6.7B). Meanwhile, the inward-facing
conformation is stabilized by salt bridging on the extracellular side formed by K38 (TM1) from
N-domain and E299 (TM7) from the C-domain (Figure 6.7E). Thus, the changes in modification
of E299 on the extracellular side are opposite to those of E329 on the other side of the transporter
(Figure 6.7D), verifying the alternating accessing motion of the membrane transporter.
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Figure 6.7. Salt bridge interactions in hGLUT1. (A) Chemical structures of the ligands for
GLUT1. (B) GEE modification extents of E329, and (C) the associated salt bridge interactions
on the intracellular side. (D) GEE modification extents of E299, and (F) the associated salt
bridge interactions on the extracellular side. In (C) and (E), the structure of hGLUT1 in the
inward- and outward-facing conformation is shown in pink and blue, respectively. (F) Effect of
substitution of E299 or E329 to alanine on the glucose-uptake ability of hGLUT1.
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Figure 6.8. Asp/Glu residues in hGLUT1 showing no significant change in the level of GEE
modification.

Examining the functional significance of the identified salt-bridge interactions (Figure 6.7F). we
found that substitution of E329 to alanine almost inactivate the uptake of D-glucose. However,
substitution of E299 slightly increases the uptake of D-glucose, all in comparison to WT. Thus,
disruption of the intracellular salt bridge (with E329) weakens the interactions between the Nand C- domains and significantly impedes the transport cycle by disfavoring the outward-facing
conformation for substrate binding. Conversely, disruption of the extracellular salt bridge (with
E299) results in hyperactivity in substrate translocation, suggesting that during the transport
cycle the inward-facing conformation needs to be maintained transient.
The intracellular salt bridge with E329 is seen by X-ray crystallography10, as disruption of the
salt bridge by substituting E329 with Gln arrests GLUT1 in an inward-facing conformation and
hence facilitates crystallography. Actually, it was believed that GLUT1 lacks conserved salt
bridge on the extracellular side. Nevertheless, we found a salt bridge with E299 on the
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extracellular side of GLUT1 by probing the in-cell dynamic structure of the transporter using
MS-based footprinting.

6.4.5 Apo GLUT1 contains outward- and inward-facing conformations in
equilibrium
It was previously hypothesized that apo GLUT1 prefers an outward-facing conformation because
of the extensive interactions between the TM and ICH domain.30 Our live-cell footprinting
results, however, show the modification extents of E299 and E329 in the ligand-free state
(control) fall into a medium level between those of the outward- and inward-facing states. This
suggests that apo GLUT1 in its the native cellular state contains both outward- and inward-facing
conformations in equilibrium.

6.4.6 Intracellular salt bridges stabilize GLUT5 in the outward-facing
conformation
GLUT5 is the only GLUT family member identified so far to translocate specifically fructose
(Figure 6.9A). We applied the live-cell protein footprinting to study the ligand-free hGLUT5 and
and its conformations in presence of glucose, fructose, and cytochalasin B. The GEE
modification extents of hGLUT5 upon addition of glucose or cytochalasin B are nearly identical
to that of the ligand-free protein. This suggests GLUT5, a fructose-specific transporter, interacts
weakly if at all with glucose or cytochalasin B (Figure 6.9B, D and Figure 6.10).
By contrast, two acidic residues, D64 and E337, in the fructose-bound GLUT5 are modified
differentially compared to those in the ligand-free protein. Similar to the effect of glucose or
maltose on GLUT1, excess fructose favors the outward-facing conformation of GLUT5. X-ray
crystal structures of GLUT5 are available for both outward- and inward-facing conformations of
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rat (rGLUT5) and bovine (bGLUT5), respectively9. rGLUT5 and bGLUT5 share ~81% sequence
identity to hGLUT5. On the basis of the rGLUT5 structure, we can conclude that for the
outward-facing conformation of rGLUT5, E336 (TM8) forms salt bridges with both R158 (TM5)
and R340 (TM9) on the intracellular side. Extrapolating to hGLUT5, we expect equivalent salt
bridges to form between the conserved residues E337, R159 and R341. To facilitate structural
analysis, we will use the hGLUT5 residue numbers to annotate the conserved residues in
rGLUT5 (Figure 6.9C, left). The above hypothesis with hGLUT5 is further supported by a
bioactivity assay of hGLUT5 mutants. Compared to the WT protein, single alanine substitutions
of R159, E337 and E401 in hGLUT5 strongly reduce the uptake of fructose by ~ 70%, and
mutation of R341 reduces the uptake by ~ 60%, indicating that salt bridging on the intracellular
side of GLUT5 is essential for stabilizing the outward-facing conformation. In contrast, as the
structure of GLUT5 rearranges to the inward-facing conformation (using bGLUT5 for
demonstration), the N- and C-domains move apart to release substrate, leading to disruption of
the interdomain R159-E401 and the E337-R341 salt bridge formed in the C-domain of GLUT5
(Figure 6.9C, right).

175

A

fructose

B

C

Fraction modified

50%
40%

Outward-facing
C-domain

hGLUT5_control
+ Glucose
+ Fructose
+ Cytochalasin B

N-domain

C-domain

N-domain

30%
20%
10%
0%

Intracellular view

E337

D
80%

Fraction modified

Inward-facing

hGLUT5_control
+ Glucose
+ Fructose
+ Cytochalasin B

E

Outward-open
C-domain

Outward-occluded

N-domain

C-domain

N-domain

60%

40%

20%

0%

D64

Extracellular view

F

Figure 6.9. Salt bridge interactions in hGLUT5. (A) Structure of fructose. (B) GEEmodification extents of E337 in hGLUT5. (C) Salt bridge interactions associated with E337
mapped onto the structure of rGLUT5 in the outward open conformation (cyan, PDB 4YBQ) and
bGLUT5 in the inward-facing conformation (violet, PDB 4YB9). To facilitate structural
comparison, rGLUT5 and bGLUT5, residues are labelled with hGLUT5 numbering. Views are
from the intracellular side, and ICHs are omitted for clarity. (D) GEE modification extents of
D64 in hGLUT5. (E) Orientation of E56 in hGLUT3 (equivalent to D64 in hGLUT5) in the
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outward-open (cyan, PDB 4ZWC) and outward-occluded (pink, PDB 4ZW9) conformations.
Views are from the extracellular side. (F) Effect of substitution of D64 or E337 to alanine on the
fructose-uptake ability of hGLUT5.
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Figure 6.10. Asp/Glu residues in hGLUT5 showing no significant change in the level of
GEE modification.

On the extracellular side, D64 undergoes increased GEE modification in the fructose-bound
hGLUT5 that presumably favors the outward-facing conformation (Figure 6.9D). The structure
of GLUT5 in the outward-open conformation obtained for rGLUT5, however, lacks resolution in
the region containing the residue equivalent to D64 in hGLUT5. As a result, we based our
analysis on the structures of hGLUT3 that has E56 equivalent to D64 in hGLUT5. Only
structures of the outward-facing hGLUT3 are available, including the outward-open and
outward-occluded conformations.24 For inward-facing hGLUT3, E56 (TM3) can salt bridge in
the N-domain with both K36 (TM2) and K39 (TM2) on the extracellular side. Figure 6.9E shows
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those putative salt bridge residues mapped onto the outward-open and outward-occluded
conformations of hGLUT3, in which the distance between the acidic and basic residues are > 9 Å
and > 4Å, respectively. These distances indicate salt bridging on the extracellular side is
abolished or severely weakened in GLUT3 in the outward-facing conformation. Assuming a
similar set of interactions with the conserved residues in hGLUT5 as in hGLUT3, the salt bridge
is between D64 (TM3) and K47 (TM2) in the N-domain of hGLUT5. Our protein footprinting
result shows that interaction of D64 is weakened in the outward-facing conformation, as
evidence by its increased GEE modification for fructose-bound GLUT5 (Figure 6.9D).
Comparing the structure of GLUT3 in the outward-open and outward-occluded conformations
shows a difference in the side-chain orientation of E56, equivalent to D64 in hGLUT5; the side
chain points inward to the translocation pore in the outward-open conformation (Figure 6.9E,
left), and rearranges to point to the extracellular side in the outward-occluded conformation
(Figure 6.9E, right), indicating that E56 in GLUT3 structurally rearranges in the translocation
cycle (we lack its structure in the inward-facing conformation for a direct comparison).
Substitution of D64 slightly increases the substrate uptake activity of hGLUT5 (Figure 6.9F),
suggesting the role of D64, similar to that of E299 in hGLUT1, on the extracellular side in
maintaining a transient inward-facing conformation.

6.5 Conclusions
We implemented a novel live-cell protein footprinting approach, combining suspension cell
expression, GFP tagging, isotope-encoded labeling, improved in-gel digestion and mass
spectrometry to identify key salt bridges that controls the alternating access motion of MFS
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transporters. As a probe of changes in protein solvent accessibility in live cells, MS-based
footprinting offers direct evidence for the alternate access model of the membrane transporters,
which is consistent with the X-ray structures and site-directed alkylation, tryptophan
fluorescence and Förster resonance energy transfer. Our results also provide a confirmation that
in the cell, the salt bridges are as predicted from X-ray.
The use of suspension cells provides sufficient amount of a membrane protein that has a low
expression level for protein footprinting. Incorporation of isotope-encoding facilitates the
detectivity of the modified peptides and allows unambiguous identification of the modification in
a complex mixture of peptides. Optimization of the downstream proteomics workflow
overcomes the problem of under-representation of peptides from hydrophobic regions by
affording high coverage across a membrane protein with multiple TM domains. The outcome is
a detailed view of the local structure of the membrane proteins. Using the method, we studied
structures of the MFS transporters, exemplified by GLUTs, in their native cellular environment
by chemical “footprints”, and identified the key salt bridges that act as molecular switches for the
conformational changes required for substrate translocation.
MFS transporters specifically, and membrane proteins in general, are heterogenous in term of
conformation and post translational modification. Advantageously, the applicability of the livecell protein footprinting method is minimally affected by this limitation. Furthermore, structure
information obtained from the membrane protein in live cell can also be used to facilitate
interpretation of X-ray crystallography for an atomic-level characterization of the membrane
protein. In addition, adapting chemical probes with different specificities and reactivities with
amino-acid residues, we envision continued expansion of the approach to study other functionrelated structural features of membrane proteins and their interactions with ligands and drugs that
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regulate/affect the biological activity. Although the focus of this study is the translocation
mechanism of MFS, we suggest that ligand-induced conformational changes, aggregation, and
effects of modification of other membrane receptors are now in reach.
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MS-based protein footprinting is a valuable tool for characterizing protein and protein
complexes. The method probes in-solution structure and provide information complementary to
that from X-ray crystallography or nuclear magnetic spectroscopy (NMR). The primary interest
in Gross lab is focused on the development and application of MS-based structural proteomics to
study protein biophysics. The six chapters in this dissertation reflect the method development
and application of MS-based protein footprinting to study protein aggregation, protein-ligand
interaction and higher order structure of membrane proteins.

7.1 FPOP and MS for monitor amyloid formation
In Chapter 2, we described the application of FPOP to characterize the oligomerization and
fibrillation of Aβ by monitoring its solvent accessibility changes that accompany these processes.
Compared to a traditional thioflavin T (ThT) fluorescence assay and an HDX approach, the level
of FPOP modification sensitively responds to the solvent accessibility of various Aβ species.
Therefore, we were able to identify different oligomeric species based on their characteristic
modification levels and to resolve a more detailed picture of the transition stages in Aβ
aggregation. Furthermore, the irreversible labeling by FPOP permits characterization of
aggregation behaviors of Aβ sub-regions and even some amino-acid residues.
We later extended the platform to evaluate the effect of a polyphenol amyloid inhibitor in
remodeling Aβ aggregation (Chapter 3) and found that binding of the inhibitor results in different
structural effects on Aβ sub-regions. The interaction leads to stabilization of small Aβ oligomers
and a significant extension in the lag phase and may provide hints for slowing aggregation in
vivo.
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For the future, in addition to small molecule inhibitors, other forms of inhibitors, including
peptides and antibodies can also be investigated by using the platform. Furthermore, the
approach should be useful for the study of Aβ mutant. Other investigations have shown that
some mutants (e.g., Tottori (D7N), Flemish (A21G), and Arctic (E22G)) and N-terminal
truncated Aβ species (e.g., pyroglutamate-modified Aβ) exhibit different early oligomer
distributions and accelerated rates of aggregation. The platform can be readily expanded to study
those Aβ species.
Another immediate interest in this field is the interaction of Aβ with lipid membranes. It is
known that there is a complex interplay between lipids and the generation, clearance, and
deposition of Aβ. Membrane surfaces can serve as catalytic sites and promote formation of toxic
Aβ aggregates. Compared to HDX, FPOP is advantageous for studying Aβ in a lipid
environment, because the irreversible modifications it imparts allow more flexibility in the postlabeling sample clean-up (e.g., acetone precipitation, chromatography or buffer exchange) to
remove lipids that are incompatible with MS analysis. Furthermore, FPOP can be applied to
study the interaction of Aβ with apolipoprotein E (Apo E), which binds to Aβ and significantly
influences the receptor-mediated Aβ uptake by neurons that ultimately leads to slow Aβ
clearance. Last but not the least, the FPOP platform can be applied to study aggregation and
misfolding of other amyloidogenic proteins such as α-synuclein and Tau protein.

7.2 FPOP for Protein-Ligand Interaction
In Chapter 4-5, we demonstrated the capabilities of three different protein footprinting
techniques, including HDX, FPOP and carboxyl-group footprinting in deciphering protein-ligand
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interaction and protein higher order structures. In the case of bromodomain-containing protein
interacting with a benzodiazepine inhibitor (Chapter 5), FPOP clearly points to a critical binding
region, whereas HDX is not sufficiently sensitive in mapping the binding interface in the protein
hydrophobic cavity. This study serves as an example for using FPOP to map directly the binding
interface of a protein for a small-molecule ligand that does not induce significant conformational
change on protein conformation. In this study, we incorporated a peptide reporter into the FPOP
experiment to provide a measure of the hydroxyl radical lifetime. Interestingly, we find the
modification on Met residues saturates as the hydroxyl radical lifetime increases (achieved
through decreasing the scavenger concentration). This phenomenon is specifically observed for
Met and is worth further investigation to help understand the modification mechanism of Met in
FPOP.

7.3

Live-cell

footprinting

for

membrane

protein

characterization
In Chapter 6, we applied protein footprinting, specifically carboxyl group footprinting, to label
proteins in a live cell and capture the structure of membrane transport proteins (i.e., hGLUT5 and
hGLUT5). We demonstrated a live-cell footprinting methodology combining suspension cell
expression, GFP tagging, improved in-gel digestion, and mass spectrometry to study structures
of MFS transporters in a native cellular environment. This proof of concept study is a template
for using chemical footprinting, a method normally performed on purified protein in buffer
solution, to interrogate a complicated, biologically relevant system such as the cell.
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Although this example is focused on using glycine ethyl ester to label specifically acidic residues
(Asp/Glu) and identify potential key salt bridges controlling the alternating access motion of
membrane transport proteins, the method should be readily expandable by adapting other
footprinting reagents into the established workflow to study many other biological activities of
interest for membrane proteins. For example, development of a hydrophobic precursor that can
enter the lipid bilayers will permit footprinting of residues in transmembrane regions. Moreover,
the methodology can be applied to characterize dynamic biological processes that happen in the
cell. For example, ferroportin, an iron-regulated transporter, undergoes ubiquitination followed
by internalization upon binding of its endogenous hormone inhibitor hepcidin. By footprinting
ferroportin in the cell at different times after its exposure to hepcidin, we should be able to
characterize the ligand-induced conformational change and ubiquitination sites of ferroportin
during degradation.
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